



3FW/1638

PATENT

Atty. Docket No. 1187-26

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Thomas Schmulling et al.

SERIAL NO.: 10/014,101

FILED: December 10, 2001 DATED: January 18, 2007

FOR: METHOD FOR MODIFYING PLANT MORPHOLOGY,
BIOCHEMISTRY AND PHYSIOLOGY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF PRIORITY DOCUMENT


Sir:

Enclosed is a certified copy of European Patent Appln. No.

01870053.4 filed on March 16, 2001, from which priority is claimed under 35

U.S.C. §119.

Respectfully submitted,


Ann R. Pokalsky
Reg. No. 34,697


Attorney for Applicant(s)

DILWORTH & BARRESE, LLP
333 Earle Ovington Blvd.
Uniondale, NY 11553
(516) 228-8484

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8 (a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to the: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 18, 2007.

Dated: January 18, 2007


Ann R. Pokalsky

THIS PAGE BLANK (USPTO)



BEST AVAILABLE COPY

Bescheinigung

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

Certificate

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Attestation

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr.

Patent application No.

Demande de brevet n°

01870053.4 / EP01870053

The organization code and number of your priority application, to be used for filing abroad under the Paris Convention, is EP01870053

**CERTIFIED COPY OF
PRIORITY DOCUMENT**

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R.C. van Dijk

THIS PAGE BLANK (USPTO)



Anmeldung Nr.:
Application no.: 01870053.4
Demande no.:

Anmeldetag:
Date of filing: 16.03.01
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

CropDesign N.V.
Technologiepark 3
9052 Zwijnaarde-Gent/BE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Method for modifying plant morphology, biochemistry and physiology

In anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)
Staat/Tag/Aktenzeichen / State/Date/File no. / Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation / International Patent Classification / Classification internationale de brevets:

C12N15/00

Am Anmeldetag benannte Vertragsstaaten / Contracting states designated at date of filing / Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

THIS PAGE BLANK (USPTO)

METHOD FOR MODIFYING PLANT MORPHOLOGY, BIOCHEMISTRY AND PHYSIOLOGY

FIELD OF THE INVENTION

5 The present invention generally relates to a method for modifying plant morphological, biochemical and physiological properties or characteristics, such as one or more developmental processes and/or environmental adaptive processes, including but not limited to the modification of initiation or stimulation or enhancement of root growth, and/or adventitious root formation, and/or lateral root formation, and/or root geotropism,
10 and/or shoot growth, and/or apical dominance, and/or branching, and/or timing of senescence, and/or timing of flowering, and/or flower formation, and/or seed development, and/or seed yield, said method comprising expressing a cytokinin degradation control protein, in particular cytokinin oxidase, in the plant, operably under the control of a regulatable promoter sequence such as a cell-specific promoter, tissue-specific promoter, or organ-specific promoter sequence. Preferably, the characteristics
15 modified by the present invention are cytokinin-mediated and/or auxin-mediated characteristics. The present invention extends to genetic constructs which are useful for performing the inventive method and to transgenic plants produced therewith having altered morphological and/or biochemical and/or physiological properties compared to
20 their otherwise isogenic counterparts.

BACKGROUND OF THE INVENTION

Roots are an important organ of higher plants. Their main functions are anchoring of the plant in the soil and uptake of water and nutrients (N-nutrition, minerals, etc.). Thus, root
25 growth has a direct or indirect influence on growth and yield of aerial organs, particularly under conditions of nutrient limitation. Roots are also relevant for the production of secondary plant products, such as defense compounds and plant hormones.

Roots are also storage organs in a number of important staple crops. Sugar beet is the most important plant for sugar production in Europe (260 Mill t/year; 38 % of world
30 production). Manioc (cassava), yams and sweet potato (batate) are important starch producers (app. 150 Mill t/year each). Their content in starch can be twice as high as that of potato. Roots are also the relevant organ for consumption in a number of vegetables (e.g. carrots, radish), herbs (e.g. ginger, kukuma) and medicinal plants (e.g. ginseng). In addition, some of the secondary plant products found in roots are of

economic importance for the chemical and pharmaceutical industry. An example is yams, which contain basic molecules for the synthesis of steroid hormones. Another example is shikonin, which is produced by the roots of *Lithospermum erythrorhizon* in hairy root cultures. Shikonin is used for its anti-inflammatory, anti-tumour and wound-healing properties.

Moreover, improved root growth of crop plants will also enhance competitiveness with weedy plants and will improve growth in arid areas, by increasing water accessibility and uptake.

Improved root growth is also relevant for ecological purposes, such as bioremediation and prevention/arrest of soil erosion.

Root architecture is an area that has remained largely unexplored through classical breeding, because of difficulties with assessing this trait in the field. Thus, biotechnology could have significant impact on the improvement of this trait, because it does not rely on large-scale screenings in the field. Rather, biotechnological approaches require a basic understanding of the molecular components that determine a specific characteristic of the plant. Today, this knowledge is only fragmentary, and as a consequence, biotechnology was so far unable to realize a break-through in this area.

A well-established regulator of root growth is auxin. Application of indole-3-acetic acid (IAA) to growing plants stimulates lateral root development and lateral root elongation (Torrey, Am J Bot 37: 257-264, 1950; Blakely *et al.*, Bot Gaz 143: 341-352, 1982; Muday and Haworth, Plant Physiol Biochem 32: 193-203, 1994). Roots exposed to a range of concentrations of IAA initiated increasing numbers of lateral roots (Kerk *et al.*, Plant Physiol, 122: 925-932, 2000). Furthermore, when roots that had produced laterals in response to a particular concentration of exogenous auxin were subsequently exposed to a higher concentration of IAA, numerous supernumerary lateral roots spaced between existing ones were formed (Kerk *et al.*, Plant Physiol, 122: 925-932, 2000). Conversely, growth of roots on agar containing auxin-transport inhibitors, including NPA, decreases the number of lateral roots (Muday and Haworth, Plant Physiol Biochem 32: 193-203, 1994).

Arabidopsis mutants containing increased levels of endogenous IAA have been isolated (Boerjan *et al.*, Plant Cell 7: 1405-141, 1995; Celenza *et al.*, Gene Dev 9: 2131-2142, 1995; King *et al.*, Plant Cell 7: 2023-2037, 1995; Lehman *et al.*, Cell 85: 183-194, 1996). They are now known to be alleles of a single locus located on chromosome 2. These

mutant seedlings have excess adventitious and lateral roots, which is in accordance with the above-described effects of external auxin application.

The stimulatory effect of auxins on adventitious and lateral root formation suggests that overproduction of auxins in transgenic plants is a valid strategy for increasing root growth. Yet, it is also questionable whether this would yield a commercial product with improved characteristics. Apart from its stimulatory effect on adventitious and lateral root formation, auxin overproduction triggers other effects, such as reduction in leaf number, abnormal leaf morphology (narrow, curled leaves), aborted inflorescences, increased apical dominance, adventitious root formation on the stem, most of which are undesirable from an agronomic perspective (Klee *et al.*, *Genes Devel* 1: 86-96, 1987; Kares *et al.*, *Plant Mol Biol* 15: 225-236, 1990). Therefore, the major problem with approaches that rely on increased auxin synthesis is a problem of containment, namely to confine the effects of auxin to the root. This problem of containment is not likely overcome by using tissue-specific promoters: auxins are transported in the plant and their action is consequently not confined to the site of synthesis. Another issue is whether auxins will always enhance the total root biomass. For agar-grown plants, it has been noticed that increasing concentrations progressively stimulated lateral root formation but concurrently inhibited the outgrowth of these roots (Kerk *et al.*, *Plant Physiol*, 122: 925-932, 2000).

WO 99/06571 discloses a *Zea mays* cytokinin oxidase gene and the protein encoding the same as well as transgenic plants comprising the same.

The above-mentioned problems related to containment of auxin effects and to maintenance of root outgrowth are solved by the embodiments in the patent claim.

SUMMARY OF THE INVENTION

The present invention relates to a genetic construct comprising a gene encoding a protein with cytokinin oxidase activity from *Arabidopsis thaliana*. This gene is expressed under control of a regulated promoter. This promoter may be regulated by endogenous tissue-specific or environment-specific factors or, alternatively, it may be induced by application of specific chemicals.

The present invention also relates to a cell or plant containing the genetic construct.

The present invention also relates to a method to modify root architecture and biomass by expression of a cytokinin oxidase gene under control of a promoter that is specific to the root or to certain tissues or cell types of the root.

DETAILED DESCRIPTION OF THE INVENTION

To by-pass above-mentioned problems associated with increasing auxin biosynthesis, it was decided to follow an alternative approach. We reasoned that down-regulation of auxin antagonists could evoke similar or even superior effects on root growth as compared to increasing auxin levels. Hormone actions and interactions are extremely complex, but we hypothesized that cytokinins could function as auxin antagonists with respect to root growth. Hormone studies on plant tissue cultures have shown that the ratio of auxin versus cytokinin is more important for organogenesis than the absolute levels of each of these hormones, which indeed indicates that these hormones function as antagonists – at least in certain biological processes. Furthermore, lateral root formation is inhibited by exogenous application of cytokinins. Interestingly, also root elongation is negatively affected by cytokinin treatment, which suggests that cytokinins control both root branching and root outgrowth.

Together, current literature data indicate that increasing cytokinin levels negatively affects root growth, but the mechanisms underlying this process are not understood. The sites of cytokinin synthesis in the plant are root tips and young tissues of the shoot. Endogenous concentrations of cytokinins are in the nM range. However, as their quantification is difficult, rather large tissue amounts need to be extracted and actual local concentrations are not known. Also the subcellular compartmentation of cytokinins is not known. It is generally thought that the free base and ribosides are localized in the cytoplasm and nucleus, while glucosides are localized in the vacuole. There exist also different cytokinins with slightly different chemical structure. As a consequence, it is not known whether the effects of exogenous cytokinins should be ascribed to a raise in total cytokinin concentration or rather to the competing out of other forms of plant-borne cytokinins (which differ either in structure, cellular or subcellular location) for receptors, translocators, transporters, modifying enzymes ...

In order to test the hypothesis that cytokinin levels in the root indeed exceed the level optimal for root growth, novel genes encoding cytokinin oxidases (which are cytokinin metabolizing enzymes) were cloned from *Arabidopsis thaliana* (designated *AtCKX*) and were subsequently expressed under a strong constitutive promoter in transgenic tobacco and *Arabidopsis*. Transformants showing *AtCKX* mRNA expression and increased cytokinin oxidase activity also manifested enhanced formation and growth of roots. Negative effects on shoot growth were also observed. The latter is in accordance with the constitutive expression of the cytokinin oxidase gene in these plants, illustrating the

importance of confined expression of the cytokinin oxidase gene for general plant growth properties. Containment of cytokinin oxidase activity can be achieved by using cell-, tissue- or organ-specific promoters, since cytokinin degradation is a process limited to the tissues or cells that express the CKX protein, this in contrast to approaches relying
5 on hormone synthesis, as explained above.

The observed negative effects of cytokinin oxidase expression on shoot growth demonstrate that cytokinin oxidases are interesting targets for the design of or screening for growth-promoting chemicals. Such chemicals should inhibit cytokinin oxidase activity, should preferably not be transported to the root and should be rapidly degraded in soil,
10 so that application of these chemicals will not inhibit root growth. Cytokinins also delay leaf senescence, which means that positive effects will include both growth and maintenance of photosynthetic tissues. In addition, the observation that cytokinins delay senescence, enhance greening (chlorophyll content) of leaves and reduce shoot apical dominance shows that strategies based on suppressing CKX activity (such as antisense,
15 ribozyme, and cosuppression technology) in the aerial parts of the plant could result in delayed senescence, enhanced leaf greening and increased branching.

Similarly, the observed positive effects of cytokinin oxidase expression on root growth demonstrate that cytokinin oxidases are interesting targets for the design of or screening for herbicides. Such herbicides should inhibit cytokinin oxidase activity, should preferably
20 not be transported to the shoot, and should be soluble and relatively stable in a solvent that can be administered to the root through the soil.

These effects of cytokinin oxidase overexpression on plant development and architecture were hitherto unknown and, as a consequence, the presented invention and its embodiments could not be envisaged.

25 Preferable embodiments of the invention relate to the positive effect of cytokinin oxidase expression on plant growth and architecture, and in particular on root growth and architecture. The cytokinin oxidase gene family contains at least six members in *Arabidopsis* (see examples below) and we have shown that there are quantitative differences in the effects achieved with some of these genes in transgenic plants. It is
30 anticipated that functional homologs of the described *Arabidopsis* cytokinin oxidases can be isolated from other organisms, given the evidence for the presence of cytokinin oxidase activity in many green plants (Hare and van Staden, *Physiol Plant* 91:128-136, 1994; Jones and Schreiber, *Plant Growth Reg* 23:123-134, 1997), as well as in other organisms (Armstrong, in *Cytokinins: Chemistry, Activity and Function*. Eds Mok and

Mok, CRC Press, pp139-154, 1994). Therefore, the sequence of the cytokinin oxidase, functional in the invention, need not to be identical to those described herein. It is envisaged that other genes with cytokinin oxidase activity or with any other cytokinin metabolizing activity (see Zažímalová *et al.*, Biochemistry and Molecular Biology of Plant Hormones, Hooykaas, Hall and Libbenga (Eds.), Elsevier Science, pp141-160, 1997) can also be used for the purpose of this invention. Similarly, genes encoding proteins that would increase endogenous cytokinin metabolizing activity can also be used for the purpose of this invention.

According to a first embodiment, the present invention relates to a method for stimulating root growth and/or enhancing the formation of lateral and adventitious roots and/or altering root geotropism comprising expression of a plant cytokinin oxidase or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts.

In the context of the present invention it should be understood that the term "expression" relates to an "enhanced and/or ectopic expression" of a plant cytokinin oxidase or any other protein that reduces the level of active cytokinins in plants. It should be clear that herewith an enhanced expression of the plant cytokinin oxidase as well as "de novo" expression of plant cytokinin oxidases or of said other proteins is meant.

Alternatively, said other protein enhances the cytokinin metabolizing activity of a plant cytokinin oxidase.

According to a further embodiment, the present invention relates to a method for stimulating root growth and/or enhancing the formation of lateral and adventitious roots and/or altering root geotropism and/or increasing yield and/or enhancing early vigor and/or modifying root/shoot ratio and/or improving resistance to lodging and/or increasing drought tolerance and/or promoting in vitro propagation of explants, comprising expression of a plant cytokinin oxidase or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts.

According to a preferred embodiment, the present invention relates to a method for stimulating root growth resulting in an increase of root mass by overexpression of a cytokinin oxidase, preferably a cytokinin oxidase according to the invention, or another protein that reduces the level of active cytokinins in plants or plant parts, preferably in roots.

Higher root biomass production due to overexpression of growth promoting sequences has a direct effect on the yield and an indirect effect of production of compounds

produced by root cells or transgenic root cells or cell cultures of said transgenic root cells. One example of an interesting compound produced in root cultures is shikonin, the yield of which can be advantageously enhanced by said methods.

According to another embodiment, the present invention relates to an isolated nucleic acid encoding a novel plant protein having cytokinin oxidase activity or encoding an immunologically active and/or functional fragment of such a protein selected from the group consisting of:

(a) nucleic acid sequences comprising a DNA sequence as given in any of SEQ ID NOs 1, 3, 5, 7, 9 or 11, or the complement thereof,

(b) nucleic acid sequences comprising the RNA sequences corresponding to any of SEQ ID NOs 1, 3, 5, 7, 9 or 11, or the complement thereof,

(c) nucleic acid sequences hybridizing to the nucleotide sequence as defined in (a) or (b) under stringent hybridization conditions,

(d) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 35% similar, preferably 36%, 37%, 38%, 39% similar, more preferably 40%, 41%, 42%, 43%, 44% similar, most preferably 45%, 50%, 60%, 70%, 80% 90% or 95% similar to the amino acid sequence as given in SEQ ID NO 2,

(e) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 35% similar, preferably 36%, 37%, 38%, 39% similar, more preferably 40%, 41%, 42%, 43%, 44% similar, most preferably 45%, 50%, 60%, 70%, 80% 90% or 95% similar to the amino acid sequence as given in SEQ ID NO 4,

(f) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 35% similar, preferably 36%, 37%, 38%, 39% similar, more preferably 40%, 41%, 42%, 43%, 44% similar, most preferably 45% 50%, 60%, 70%, 80% 90% or 95% similar to the amino acid sequence as given in SEQ ID NO 6,

(g) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 35% similar, preferably 36%, 37%, 38%, 39% similar, more preferably 40%, 41%, 42%, 43%, 44% similar, most preferably 45% 50%, 60%, 70%, 80% 90% or 95% similar to the amino acid sequence as given in SEQ ID NO 8,

(h) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 35% similar, preferably 36%, 37%, 38%, 39% similar, more preferably 40%, 41%, 42%, 43%, 44% similar, most preferably 45% 50%, 60%, 70%, 80% 90% or 95% similar to the amino acid sequence as given in SEQ ID NO 10,

- (i) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 35% similar, preferably 36%, 37%, 38%, 39% similar, more preferably 40%, 41%, 42%, 43%, 44% similar, most preferably 45% 50%, 60%, 70%, 80% 90% or 95% similar to the amino acid sequence as given in SEQ ID NO 12,
- 5 (j) nucleic acid sequences encoding a protein comprising the amino acid sequence as given in any of SEQ ID NOs 2, 4, 6, 8, 10 or 12,
- (k) nucleic acid sequences which are degenerated as a result of the genetic code to a nucleotide sequence of a nucleic acid as given in any of SEQ ID NOs 1, 3, 5, 7, 9 or 11, or as defined in (a) to (j),
- 10 (l) nucleic acid sequences which are diverging due to the differences in codon usage between the organisms to a nucleotide sequence encoding a protein as given in any of SEQ ID NOs 2, 4, 6, 8, 10, 12 or as defined in (a) to (j),
- (m) nucleic acid sequences which are diverging due to the differences between alleles encoding a protein as given in SEQ ID NOs 2, 4, 6, 8, 10 or 12, or as defined in (a) to (j),
- 15 (n) nucleic acid sequences encoding an immunologically active and/or functional fragment of a protein encoded by a DNA sequence as given in any of SEQ ID NOs 1, 3, 5, 7, 9 or 11, or a functional fragment of a nucleic acid as defined in any one of (a) to (m), and,
- 20 (o) nucleic acid sequences encoding a protein as defined in SEQ ID NO 2, 4, 6, 8, 10 or 12 or a nucleic acid as defined in any one of (a) to (n) characterized in that said sequence is a cDNA sequence.

The invention also relates to an isolated nucleic acid according to claim 2 which is DNA, cDNA, genomic DNA or synthetic DNA, or RNA wherein T is replaced by U.

25 The invention also relates to a nucleic acid molecule of at least 15 nucleotides in length hybridizing specifically with or specifically amplifying a nucleic acid of claim 2 or 3.

According to another embodiment, the invention also relates to a vector comprising a nucleic acid sequence according to claim 2 or 3. In a preferred embodiment, said vector is an expression vector wherein the nucleic acid sequence is operably linked to one or
30 more control sequences allowing the expression of said sequence in prokaryotic and/or eukaryotic host cells.

It should be understood that for expression of the cytokinin oxidase genes of the invention in monocots, a nucleic acid sequence corresponding to the cDNA sequence should be used to avoid mis-splicing of introns in monocots.

The invention also relates to a host cell containing any of the nucleic acid molecules or vectors of the invention. Said host cell is chosen from the group comprising bacterial, insect, fungal, plant or animal cells.

Another embodiment of the invention relates to an isolated polypeptide encodable by a nucleic acid of claim 2 or 3, or a homologue or a derivative thereof, or an immunologically active and/or functional fragment thereof.

In a preferred embodiment, the invention relates to a polypeptide according to claim 10 which has an amino acid sequence as given in SEQ ID NO 2, 4, 6, 8, 10 or 12, or a homologue or a derivative thereof, or an immunologically active and/or functional fragment thereof.

According to yet another embodiment, the invention relates to a method for producing a polypeptide according to claim 10 or 11 comprising culturing a host cell of claim 8 or 9 under conditions allowing the expression of the polypeptide and recovering the produced polypeptide from the culture.

The invention also relates to an antibody specifically recognizing a polypeptide of claim 10 or 11 or a specific epitope thereof.

The invention further relates to a method for the production of transgenic plants, plant cells or plant tissues comprising the introduction of a nucleic acid molecule according to any of claims 2 or 3 in an expressible format or a vector according to claim 6 or 7 in said plant, plant cell or plant tissue.

The invention also relates to a method for the production of altered plants, plant cells or plant tissues comprising the introduction of a polypeptide of claim 10 or 11 directly into a cell, a tissue or an organ of said plant.

According to another embodiment, the invention relates to a method for effecting the expression of a polypeptide of claim 10 or 11 comprising the introduction of a nucleic acid molecule of claim 2 or 3 operably linked to one or more control sequences or a vector according to claim 6 or 7 stably into the genome of a plant cell.

The invention further relates to a method of claim 15 or 16 further comprising regenerating a plant from said plant cell.

The invention also relates to a transgenic plant cell comprising a nucleic acid sequence of claim 2 or 3 which is operably linked to regulatory elements allowing transcription and/or expression of said nucleic acid in plant cells or obtainable by a method of claim 15 or 16.

According to a preferred embodiment, the invention relates to a transgenic plant cell of claim 18 wherein said nucleic acid of claim 2 or 3 is stably integrated into the genome of said plant cell.

5 The invention also relates to a transgenic plant or plant tissue comprising plant cells of claim 18 or 19 and to a harvestable part of said transgenic plant.

According to the invention, the harvestable part of said transgenic plant is selected from the group consisting of seeds, leaves, fruits, stem cultures, roots, tubers, rhizomes and bulbs.

10 The invention also relates to the progeny derived from any of the plants or plant parts of any of claims 20 to 22.

According to another embodiment, the invention relates to a method for stimulating root growth comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts.

15 The invention further relates to a method for enhancing the formation of lateral and adventitious roots comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts.

20 The invention also relates to method for altering root geotropism comprising altering the expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that that reduces the level of active cytokinins in plants or plant parts.

25 The invention also relates to methods for enhancing early vigor and/or for modifying root/shoot ratio and/or for improving resistance to lodging and/or for increasing drought tolerance and/or for promoting *in vitro* propagation of explants comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts.

30 According to a preferred embodiment the invention relates to a method for delaying leaf senescence comprising downregulation of expression of any of the cytokinin oxidases of the invention in leaves, preferably in senescing leaves. Also the invention relates to a method for altering leaf senescence comprising expression of one of the cytokinin oxidases in senescing leaves.

The invention further relates to methods for increasing the root size or the size of the root meristem comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts, preferably in roots.

According to yet another embodiment, the invention relates to a method for increasing the size of the shoot meristem comprising downregulation of expression of a nucleic acid of claim 2 or 3, preferably in shoots.

5 The invention also relates to methods for increasing leaf thickness comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts, preferably in leaves.

The invention also relates to a method for reducing the vessel size comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in vessels.

10 The invention further relates to a method for increasing the vessel size comprising downregulation of expression of a nucleic acid of claim 2 or 3 in vessels.

According to another embodiment, the invention relates to a method for improving standability of seedlings comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in
15 seedlings.

Furthermore, the invention relates to any of the above described methods, preferably a method of any of claims 24 to 26, said method leading to an increase in yield.

The invention further relates to any of the above described methods, preferably a method of any of claims 24 to 27, wherein said expression of said nucleic acid occurs
20 under the control of a strong constitutive promoter.

In a preferred embodiment the invention relates to any of the above described methods, preferably a method of any of claims 24 to 27, wherein said expression of said nucleic acid occurs under the control of a promoter that is preferentially expressed in roots.

25 According to yet another embodiment, the invention relates to a method for modifying cell fate and/or modifying plant development and/or modifying plant morphology and/or modifying plant biochemistry and/or modifying plant physiology and/or modifying the cell cycle progression rate comprising the modification of expression in particular cells, tissues or organs of a plant, of a nucleic acid sequence of claim 2 or 3.

30 The invention also relates to a method for obtaining enhanced growth, and/or increased yield and/or altered senescence of a plant cell, tissue and/or organ and/or increased frequency of formation of lateral organs in a plant, comprising the ectopic expression of a nucleic acid sequence of claim 2 or 3.

The invention also relates to a method for promoting and extending cell division activity in cells in adverse growth conditions and/or in stress, comprising the ectopic expression of a nucleic acid sequence of claim 2 or 3.

5 According to yet another embodiment, the invention relates to a method for identifying and obtaining proteins interacting with a polypeptide of claim 10 or 11 comprising a screening assay wherein a polypeptide of claim 10 or 11 is used.

In a more preferred embodiment, the invention relates to a method for identifying and obtaining proteins interacting with a polypeptide of claim 10 or 11 comprising a two-hybrid screening assay wherein a polypeptide of claim 10 or 11 as a bait and a cDNA
10 library as prey are used.

The invention further relates to a method for modulating the interaction between a polypeptide of claim 10 or 11 and interacting protein partners obtainable by a method according to claim 30 or 31.

In a further embodiment, the invention relates to a method for identifying and obtaining
15 compounds interacting with a polypeptide of claim 10 or 11 comprising the steps of:

- a) providing a two-hybrid system wherein a polypeptide of claim 10 or 11 and an interacting protein partner obtainable by a method according to claim 30 or 31 are expressed,
- 20 b) interacting said compound with the complex formed by the expressed polypeptides as defined in a), and,
- c) performing (real-time) measurement of interaction of said compound with said polypeptide or the complex formed by the expressed polypeptides as defined in a).

The invention further relates to a method for identifying compounds or mixtures of
25 compounds which specifically bind to a polypeptide of claim 10 or 11, comprising:

- a) combining a polypeptide of claim 10 or 11 with said compound or mixtures of compounds under conditions suitable to allow complex formation, and,
- b) detecting complex formation, wherein the presence of a complex identifies a compound or mixture which specifically binds said polypeptide.

30 The invention also relates to a method of any of claims 30 to 34 wherein said compound or mixture inhibits the activity of said polypeptide of claim 10 or 11 and can be used for the rational design of chemicals.

According to another embodiment, the invention relates to the use of a compound or mixture identified by means of a method of any of claims 30 to 34 as a plant growth regulator or herbicide.

5 The invention also relates to a method for production of a plant growth regulator or herbicide composition comprising the steps of the method of any of claims 30 to 34 and formulating the compounds obtained from said steps in a suitable form for the application in agriculture or plant cell or tissue culture.

The invention also relates to a method for increasing branching comprising expression of a nucleic acid of claim 2 or 3 in plants or plant parts, preferably in stems or axillary buds.

10 The invention also relates to a method for improving lodging resistance comprising expression of a nucleic acid of claim 2 or 3 in plants or plant parts, preferably in stems or axillary buds.

The invention also relates to a method for the design of or screening for growth-promoting chemicals or herbicides comprising the use of a nucleic acid of claim 2 or 3 or
15 a vector of claim 6 or 7.

According to another embodiment, the invention relates to the use of a nucleic acid molecule of claim 2 or 3, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 for increasing yield.

20 The invention also relates to the use of a nucleic acid molecule of claim 2 or 3, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 for stimulating root growth.

The invention also relates to the use of a nucleic acid molecule of claim 2 or 3, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 for enhancing the formation of lateral and adventitious roots.

25 The invention also relates to the use of a nucleic acid molecule of claim 2 or 3, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 for altering root geotropism.

The invention further relates to the use of a nucleic acid molecule of claim 2 or 3, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 for enhancing early vigor and/or for modifying root/shoot ratio and/or for improving resistance to lodging and/or for increasing drought tolerance and/or for promoting *in vitro* propagation of explants.

30 The invention also relates to the use of a nucleic acid molecule of claim 2 or 3, the recombinant vector of claim 6 or 7, a polypeptide of claim 10 or 11 for modifying plant development and/or for modifying plant morphology and/or for modifying plant biochemistry and/or for modifying plant physiology.

According to yet another embodiment, the invention relates to a diagnostic composition comprising at least a nucleic acid molecule of any of claims 2 to 5, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 or an antibody of claim 13.

As mentioned supra, auxins and cytokinins act as antagonists in certain biological processes. For example, the cytokinin/auxin ratio regulates the production of roots and shoots with a high concentration of auxin resulting in organized roots and a high concentration of cytokinins resulting in shoot production. Another example is apical dominance, which is due to the inhibitory influence of auxins on lateral bud development. Treatment of lateral buds with cytokinins often causes the bud to grow, thus counteracting the auxin effect and modifying apical dominance. As disclosed in this invention, expression of cytokinin oxidases in tobacco and Arabidopsis results in enhanced root development and axillary shoot formation consistent with enhanced auxin effects. Auxins are also involved in the development of fruit. Treatment of female flower parts with auxin results in the development of parthenocarpic fruit in some plant species. Parthenocarpic fruit development has been genetically engineered in several horticultural crop plants through increased biosynthesis of auxins in the female reproductive organs (WO0105985).

Therefore, according to another embodiment, this invention relates to a method for inducing the parthenocarpic trait in plants, said method consisting of downregulating the expression of one or more cytokinin oxidases or of another protein that reduces the level of active cytokinins in plants or plant parts, preferably in the female reproductive organs such as the placenta, ovules and tissues derived therefrom. The DefH9 promoter region from *Antirrhinum majus* or one of its homologues which confers a high expression specificity in placenta and ovules can be used for this purpose.

DEFINITIONS AND ELABORATIONS TO THE EMBODIMENTS

Those skilled in the art will be aware that the invention described herein is subject to variations and modifications other than those specifically described. It is to be understood that the invention described herein includes all such variations and modifications. The invention also includes all such steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any or more of said steps or features.

The present invention is applicable to any plant, in particular a monocotyledonous plants and dicotyledonous plants including a fodder or forage legume, ornamental plant, food

crop, tree, or shrub selected from the list comprising *Acacia* spp., *Acer* spp., *Actinidia* spp., *Aesculus* spp., *Agathis australis*, *Albizia amara*, *Alsophila tricolor*, *Andropogon* spp., *Arachis* spp, *Areca catechu*, *Astelia fragrans*, *Astragalus cicer*, *Baikiaea plurijuga*, *Betula* spp., *Brassica* spp., *Bruguiera gymnorhiza*, *Burkea africana*, *Butea frondosa*, *Cadaba* 5 *farinosa*, *Calliandra* spp, *Camellia sinensis*, *Canna indica*, *Capsicum* spp., *Cassia* spp., *Centroema pubescens*, *Chaenomeles* spp., *Cinnamomum cassia*, *Coffea arabica*, *Colophospermum mopane*, *Coronillia varia*, *Cotoneaster serotina*, *Crataegus* spp., *Cucumis* spp., *Cupressus* spp., *Cyathea dealbata*, *Cydonia oblonga*, *Cryptomeria japonica*, *Cymbopogon* spp., *Cynthea dealbata*, *Cydonia oblonga*, *Dalbergia monetaria*, 10 *Davallia divaricata*, *Desmodium* spp., *Dicksonia squarosa*, *Diheteropogon amplexans*, *Dioclea* spp, *Dolichos* spp., *Dorycnium rectum*, *Echinochloa pyramidalis*, *Ehrartia* spp., *Eleusine coracana*, *Eragrestis* spp., *Erythrina* spp., *Eucalyptus* spp., *Euclea schimperi*, *Eulalia villosa*, *Fagopyrum* spp., *Feijoa sellowiana*, *Fragaria* spp., *Flemingia* spp, *Freycinetia banksii*, *Geranium thunbergii*, *Ginkgo biloba*, *Glycine javanica*, *Gliricidia* spp, 15 *Gossypium hirsutum*, *Grevillea* spp., *Guibourtia coleosperma*, *Hedysarum* spp., *Hemarthia altissima*, *Heteropogon contortus*, *Hordeum vulgare*, *Hyparrhenia rufa*, *Hypericum erectum*, *Hyperthelia dissoluta*, *Indigo incarnata*, *Iris* spp., *Leptarrhena pyrolifolia*, *Lespedeza* spp., *Lettuca* spp., *Leucaena leucocephala*, *Loudetia simplex*, *Lotonus bainesii*, *Lotus* spp., *Macrotyloma axillare*, *Malus* spp., *Manihot esculenta*, 20 *Medicago sativa*, *Metasequoia glyptostroboides*, *Musa sapientum*, *Nicotianum* spp., *Onobrychis* spp., *Ornithopus* spp., *Oryza* spp., *Peltophorum africanum*, *Pennisetum* spp., *Persea gratissima*, *Petunia* spp., *Phaseolus* spp., *Phoenix canariensis*, *Phormium cookianum*, *Photinia* spp., *Picea glauca*, *Pinus* spp., *Pisum sativum*, *Podocarpus totara*, *Pogonarthria fleckii*, *Pogonarthria squarrosa*, *Populus* spp., *Prosopis cineraria*, 25 *Pseudotsuga menziesii*, *Pterolobium stellatum*, *Pyrus communis*, *Quercus* spp., *Rhaphiolepis umbellata*, *Rhopalostylis sapida*, *Rhus natalensis*, *Ribes grossularia*, *Ribes* spp., *Robinia pseudoacacia*, *Rosa* spp., *Rubus* spp., *Salix* spp., *Schyzachyrium sanguineum*, *Sciadopitys verticillata*, *Sequoia sempervirens*, *Sequoiadendron giganteum*, *Sorghum bicolor*, *Spinacia* spp., *Sporobolus fimbriatus*, *Stiburus alopecuroides*, *Stylosanthos humilis*, *Tadehagi* spp, *Taxodium distichum*, *Themeda* 30 *triandra*, *Trifolium* spp., *Triticum* spp., *Tsuga heterophylla*, *Vaccinium* spp., *Vicia* spp. *Vitis vinifera*, *Watsonia pyramidata*, *Zantedeschia aethiopica*, *Zea mays*, amaranth, artichoke, asparagus, broccoli, brussel sprout, cabbage, canola, carrot, cauliflower, celery, collard greens, flax, kale, lentil, oilseed rape, okra, onion, potato, rice, soybean,

straw, sugarbeet, sugar cane, sunflower, tomato, squash, and tea, amongst others, or the seeds of any plant specifically named above or a tissue, cell or organ culture of any of the above species.

Throughout this specification, unless the context requires otherwise the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

As used herein, the term "derived from" shall be taken to indicate that a particular integer or group of integers has originated from the species specified, but has not necessarily been obtained directly from the specified source.

The terms "protein(s)", "peptide(s)" or "oligopeptide(s)", when used herein refer to amino acids in a polymeric form of any length. Said terms also include known amino acid modifications such as disulphide bond formation, cysteinylolation, oxidation, glutathionylation, methylation, acetylation, farnesylation, biotinylation, stearylolation, formylation, lipoic acid addition, phosphorylation, sulphation, ubiquitination, myristoylation, palmitoylation, geranylgeranylation, cyclization (e.g. pyroglutamic acid formation), oxidation, deamidation, dehydration, glycosylation (e.g. pentoses, hexosamines, N-acetylhexosamines, deoxyhexoses, hexoses, sialic acid etc.) and acylation as well as non-naturally occurring amino acid residues, L-amino acid residues and D-amino acid residues.

"Homologues" of a protein of the invention are those peptides, oligopeptides, polypeptides, proteins and enzymes which contain amino acid substitutions, deletions and/or additions relative to the said protein with respect to which they are a homologue, without altering one or more of its functional properties, in particular without reducing the activity of the resulting. For example, a homologue of said protein will consist of a bioactive amino acid sequence variant of said protein. To produce such homologues, amino acids present in the said protein can be replaced by other amino acids having similar properties, for example hydrophobicity, hydrophilicity, hydrophobic moment, antigenicity, propensity to form or break α -helical structures or β -sheet structures, and so on. An overview of physical and chemical properties of amino acids is given in Table 1.

Substitutional variants of a protein of the invention are those in which at least one residue in said protein amino acid sequence has been removed and a different residue inserted in its place. Amino acid substitutions are typically of single residues, but may be clustered depending upon functional constraints placed upon the polypeptide; insertions

will usually be of the order of about 1-10 amino acid residues. and deletions will range from about 1-20 residues. Preferably, amino acid substitutions will comprise conservative amino acid substitutions, such as those described *supra*.

5

Table 1. Properties of naturally occurring amino acids.

10

Charge properties / hydrophobicity	Side group	Amino Acid
nonpolar hydrophobic	Aliphatic aliphatic, S-containing aromatic imino	ala, ile, leu, val met phe, trp pro
polar uncharged	Aliphatic amide aromatic hydroxyl sulfhydryl	gly asn, gln tyr ser, thr cys
positively charged	Basic	arg, his, lys
negatively charged	Acidic	asp, glu

Insertional amino acid sequence variants of a protein of the invention are those in which one or more amino acid residues are introduced into a predetermined site in said protein. Insertions can comprise amino-terminal and/or carboxy-terminal fusions as well as intra-sequence insertions of single or multiple amino acids. Generally, insertions within the amino acid sequence will be smaller than amino or carboxyl terminal fusions, of the order of about 1 to 10 residues. Examples of amino- or carboxy-terminal fusion proteins or peptides include the binding domain or activation domain of a transcriptional activator as used in a two-hybrid system, phage coat proteins, (histidine)₆-tag, glutathione S-transferase, protein A, maltose-binding protein, dihydrofolate reductase, Tag•100 epitope (EETARFQPGYRS), c-myc epitope (EQKLISEEDL), FLAG[®]-epitope

(DYKDDDK), lacZ, CMP (calmodulin-binding peptide), HA epitope (YPYDVPDYA), protein C epitope (EDQVDPRLIDGK) and VSV epitope (YTDIEMNRLGK).

Deletional variants of a protein of the invention are characterised by the removal of one or more amino acids from the amino acid sequence of said protein.

5 Amino acid variants of a protein of the invention may readily be made using peptide synthetic techniques well known in the art, such as solid phase peptide synthesis and the like, or by recombinant DNA manipulations. The manipulation of DNA sequences to produce variant proteins which manifest as substitutional, insertional or deletional variants are well known in the art. For example, techniques for making substitution
10 mutations at predetermined sites in DNA having known sequence are well known to those skilled in the art, such as by M13 mutagenesis, T7-Gen in vitro mutagenesis kit (USB, Cleveland, OH), QuickChange Site Directed mutagenesis kit (Stratagene, San Diego, CA), PCR-mediated site-directed mutagenesis or other site-directed mutagenesis protocols.

15 In the current invention "homology" and "similarity" percentages between proteins are calculated using computer programs known in the art such as the Dnastar/MegAlign programs in combination with the Clustal method.

"Derivatives" of a protein of the invention are those peptides, oligopeptides, polypeptides, proteins and enzymes which comprise at least about five contiguous
20 amino acid residues of said polypeptide but which retain the biological activity of said protein. A "derivative" may further comprise additional naturally-occurring, altered glycosylated, acylated or non-naturally occurring amino acid residues compared to the amino acid sequence of a naturally-occurring form of said polypeptide. Alternatively or in addition, a derivative may comprise one or more non-amino acid substituents compared
25 to the amino acid sequence of a naturally-occurring form of said polypeptide, for example a reporter molecule or other ligand, covalently or non-covalently bound to the amino acid sequence such as, for example, a reporter molecule which is bound thereto to facilitate its detection.

With "immunologically active" is meant that a molecule or specific fragments thereof
30 such as specific epitopes or haptens are recognized by, i.e. bind to antibodies. Specific epitopes may be determined using, for example, peptide scanning techniques as described in Geysen *et al.* (1996) (Geysen, H.M., Rodda, S.J. and Mason, T.J. (1986). A priori delineation of a peptide which mimics a discontinuous antigenic determinant. *Mol. Immunol.* **23**, 709-715.).

The term "fragment of a sequence" or "part of a sequence" means a truncated sequence of the original sequence referred to. The truncated sequence (nucleic acid or protein sequence) can vary widely in length; the minimum size being a sequence of sufficient size to provide a sequence with at least a comparable function and/or activity or the original sequence referred to (e. g. "functional fragment"), while the maximum size is not critical. In some applications, the maximum size usually is not substantially greater than that required to provide the desired activity and/or function(s) of the original sequence. Typically, the truncated amino acid sequence will range from about 5 to about 60 amino acids in length. More typically, however, the sequence will be a maximum of about 50 amino acids in length, preferably a maximum of about 60 amino acids. It is usually desirable to select sequences of at least about 10, 12 or 15 amino acids, up to a maximum of about 20 or 25 amino acids.

Functional fragments include those comprising an epitope which is specific for the proteins according to the invention. Preferred functional fragments have a length of at least, for example, 5, 10, 25, 100, 150 or 200 amino acids.

In the context of the current invention are embodied homologues, derivatives and/or immunologically active and/or functional fragments of inventive cytokinin oxidases as defined supra. Particularly preferred homologues, derivatives and/or immunologically active and/or functional fragments of the cytokinin oxidase proteins which are contemplated for use in the current invention are derived from plants, more specifically from *Arabidopsis thaliana*, even more specifically said cytokinin oxidases are the *Arabidopsis thaliana* (At)CKX, or are capable of being expressed therein. The present invention clearly contemplates the use of functional homologues or derivatives and/or immunologically active fragments of the AtCKX proteins and is not to be limited in application to the use of a nucleotide sequence encoding one of said AtCKX proteins.

Any of said proteins, polypeptides, peptides and fragments thereof can be produced in a biological system, e.g. a cell culture. Alternatively any of said proteins, polypeptides, peptides and fragments thereof can be chemically manufactured e.g. by solid phase peptide synthesis. Said proteins or fragments thereof can be part of a fusion protein as is the case in e.g. a two-hybrid assay which enables e.g. the identification of proteins interacting with a cytokinin oxidase according to the invention.

The proteins or fragments thereof are furthermore useful e.g. to modulate the interaction between a cytokinin oxidase according to the invention and interacting protein partners

obtained by a method of the invention. Chemically synthesized peptides are particularly useful e.g. as a source of antigens for the production of antisera and/or antibodies.

"Antibodies" include monoclonal, polyclonal, synthetic or heavy chain camel antibodies as well as fragments of antibodies such as Fab, Fv or scFv fragments. Monoclonal antibodies can be prepared by the techniques as described in e.g. Liddle and Cryer (1991) which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized animals. Furthermore, antibodies or fragments thereof to a molecule or fragments thereof can be obtained by using methods as described in e.g. Harlow and Lane (1988). In the case of antibodies directed against small peptides such as fragments of a protein of the invention, said peptides are generally coupled to a carrier protein before immunization of animals. Such protein carriers include keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), ovalbumin and Tetanus toxoid. The carrier protein enhances the immune response of the animal and provides epitopes for T-cell receptor binding sites. The term "antibodies" furthermore includes derivatives thereof such as labelled antibodies. Antibody labels include alkaline phosphatase, PKH2, PKH26, PKH67, fluorescein (FITC), Hoechst 33258, R-phycoerythrin (PE), rhodamine (TRITC), Quantum Red, Texas Red, Cy3, biotin, agarose, peroxidase and gold spheres. Tools in molecular biology relying on antibodies against a protein include protein gel blot analysis, screening of expression libraries allowing gene identification, protein quantitative methods including ELISA and RIA, immunoaffinity purification of proteins, immunoprecipitation of proteins (see e.g. Example 5) and immunolocalization (see e.g. Example 6). Other uses of antibodies and especially of peptide antibodies include the study of proteolytic processing (Loffler et al. 1994, Woulfe et al. 1994), determination of protein active sites (Lerner 1982), the study of precursor and post-translational processing (Baron and Baltimore 1982, Lerner et al. 1981, Semier et al. 1982), identification of protein domains involved in protein-protein interactions (Murakami et al. 1992) and the study of exon usage in gene expression (Tamura et al. 1991).

Embodied in the current invention are antibodies specifically recognizing a cytokinin oxidase or homologue, derivative or fragment thereof as defined supra. Preferably said cytokinin oxidase is a plant cytokinin oxidase, more specifically one of the *Arabidopsis thaliana* cytokinin oxidases (AtCKX).

The terms "gene(s)", "polynucleotide(s)", "nucleic acid sequence(s)", "nucleotide sequence(s)", or "nucleic acid molecule(s)", when used herein refer to nucleotides, either

ribonucleotides or deoxyribonucleotides or a combination of both, in a polymeric form of any length. Said terms furthermore include double-stranded and single-stranded DNA and RNA. Said terms also include known nucleotide modifications such as methylation, cyclization and 'caps' and substitution of one or more of the naturally occurring

5 nucleotides with an analog such as inosine. Modifications of nucleotides include the addition of acridine, amine, biotin, cascade blue, cholesterol, Cy3®, Cy5®, Cy5.5® Dabcyl, digoxigenin, dinitrophenyl, Edans, 6-FAM, fluorescein, 3'-glyceryl, HEX, IRD-700, IRD-800, JOE, phosphate psoralen, rhodamine, ROX, thiol (SH), spacers, TAMRA, TET, AMCA-S®, SE, BODIPY®, Marina Blue®, Pacific Blue®, Oregon Green®, Rhodamine

10 Green®, Rhodamine Red®, Rhodol Green® and Texas Red®. Polynucleotide backbone modifications include methylphosphonate, 2'-OMe-methylphosphonate RNA, phosphorothiorate, RNA, 2'-OMeRNA. Base modifications include 2-amino-dA, 2-aminopurine, 3'-(ddA), 3'dA(cordycepin), 7-deaza-dA, 8-Br-dA, 8-oxo-dA, N⁶-Me-dA, abasic site (dSpacer), biotin dT, 2'-OMe-5Me-C, 2'-OMe-propynyl-C, 3'-(5-Me-dC), 3'-(ddC), 5-Br-dC, 5-I-dC, 5-Me-dC, 5-F-dC, carboxy-dT, convertible dA, convertible dC,

15 convertible dG, convertible dT, convertible dU, 7-deaza-dG, 8-Br-dG, 8-oxo-dG, O⁶-Me-dG, S6-DNP-dG, 4-methyl-indole, 5-nitroindole, 2'-OMe-inosine, 2'-dI, O⁶-phenyl-dI, 4-methyl-indole, 2'-deoxynebularine, 5-nitroindole, 2-aminopurine, dP(purine analogue), dK(pyrimidine analogue), 3-nitropyrrole, 2-thio-dT, 4-thio-dT, biotin-dT, carboxy-dT, O⁴-

20 Me-dT, O⁴-triazol dT, 2'-OMe-propynyl-U, 5-Br-dU, 2'-dU, 5-F-dU, 5-I-dU, O⁴-triazol dU. Said terms also encompass peptide nucleic acids (PNAs), a DNA analogue in which the backbone is a pseudopeptide consisting of N-(2-aminoethyl)-glycine units rather than a sugar. PNAs mimic the behaviour of DNA and bind complementary nucleic acid strands. The neutral backbone of PNA results in stronger binding and greater specificity than

25 normally achieved. In addition, the unique chemical, physical and biological properties of PNA have been exploited to produce powerful biomolecular tools, antisense and antigene agents, molecular probes and biosensors.

The present invention also advantageously provides nucleic acid sequences of at least approximately 15 contiguous nucleotides of a nucleic acid according to the invention and

30 preferably from 15 to 50 nucleotides. These sequences may, advantageously be used as probes to specifically hybridise to sequences of the invention as defined above or primers to initiate specific amplification or replication of sequences of the invention as defined above, or the like. Such nucleic acid sequences may be produced according to techniques well known in the art, such as by recombinant or synthetic means. They may

also be used in diagnostic kits or the like for detecting the presence of a nucleic acid according to the invention. These tests generally comprise contacting the probe with the sample under hybridising conditions and detecting the presence of any duplex or triplex formation between the probe and any nucleic acid in the sample.

5 Advantageously, the nucleic acid sequences, according to the invention may be produced using such recombinant or synthetic means, such as for example using PCR cloning mechanisms which generally involve making a pair of primers, which may be from approximately 15 to 50 nucleotides to a region of the gene which is desired to be cloned, bringing the primers into contact with mRNA, cDNA or genomic DNA from a cell,
10 performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified region or fragment and recovering the amplified DNA. Generally, such techniques as defined herein are well known in the art, such as described in Sambrook et al. (Molecular Cloning: a Laboratory Manual, 1989).
A "coding sequence" or "open reading frame" or "ORF" is defined as a nucleotide
15 sequence that can be transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate control sequences or regulatory sequences, i.e. when said coding sequence or ORF is present in an expressible format. Said coding sequence or ORF is bounded by a 5' translation start codon and a 3' translation stop codon. A coding sequence or ORF can include, but is not limited to RNA, mRNA, cDNA,
20 recombinant nucleotide sequences, synthetically manufactured nucleotide sequences or genomic DNA. Said coding sequence or ORF can be interrupted by intervening nucleic acid sequences.

Genes and coding sequences essentially encoding the same protein but isolated from different sources can consist of substantially divergent nucleic acid sequences.
25 Reciprocally, substantially divergent nucleic acid sequences can be designed to effect expression of essentially the same protein. Said nucleic acid sequences are the result of e.g. the existence of different alleles of a given gene, of the degeneracy of the genetic code or of differences in codon usage. Thus, as indicated in Table 2, amino acids such as methionine and tryptophan are encoded by a single codon whereas other amino
30 acids such as arginine, leucine and serine can each be translated from up to six different codons. Differences in preferred codon usage are illustrated in Table 3 for *Agrobacterium tumefaciens* (a bacterium), *A. thaliana*, *M. sativa* (two dicotyledonous plants) and *Oryza sativa* (a monocotyledonous plant). To extract one example, the codon GGC (for glycine) is the most frequently used codon in *A. tumefaciens* (36.2 %),

is the second most frequently used codon in *O. sativa* but is used at much lower frequencies in *A. thaliana* and *M. sativa* (9 % and 8.4 %, respectively). Of the four possible codons encoding glycine (see Table 2), said GGC codon is most preferably used in *A. tumefaciens* and *O. sativa*. However, in *A. thaliana* this is the GGA (and GGU) codon whereas in *M. sativa* this is the GGU (and GGA) codon.

DNA sequences as defined in the current invention can be interrupted by intervening sequences. With "intervening sequences" is meant any nucleic acid sequence which disrupts a coding sequence comprising said inventive DNA sequence or which disrupts the expressible format of a DNA sequence comprising said inventive DNA sequence.

Removal of the intervening sequence restores said coding sequence or said expressible format. Examples of intervening sequences include introns and mobilizable DNA sequences such as transposons. With "mobilizable DNA sequence" is meant any DNA sequence that can be mobilized as the result of a recombination event.

Table 2. Degeneracy of the genetic code.

Amino Acid	Three-letter code	One-letter code	Possible codons					
Alanine	Ala	A	GCA	GCC	GCG	GCU		
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU
Asparagine	Asn	N	AAC	AAU				
Aspartic Acid	Asp	D	GAC	GAU				
Cysteine	Cys	C	UGC	UGU				
Glutamic Acid	Glu	E	GAA	GAG				
Glutamine	Gln	Q	CAA	CAG				
Glycine	Gly	G	GGA	GGC	GGG	GGU		
Histidine	His	H	CAC	CAU				
Isoleucine	Ile	I	AUA	AUC	AUU			
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU
Lysine	Lys	K	AAA	AAG				
Methionine	Met	M	AUG					
Phenylalanine	Phe	F	UUC	UUU				
Proline	Pro	P	CCA	CCC	CCG	CCU		
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU
Threonine	Thr	T	ACA	ACC	ACG	ACU		
Tryptophan	Trp	W	UGG					
Tyrosine	Tyr	Y	UAC	UAU				
Valine	Val	V	GUA	GUC	GUG	GUU		
Possible "STOP" codons								
			UAA	UAG	UGA			

5 **Table 3.** Usage of the indicated codons in the different organisms given as frequency per thousand codons (<http://www.kazusa.or.jp/codon>).

Codon	<i>Agrobacterium tumefaciens</i>	<i>Arabidopsis thaliana</i>	<i>Medicago sativa</i>	<i>Oryza sativa</i>
UUU	13.9	22.5	24.1	11.3
UUC	24.3	20.7	16.9	26.3
UUA	3.5	12.9	10.4	4.7
UUG	13.2	21.0	22.4	11.8
UCU	7.0	24.6	19.8	10.1
UCC	14.8	10.8	7.7	16.9
UCA	7.4	17.8	17.2	9.7
UCG	18.2	8.9	3.2	10.8
UAU	12.3	15.2	16.6	9.2
UAC	10.3	13.7	14.0	20.6
UAA	0.9	0.9	1.2	0.9
UAG	0.6	0.5	0.8	0.8
UGU	3.0	10.8	10.6	5.0
UGC	7.4	7.2	5.8	14.3
UGA	1.8	1.0	0.8	1.3
UGG	12.2	12.7	10.0	12.8
CUU	19.1	24.3	28.3	14.6
CUC	25.7	15.9	12.0	28.0
CUA	5.2	10.0	8.8	5.7
CUG	31.6	9.9	8.5	22.1
CCU	7.7	18.3	23.2	11.8
CCC	10.6	5.3	5.3	12.5
CCA	8.9	16.1	22.6	12.2
CCG	20.7	8.3	3.6	16.7
CAU	10.6	14.0	14.6	9.2
CAC	9.1	8.7	9.1	14.6
CAA	11.2	19.7	23.2	11.9
CAG	24.9	15.2	12.3	24.6
CGU	12.2	8.9	10.1	6.8
CGC	25.5	3.7	4.2	15.9
CGA	8.2	6.2	4.2	4.2
CGG	13.2	4.8	1.8	9.7
AUU	15.4	22.0	29.4	13.8
AUC	36.9	18.5	14.7	25.5
AUA	6.2	12.9	11.7	7.2
AUG	24.7	24.5	21.7	24.4
ACU	6.4	17.8	20.8	10.3
ACC	20.9	10.3	11.7	18.6
ACA	9.1	15.9	18.9	10.0

ACG	18.8	7.6	2.8	10.8
AAU	13.5	22.7	25.0	12.9
AAC	18.7	20.9	18.7	25.1
AAA	13.6	31.0	32.2	12.0
AAG	24.4	32.6	35.1	39.4
AGU	5.7	14.0	12.6	7.3
AGC	15.8	11.1	8.8	16.9
AGA	5.3	18.7	13.6	7.7
AGG	6.5	10.9	11.7	14.9
GUU	16.6	27.3	34.7	15.0
GUC	29.3	12.7	9.9	22.8
GUA	6.1	10.1	10.0	5.7
GUG	19.7	17.5	16.5	25.0
GCU	17.4	28.0	34.6	19.8
GCC	35.8	10.3	11.4	33.2
GCA	19.5	17.6	25.9	15.6
GCG	31.7	8.8	3.4	25.3
GAU	25.8	36.8	40.0	21.5
GAC	28.0	17.3	15.5	31.6
GAA	29.9	34.4	35.9	17.1
GAG	26.3	32.2	27.4	41.1
GGU	16.5	22.2	28.7	16.3
GGC	36.2	9.0	8.4	34.7
GGA	12.5	23.9	27.3	15.0
GGG	11.3	10.2	7.4	16.6

"Hybridization" is the process wherein substantially homologous complementary nucleotide sequences anneal to each other. The hybridization process can occur entirely in solution, i.e. both complementary nucleic acids are in solution. Tools in molecular biology relying on such a process include PCR, subtractive hybridization and DNA sequence determination. The hybridization process can also occur with one of the complementary nucleic acids immobilized to a matrix such as magnetic beads, Sepharose beads or any other resin. Tools in molecular biology relying on such a process include the isolation of poly (A+) mRNA. The hybridization process can furthermore occur with one of the complementary nucleic acids immobilized to a solid support such as a nitrocellulose or nylon membrane or immobilized by e.g. photolithography to e.g. a silicious glass support (the latter known as nucleic acid arrays or microarrays or as nucleic acid chips). Tools in molecular biology relying on such a process include RNA and DNA gel blot analysis, colony hybridization, plaque hybridization and microarray hybridization. In order to allow hybridization to occur, the nucleic acid molecules are generally thermally or chemically (e.g. by NaOH) denatured to melt a double strand into two single strands and/or to remove hairpins or other

secondary structures from single stranded nucleic acids. The stringency of hybridization is influenced by conditions such as temperature, salt concentration and hybridization buffer composition. High stringency conditions for hybridization include high temperature and/or low salt concentration (salts include NaCl and Na₃-citrate) and/or the inclusion of
5 formamide in the hybridization buffer and/or lowering the concentration of compounds such as SDS (detergent) in the hybridization buffer and/or exclusion of compounds such as dextran sulfate or polyethylene glycol (promoting molecular crowding) from the hybridization buffer. Conventional hybridization conditions are described in e.g. Sambrook et al. (1989) but the skilled craftsman will appreciate that numerous different
10 hybridization conditions can be designed in function of the known or the expected homology and/or length of the nucleic acid sequence. Sufficiently low stringency hybridization conditions are particularly preferred to isolate nucleic acids heterologous to the DNA sequences of the invention defined supra. Elements contributing to said heterology include allelism, degeneration of the genetic code and differences in preferred codon usage as discussed supra.
15

Clearly, the current invention embodies the use of the inventive DNA sequences encoding a cytokinin oxidase, homologue, derivative or immunologically active and/or functional fragment thereof as defined higher in any method of hybridization . The current invention furthermore also related to DNA sequences hybridizing to said
20 inventive DNA sequences. Preferably said cytokinin oxidase is a plant cytokinin oxidase, more specifically the *Arabidopsis thaliana* (At)CKX.

To effect expression of a protein in a cell, tissue or organ, preferably of plant origin, either the protein may be introduced directly to said cell, such as by microinjection or ballistic means or alternatively, an isolated nucleic acid molecule encoding said protein
25 may be introduced into said cell, tissue or organ in an expressible format.

Preferably, the DNA sequence of the invention comprises a coding sequence or open reading frame (ORF) encoding a cytokinin oxidase protein or a homologue or derivative thereof or an immunologically active and/or functional fragment thereof as defined supra. The preferred protein of the invention comprises the amino acid sequence of said
30 cytokinin oxidase. Preferably said cytokinin oxidase is a plant cytokinin oxidase and more specifically a *Arabidopsis thaliana* (At)CKX.

With "vector" or "vector sequence" is meant a DNA sequence which can be introduced in an organism by transformation and can be stably maintained in said organism. Vector maintenance is possible in e.g. cultures of *Escherichia coli*, *A. tumefaciens*,

Saccharomyces cerevisiae or *Schizosaccharomyces pombe*. Other vectors such as phagemids and cosmid vectors can be maintained and multiplied in bacteria and/or viruses. Vector sequences generally comprise a set of unique sites recognized by restriction enzymes, the multiple cloning site (MCS), wherein one or more non-vector
5 sequence(s) can be inserted.

With "non-vector sequence" is accordingly meant a DNA sequence which is integrated in one or more of the sites of the MCS comprised within a vector.

"Expression vectors" form a subset of vectors which, by virtue of comprising the appropriate regulatory or control sequences enable the creation of an expressible format
10 for the inserted non-vector sequence(s), thus allowing expression of the protein encoded by said non-vector sequence(s). Expression vectors are known in the art enabling protein expression in organisms including bacteria (e.g. *E. coli*), fungi (e.g. *S. cerevisiae*, *S. pombe*, *Pichia pastoris*), insect cells (e.g. baculoviral expression vectors), animal cells (e.g. COS or CHO cells) and plant cells (e.g. potato virus X-based expression vectors).

15 The current invention clearly includes any cytokinin oxidase, homologue, derivative and/or immunologically active and/or functional fragment thereof as defined supra. Preferably said cytokinin oxidase is a plant cytokinin oxidase, more specifically a *Arabidopsis thaliana* (At)CKX.

As an alternative to expression vector-mediated protein production in biological systems,
20 chemical protein synthesis can be applied. Synthetic peptides can be manufactured in solution phase or in solid phase. Solid phase peptide synthesis (Merrifield 1963) is, however, the most common way and involves the sequential addition of amino acids to create a linear peptide chain. Solid phase peptide synthesis includes cycles consisting of three steps: (i) immobilization of the carboxy-terminal amino acid of the growing peptide
25 chain to a solid support or resin; (ii) chain assembly, a process consisting of activation, coupling and deprotection of the amino acid to be added to the growing peptide chain; and (iii) cleavage involving removal of the completed peptide chain from the resin and removal of the protecting groups from the amino acid side chains. Common approaches in solid phase peptide synthesis include Fmoc/tBu (9-fluorenylmethyloxycarbonyl/t-butyl)
30 and Boc (t-butyloxycarbonyl) as the amino-terminal protecting groups of amino acids. Amino acid side chain protecting groups include methyl (Me), formyl (CHO), ethyl (Et), acetyl (Ac), t-butyl (t-Bu), anisyl, benzyl (Bzl), trifluoroacetyl (Tfa), N-hydroxysuccinimide (ONSu, OSu), benzoyl (Bz), 4-methylbenzyl (Meb), thioanisyl, thiocresyl, benzyloxymethyl (Bom), 4-nitrophenyl (ONp), benzyloxycarbonyl (Z), 2-nitrobenzoyl

(NBz), 2-nitrophenylsulphenyl (Nps), 4-toluenesulphonyl (Tosyl, Tos), pentafluorophenyl (Pfp), diphenylmethyl (Dpm), 2-chlorobenzyloxycarbonyl (Cl-Z), 2,4,5-trichlorophenyl, 2-bromobenzyloxycarbonyl (Br-Z), triphenylmethyl (Trityl, Trt), and 2,5,7,8-pentamethylchroman-6-sulphonyl (Pmc). During chain assembly, Fmoc or Boc are removed resulting in an activated amino-terminus of the amino acid residue bound to the growing chain. The carboxy-terminus of the incoming amino acid is activated by conversion into a highly reactive ester, e.g. by HBTU. With current technologies (e.g. PerSeptive Biosystems 9050 synthesizer, Applied Biosystems Model 431A Peptide Synthesizer), linear peptides of up to 50 residues can be manufactured. A number of guidelines is available to produce peptides that are suitable for use in biological systems including (i) limiting the use of difficult amino acids such as cys, met, trp (easily oxidized and/or degraded during peptide synthesis) or arg; (ii) minimize hydrophobic amino acids (can impair peptide solubility); and (iii) prevent an amino-terminal glutamic acid (can cyclize to pyroglutamate).

By "expressible format" is meant that the isolated nucleic acid molecule is in a form suitable for being transcribed into mRNA and/or translated to produce a protein, either constitutively or following induction by an intracellular or extracellular signal, such as an environmental stimulus or stress (mitogens, anoxia, hypoxia, temperature, salt, light, dehydration, etc) or a chemical compound such as IPTG (isopropyl- β -D-thiogalactopyranoside) or such as an antibiotic (tetracycline, ampicillin, rifampicin, kanamycin), hormone (e.g. gibberellin, auxin, cytokinin, glucocorticoid, brassinosteroid, ethylene, abscisic acid etc), hormone analogue (indolacetic acid (IAA), 2,4-D, etc) , metal (zinc, copper, iron, etc), or dexamethasone, amongst others. As will be known to those skilled in the art, expression of a functional protein may also require one or more post-translational modifications, such as glycosylation, phosphorylation, dephosphorylation, or one or more protein-protein interactions, amongst others. All such processes are included within the scope of the term "expressible format".

Preferably, expression of a protein in a specific cell, tissue, or organ, preferably of plant origin, is effected by introducing and expressing an isolated nucleic acid molecule encoding said protein, such as a cDNA molecule, genomic gene, synthetic oligonucleotide molecule, mRNA molecule or open reading frame, to said cell, tissue or organ, wherein said nucleic acid molecule is placed operably in connection with suitable regulatory or control sequences including a promoter, preferably a plant-expressible promoter, and a terminator sequence.

Reference herein to a "promoter" is to be taken in its broadest context and includes the transcriptional regulatory sequences derived from a classical eukaryotic genomic gene, including the TATA box which is required for accurate transcription initiation, with or without a CCAAT box sequence and additional regulatory or control elements (i.e. upstream activating sequences, enhancers and silencers) which alter gene expression in response to developmental and/or external stimuli, or in a tissue-specific manner.

The term "promoter" also includes the transcriptional regulatory sequences of a classical prokaryotic gene, in which case it may include a -35 box sequence and/or a -10 box transcriptional regulatory sequences.

The term "promoter" is also used to describe a synthetic or fusion molecule, or derivative which confers, activates or enhances expression of a nucleic acid molecule in a cell, tissue or organ.

Promoters may contain additional copies of one or more specific regulatory elements, to further enhance expression and/or to alter the spatial expression and/or temporal expression of a nucleic acid molecule to which it is operably connected. Such regulatory elements may be placed adjacent to a heterologous promoter sequence to drive expression of a nucleic acid molecule in response to e.g. copper, glucocorticoids, dexamethasone, tetracycline, gibberellin, cAMP, abscisic acid, auxin, wounding, ethylene, jasmonate or salicylic acid or to confer expression of a nucleic acid molecule to specific cells, tissues or organs such as meristems, leaves, roots, embryo, flowers, seeds or fruits.

In the context of the present invention, the promoter preferably is a plant-expressible promoter sequence. Promoters that also function or solely function in non-plant cells such as bacteria, yeast cells, insect cells and animal cells are not excluded from the invention. By "plant-expressible" is meant that the promoter sequence, including any additional regulatory elements added thereto or contained therein, is at least capable of inducing, conferring, activating or enhancing expression in a plant cell, tissue or organ, preferably a monocotyledonous or dicotyledonous plant cell, tissue, or organ.

Regulatable promoters as part of a binary viral plant expression system are also known to the skilled artisan (Yadav 1999 – WO9922003; Yadav 2000 – WO0017365).

The terms "plant-operable" and "operable in a plant" when used herein, in respect of a promoter sequence, shall be taken to be equivalent to a plant-expressible promoter sequence.

In the present context, a "regulatable promoter sequence" is a promoter that is capable of conferring expression on a structural gene in a particular cell, tissue, or organ or group of cells, tissues or organs of a plant, optionally under specific conditions, however does generally not confer expression throughout the plant under all conditions.

5 Accordingly, a regulatable promoter sequence may be a promoter sequence that confers expression on a gene to which it is operably connected in a particular location within the plant or alternatively, throughout the plant under a specific set of conditions, such as following induction of gene expression by a chemical compound or other elicitor.

10 Preferably, the regulatable promoter used in the performance of the present invention confers expression in a specific location within the plant, either constitutively or following induction, however not in the whole plant under any circumstances. Included within the scope of such promoters are cell-specific promoter sequences, tissue-specific promoter sequences, organ-specific promoter sequences, cell cycle specific gene promoter sequences, inducible promoter sequences and constitutive promoter sequences that
15 have been modified to confer expression in a particular part of the plant at any one time, such as by integration of said constitutive promoter within a transposable genetic element (*Ac*, *Ds*, *Spm*, *En*, or other transposon).

The term "cell-specific" shall be taken to indicate that expression is predominantly in a particular cell or cell-type, preferably of plant origin, albeit not necessarily exclusively in
20 said cell or cell-type.

Similarly, the term "tissue-specific" shall be taken to indicate that expression is predominantly in a particular tissue or tissue-type, preferably of plant origin, albeit not necessarily exclusively in said tissue or tissue-type.

25 Similarly, the term "organ-specific" shall be taken to indicate that expression is predominantly in a particular organ, preferably of plant origin, albeit not necessarily exclusively in said organ.

30 Similarly, the term "cell cycle specific" shall be taken to indicate that expression is predominantly cyclic and occurring in one or more, not necessarily consecutive phases of the cell cycle albeit not necessarily exclusively in cycling cells, preferably of plant origin.

Those skilled in the art will be aware that an "inducible promoter" is a promoter the transcriptional activity of which is increased or induced in response to a developmental, chemical, environmental, or physical stimulus. Similarly, the skilled craftsman will understand that a "constitutive promoter" is a promoter that is transcriptionally active

throughout most, but not necessarily all parts of an organism, preferably a plant, during most, but not necessarily all phases of its growth and development.

Those skilled in the art will readily be capable of selecting appropriate promoter sequences for use in regulating appropriate expression of the cytokinin oxidase protein
5 from publicly-available or readily-available sources, without undue experimentation.

Placing a nucleic acid molecule under the regulatory control of a promoter sequence, or in operable connection with a promoter sequence, means positioning said nucleic acid molecule such that expression is controlled by the promoter sequence. A promoter is usually, but not necessarily, positioned upstream, or at the 5'-end, and within 2 kb of the
10 start site of transcription, of the nucleic acid molecule which it regulates. In the construction of heterologous promoter/structural gene combinations it is generally preferred to position the promoter at a distance from the gene transcription start site that is approximately the same as the distance between that promoter and the gene it controls in its natural setting (i.e., the gene from which the promoter is derived). As is
15 known in the art, some variation in this distance can be accommodated without loss of promoter function. Similarly, the preferred positioning of a regulatory sequence element with respect to a heterologous gene to be placed under its control is defined by the positioning of the element in its natural setting (i.e., the gene from which it is derived). Again, as is known in the art, some variation in this distance can also occur.

20 Examples of promoters suitable for use in gene constructs of the present invention include those listed in Table 4, amongst others. The promoters listed in Table 4 are provided for the purposes of exemplification only and the present invention is not to be limited by the list provided therein. Those skilled in the art will readily be in a position to provide additional promoters that are useful in performing the present invention.

25 In the case of constitutive promoters or promoters that induce expression throughout the entire plant, it is preferred that such sequences are modified by the addition of nucleotide sequences derived from one or more of the tissue-specific promoters listed in Table 4, or alternatively, nucleotide sequences derived from one or more of the above-mentioned tissue-specific inducible promoters, to confer tissue-specificity thereon. For
30 example, the CaMV 35S promoter may be modified by the addition of maize *Adh1* promoter sequence, to confer anaerobically-regulated root-specific expression thereon, as described previously (Ellis *et al.*, 1987). Another example describes conferring root specific or root abundant gene expression by fusing the CaMV35S promoter to elements

of the maize glycine-rich protein GRP3 gene (Feix and Wulff 2000 - WO0015662). Such modifications can be achieved by routine experimentation by those skilled in the art.

5 The term "terminator" refers to a DNA sequence at the end of a transcriptional unit which signals termination of transcription. Terminators are 3'-non-translated DNA sequences containing a polyadenylation signal, which facilitates the addition of polyadenylate sequences to the 3'-end of a primary transcript. Terminators active in cells derived from viruses, yeasts, moulds, bacteria, insects, birds, mammals and plants are known and described in the literature. They may be isolated from bacteria, fungi, viruses, animals and/or plants.

Table 4. Exemplary plant-expressible promoters for use in the performance of the present invention

I: CELL-SPECIFIC, TISSUE-SPECIFIC, AND ORGAN-SPECIFIC PROMOTERS		
GENE SOURCE	EXPRESSION PATTERN	REFERENCE
α -amylase (<i>Amy32b</i>)	aleurone	Lanahan, M.B., <i>et al.</i> , <i>Plant Cell</i> 4:203-211, 1992; Skriver, K., <i>et al. Proc. Natl. Acad. Sci. (USA)</i> 88: 7266-7270, 1991
cathepsin β -like gene	aleurone	Cejudo, F.J., <i>et al. Plant Molecular Biology</i> 20:849-856, 1992.
<i>Agrobacterium rhizogenes rolB</i>	cambium	Nilsson <i>et al.</i> , <i>Physiol. Plant.</i> 100:456-462, 1997
AtPRP4	flowers	http://salus.medium.edu/mmg/tierney/html
chalcone synthase (<i>chsA</i>)	flowers	Van der Meer, <i>et al.</i> , <i>Plant Mol. Biol.</i> 15, 95-109, 1990.
LAT52	anther	Twell <i>et al</i> <i>Mol. Gen Genet.</i> 217:240-245 (1989)
<i>apetala-3</i>	flowers	
chitinase	fruit (berries, grapes, etc)	Thomas <i>et al.</i> CSIRO Plant Industry, Urrbrae, South Australia, Australia; http://winetitles.com.au/gwrdc/csh95-1.html
<i>rbcs-3A</i>	green tissue (eg leaf)	Lam, E. <i>et al.</i> , <i>The Plant Cell</i> 2: 857-866, 1990.; Tucker <i>et al.</i> , <i>Plant Physiol.</i> 113: 1303-1308, 1992.
leaf-specific genes	leaf	Baszczynski, <i>et al.</i> , <i>Nucl. Acid Res.</i> 16: 4732, 1988.
AtPRP4	leaf	http://salus.medium.edu/mmg/tierney/html
chlorella virus adenine methyltransferase gene promoter	leaf	Mitra and Higgins, 1994, <i>Plant Molecular Biology</i> 26: 85-93
aldP gene promoter from rice	leaf	Kagaya <i>et al.</i> , 1995, <i>Molecular and General Genetics</i> 248: 668-674
<i>rbcs</i> promoter from rice or tomato	leaf	Kyozuka <i>et al.</i> , 1993, <i>Plant Physiology</i> 102: 991-1000
<i>Pinus cab-6</i>	leaf	Yamamoto <i>et al.</i> , <i>Plant Cell Physiol.</i> 35:773-778, 1994.
rubisco promoter	leaf	
<i>cab</i> (chlorophyll)	leaf	

a/b/binding protein		
SAM22	senescent leaf	Crowell, <i>et al.</i> , <i>Plant Mol. Biol.</i> 18: 459-466, 1992.
<i>ltp</i> gene (lipid transfer gene)		Fleming, <i>et al.</i> , <i>Plant J.</i> 2, 855-862.
<i>R. japonicum nif</i> gene	Nodule	United States Patent No. 4, 803, 165
<i>B. japonicum nifH</i> gene	Nodule	United States Patent No. 5, 008, 194
GmENOD40	Nodule	Yang, <i>et al.</i> , <i>The Plant J.</i> 3: 573-585.
PEP carboxylase (PEPC)	Nodule	Pathirana, <i>et al.</i> , <i>Plant Mol. Biol.</i> 20: 437-450, 1992.
leghaemoglobin (Lb)	Nodule	Gordon, <i>et al.</i> , <i>J. Exp. Bot.</i> 44: 1453-1465, 1993.
<i>Tungro bacilliform</i> virus gene	phloem	Bhattacharyya-Pakrasi, <i>et al.</i> , <i>The Plant J.</i> 4: 71-79, 1992.
pollen-specific genes	pollen; microspore	Albani, <i>et al.</i> , <i>Plant Mol. Biol.</i> 15: 605, 1990; Albani, <i>et al.</i> , <i>Plant Mol. Biol.</i> 16: 501, 1991)
Zm13	pollen	Guerrero <i>et al.</i> <i>Mol. Gen. Genet.</i> 224:161-168 (1993)
apg gene	microspore	Twell <i>et al.</i> <i>Sex. Plant Reprod.</i> 6:217-224 (1993)
maize pollen-specific gene	pollen	Hamilton, <i>et al.</i> , <i>Plant Mol. Biol.</i> 18: 211-218, 1992.
sunflower pollen-expressed gene	pollen	Baltz, <i>et al.</i> , <i>The Plant J.</i> 2: 713-721, 1992.
<i>B. napus</i> pollen-specific gene	pollen;anther; tapetum	Arnoldo, <i>et al.</i> , <i>J. Cell. Biochem.</i> , Abstract No. Y101, 204, 1992.
root-expressible genes	roots	Tingey, <i>et al.</i> , <i>EMBO J.</i> 6: 1, 1987.
tobacco auxin-inducible gene	root tip	Van der Zaal, <i>et al.</i> , <i>Plant Mol. Biol.</i> 16, 983, 1991.
β -tubulin	root	Oppenheimer, <i>et al.</i> , <i>Gene</i> 63: 87, 1988.
tobacco root-specific genes	root	Conkling, <i>et al.</i> , <i>Plant Physiol.</i> 93: 1203, 1990.
<i>B. napus</i> G1-3b gene	root	United States Patent No. 5, 401, 836
SbPRP1	roots	Suzuki <i>et al.</i> , <i>Plant Mol. Biol.</i> 21: 109-119, 1993.
AtPRP1; AtPRP3	roots; root hairs	http://salus.medium.edu/mmg/tierney/html
RD2 gene	root cortex	http://www2.cnsu.edu/ncsu/research
TobRB7 gene	root vasculature	http://www2.cnsu.edu/ncsu/research
AtPRP4	leaves; flowers; lateral root primordia	http://salus.medium.edu/mmg/tierney/html
seed-specific genes	seed	Simon, <i>et al.</i> , <i>Plant Mol. Biol.</i> 5: 191,

		1985; Scofield, <i>et al.</i> , <i>J. Biol. Chem.</i> 262: 12202, 1987.; Baszczyński, <i>et al.</i> , <i>Plant Mol. Biol.</i> 14: 633, 1990.
Brazil Nut albumin	seed	Pearson, <i>et al.</i> , <i>Plant Mol. Biol.</i> 18: 235-245, 1992.
legumin	seed	Ellis, <i>et al.</i> , <i>Plant Mol. Biol.</i> 10: 203-214, 1988.
glutelin (rice)	seed	Takaiwa, <i>et al.</i> , <i>Mol. Gen. Genet.</i> 208: 15-22, 1986; Takaiwa, <i>et al.</i> , <i>FEBS Letts.</i> 221: 43-47, 1987.
zein	seed	Matzke <i>et al</i> <i>Plant Mol Biol</i> , 14(3):323-32 1990
napA	seed	Stalberg, <i>et al</i> , <i>Planta</i> 199: 515-519, 1996.
wheat LMW and HMW glutenin-1	endosperm	<i>Mol Gen Genet</i> 216:81-90, 1989; <i>NAR</i> 17:461-2, 1989
wheat SPA	seed	Albani <i>et al</i> , <i>Plant Cell</i> , 9: 171-184, 1997
wheat α , β , γ -gliadins	endosperm	<i>EMBO</i> 3:1409-15, 1984
barley <i>ltr1</i> promoter	endosperm	
barley B1, C, D, hordein	endosperm	<i>Theor Appl Gen</i> 98:1253-62, 1999; <i>Plant J</i> 4:343-55, 1993; <i>Mol Gen Genet</i> 250:750-60, 1996
barley DOF	endosperm	Mena <i>et al</i> , <i>The Plant Journal</i> , 116(1): 53-62, 1998
<i>blz2</i>	endosperm	EP99106056.7
synthetic promoter	endosperm	Vicente-Carbajosa <i>et al.</i> , <i>Plant J.</i> 13: 629-640, 1998.
rice prolamin NRP33	endosperm	Wu <i>et al</i> , <i>Plant Cell Physiology</i> 39(8) 885-889, 1998
rice α -globulin G1b-1	endosperm	Wu <i>et al</i> , <i>Plant Cell Physiology</i> 39(8) 885-889, 1998
rice OSH1	embryo	Sato <i>et al</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 93: 8117-8122, 1996
rice α -globulin REB/OHP-1	endosperm	Nakase <i>et al</i> . <i>Plant Mol. Biol.</i> 33: 513-522, 1997
rice ADP-glucose PP	endosperm	<i>Trans Res</i> 6:157-68, 1997
maize ESR gene family	endosperm	<i>Plant J</i> 12:235-46, 1997
sorgum γ -kafirin	endosperm	<i>PMB</i> 32:1029-35, 1996
KNOX	embryo	Postma-Haarsma <i>et al</i> , <i>Plant Mol. Biol.</i> 39:257-71, 1999
rice oleosin	embryo and aleuron	Wu <i>et al</i> , <i>J. Biochem.</i> , 123:386, 1998
sunflower oleosin	seed (embryo and dry seed)	Cummins, <i>et al.</i> , <i>Plant Mol. Biol.</i> 19: 873-876, 1992
LEAFY	shoot meristem	Weigel <i>et al.</i> , <i>Cell</i> 69:843-859, 1992.

<i>Arabidopsis thaliana</i> <i>knat1</i>	shoot meristem	Accession number AJ131822
<i>Malus domestica</i> <i>kn1</i>	shoot meristem	Accession number Z71981
<i>CLAVATA1</i>	shoot meristem	Accession number AF049870
stigma-specific genes	stigma	Nasrallah, et al., Proc. Natl. Acad. Sci. USA 85: 5551, 1988; Trick, et al., <i>Plant Mol. Biol.</i> 15: 203, 1990.
class I patatin gene	tuber	Liu et al., <i>Plant Mol. Biol.</i> 153:386-395, 1991.
PCNA rice	meristem	Kosugi et al, <i>Nucleic Acids Research</i> 19:1571-1576, 1991; Kosugi S. and Ohashi Y, <i>Plant Cell</i> 9:1607-1619, 1997.
Pea TubA1 tubulin	Dividing cells	Stotz and Long, <i>Plant Mol.Biol.</i> 41, 601-614. 1999
<i>Arabidopsis</i> <i>cdc2a</i>	cycling cells	Chung and Parish, FEBS Lett, 3;362(2):215-9, 1995
<i>Arabidopsis</i> Rop1A	Anthers; mature pollen + pollen tubes	Li et al. 1998 <i>Plant Physiol</i> 118, 407-417.
<i>Arabidopsis</i> AtDMC1	Meiosis-associated	Klimyuk and Jones 1997 <i>Plant J.</i> 11, 1-14.
Pea PS-IAA4/5 and PS-IAA6	Auxin-inducible	Wong et al. 1996 <i>Plant J.</i> 9, 587-599.
Pea farnesyltransferase	Meristematic tissues; phloem near growing tissues; light- and sugar-repressed	Zhou et al. 1997 <i>Plant J.</i> 12, 921-930
Tobacco (<i>N. sylvestris</i>) cyclin B1;1	Dividing cells / meristematic tissue	Trehin et al. 1997 <i>Plant Mol.Biol.</i> 35, 667-672.
<i>Catharanthus roseus</i> Mitotic cyclins CYS (A-type) and CYM (B-type)	Dividing cells / meristematic tissue	Ito et al. 1997 <i>Plant J.</i> 11, 983-992
<i>Arabidopsis</i> <i>cyc1At</i> (=cyc B1;1) and <i>cyc3aAt</i> (A-type)	Dividing cells / meristematic tissue	Shaul et al. 1996 <i>Proc.Natl.Acad.Sci.U.S.A</i> 93, 4868-4872.
<i>Arabidopsis</i> <i>tef1</i> promoter box	Dividing cells / meristematic tissue	Regad et al. 1995 <i>Mol.Gen.Genet.</i> 248, 703-711.
<i>Catharanthus roseus</i> <i>cyc07</i>	Dividing cells / meristematic tissue	Ito et al. 1994 <i>Plant Mol.Biol.</i> 24, 863-878.

Table 4 (continued). Exemplary plant-expressible promoters for use in the performance of the present invention

II: EXEMPLARY CONSTITUTIVE PROMOTERS		
GENE SOURCE	EXPRESSION PATTERN	REFERENCE
Actin	constitutive	McElroy <i>et al</i> , Plant Cell, 2: 163-171, 1990
CAMV 35S	constitutive	Odell <i>et al</i> , Nature, 313: 810-812, 1985
CaMV 19S	constitutive	Nilsson <i>et al.</i> , Physiol. Plant. 100:456-462, 1997
GOS2	constitutive	de Pater <i>et al</i> , Plant J. 2:837-844, 1992
ubiquitin	constitutive	Christensen <i>et al</i> , Plant Mol. Biol. 18: 675-689, 1992
rice cyclophilin	constitutive	Buchholz <i>et al</i> , Plant Mol Biol. 25: 837-843, 1994
maize histone H3	constitutive	Lepetit <i>et al</i> , Mol. Gen. Genet. 231:276-285, 1992
alfalfa histone H3	constitutive	Wu <i>et al.</i> , Nucleic Acids Res. 17: 3057-3063, 1989; Wu <i>et al.</i> , Plant Mol. Biol. 11:641-649, 1988
actin 2	constitutive	An <i>et al</i> , Plant J. 10(1); 107-121, 1996

Table 4 (continued). Exemplary plant-expressible promoters for use in the performance of the present invention

III: EXEMPLARY STRESS-INDUCIBLE PROMOTERS		
NAME	STRESS	REFERENCE
P5CS (delta(1)-pyrroline-5-carboxylate syntase)	salt, water	Zhang et al. Plant Science. 129: 81-89, 1997
cor15a	cold	Hajela et al., Plant Physiol. 93: 1246-1252, 1990
cor15b	cold	Wlihelm et al., Plant Mol Biol. 23:1073-1077, 1993
cor15a (-305 to +78 nt)	cold, drought	Baker et al., Plant Mol Biol. 24: 701-713, 1994
rd29	salt, drought, cold	Kasuga et al., Nature Biotechnology 18:287-291, 1999
heat shock proteins, including artificial promoters containing the heat shock element (HSE)	heat	Barros et al., Plant Mol Biol 19: 665-75, 1992. Marrs et al., Dev Genet.14: 27-41, 1993. Schoffl et al., Mol Gen Gent, 217: 246-53, 1989.
smHSP (small heat shock proteins)	heat	Waters et al, J Experimental Botany 47:325-338, 1996
wcs120	cold	Ouellet et al., FEBS Lett. 423: 324-328, 1998
ci7	cold	Kirch et al., Plant Mol Biol 33: 897-909, 1997
Adh	cold, drought, hypoxia	Dolferus et al., Plant Physiol 105: 1075-87, 1994
pws18	water: salt and drought	Joshee et al., Plant Cell Physiol 39: 64-72, 1998
ci21A	cold	Schneider et al., Plant Physiol 113: 335-45, 1997
Trg-31	drought	Chaudhary et al., Plant Mol Biol 30: 1247-57, 1996
osmotin	osmotic	Raghothama et al., Plant Mol Biol 23: 1117-28, 1993
Rab17	osmotic, ABA	Vilardell et al., Plant Mol Biol 17: 985-93, 1991
lapA	wounding, enviromental	WO99/03977 University of California/INRA

Table 4 (continued). Exemplary plant-expressible promoters for use in the performance of the present invention

5

IV: EXEMPLARY PATHOGEN-INDUCIBLE PROMOTERS		
NAME	PATHOGEN	REFERENCE
RB7	Root-knot nematodes (Meloidogyne spp.)	US5760386 - North Carolina State University; Opperman et al (1994) <i>Science</i> 263: 221-23.
PR-1, 2, 3, 4, 5, 8, 11	fungal, viral, bacterial	Ward et al (1991) <i>Plant Cell</i> 3: 1085-1094; Reiss et al 1996; Lebel et al (1998), <i>Plant J</i> , 16(2):223-33; Melchers et al (1994), <i>Plant J</i> , 5(4):469-80; Lawton et al (1992), <i>Plant Mol Biol</i> , 19(5):735-43.
HMG2	nematodes	WO9503690 - Virginia Tech Intellectual Properties Inc .
Abi3	Cyst nematodes (Heterodera spp.)	Unpublished
ARM1	nematodes	Barthels et al., (1997) <i>The Plant Cell</i> 9, 2119-2134. WO 98/31822 – Plant Genetic Systems
Att0728	nematodes	Barthels et al., (1997) <i>The Plant Cell</i> 9, 2119-2134. <i>PCT/EP98/07761</i>
Att1712	nematodes	Barthels et al., (1997) <i>The Plant Cell</i> 9, 2119-2134. <i>PCT/EP98/07761</i>
Gst1	Different types of pathogens	Strittmatter et al (1996) <i>Mol. Plant-Microbe Interact.</i> 9, 68-73.
LEMMI	nematodes	WO 92/21757 – Plant Genetic Systems
CLE	geminivirus	<i>PCT/EP99/03445 - CINESTAV</i>
PDF1.2	Fungal including <i>Alternaria brassicicola</i> and <i>Botrytis cinerea</i>	Manners et al (1998), <i>Plant Mol Biol</i> , 38(6):1071-80.
Thi2.1	Fungal – <i>Fusarium oxysporum f sp. matthiolae</i>	Vignutelli et al (1998) <i>Plant J</i> ;14(3):285-95
DB#226	nematodes	Bird and Wilson (1994) <i>Mol. Plant-Microbe Interact.</i> , 7, 419-42 WO 95.322888

DB#280	nematodes	Bird and Wilson (1994) Mol. Plant-Microbe Interact., 7, 419-42 WO 95.322888
Cat2	nematodes	Niebel et al (1995) Mol Plant Microbe Interact 1995 May-Jun;8(3):371-8
□Tub	nematodes	Aristizabal et al (1996), 8 th International Congress on Plant-Microbe Interaction, Knoxville US B-29
SHSP	nematodes	Fenoll et al (1997) In: Cellular and molecular aspects of plant-nematode interactions. Kluwer Academic, C. Fenoll, F.M.W. Grundler and S.A. Ohi (Eds.),
Tsw12	nematodes	Fenoll et al (1997) In: Cellular and molecular aspects of plant-nematode interactions. Kluwer Academic, C. Fenoll, F.M.W. Grundler and S.A. Ohi (Eds.)
Hs1(pro1)	nematodes	WO 98/122335 - Jung
NsLTP	viral, fungal, bacterial	Molina & García-Olmedo (1993) FEBS Lett, 316(2):119-22
RIP	viral, fungal	Tumer et al (1997) Proc Natl Acad Sci U S A, 94(8):3866-71

Examples of terminators particularly suitable for use in the gene constructs of the present invention include the *Agrobacterium tumefaciens* nopaline synthase (NOS) gene terminator, the *Agrobacterium tumefaciens* octopine synthase (OCS) gene terminator sequence, the Cauliflower mosaic virus (CaMV) 35S gene terminator sequence, the *Oryza sativa* ADP-glucose pyrophosphorylase terminator sequence (t3'Bt2), the *Zea mays* zein gene terminator sequence, the *rbcS-1A* gene terminator, and the *rbcS-3A* gene terminator sequences, amongst others.

Preferred promoter sequences of the invention include root specific promoters such as but not limited to the ones listed in Table 5 and as outlined in the Examples.

Table 5. Exemplary root specific promoters for use in the performance of the present invention

NAME	ORIGIN	REFERENCE
SbPRP1	Soybean	Suzuki et al., Plant Mol Biol, 21: 109-119, 1993
636 bp fragment of TobRB7	Tobacco	Yamamoto et al., Plant Cell 3:371-382, 1991
GGPS3	Arabidopsis	Okada et al., Plant Physiol 122: 1045-1056, 2000
580 bp fragment of prxEa	Arabidopsis	Wanapu and Shinmyo, Ann N Y Acad Sci 782: 107-114, 1996
lds2 promoter	Barley	Okumura et al., Plant Mol Biol 25: 705-719, 1994
AtPRP3	Arabidopsis	Fowler et al., Plant Physiol 121: 1081-1092, 1999

5

Those skilled in the art will be aware of additional promoter sequences and terminator sequences which may be suitable for use in performing the invention. Such sequences may readily be used without any undue experimentation.

10 In the context of the current invention, "ectopic expression" or "ectopic overexpression" of a gene or a protein are conferring to expression patterns and/or expression levels of said gene or protein normally not occurring under natural conditions, more specifically is meant increased expression and/or increased expression levels. Ectopic expression can be achieved in a number of ways including operably linking of a coding sequence encoding said protein to an isolated homologous or heterologous promoter in order to
15 create a chimeric gene and/or operably linking said coding sequence to its own isolated promoter (i.e. the unisolated promoter naturally driving expression of said protein) in order to create a recombinant gene duplication or gene multiplication effect. With "ectopic co-expression" is meant the ectopic expression or ectopic overexpression of two or more genes or proteins. The same or, more preferably, different promoters are
20 used to confer ectopic expression of said genes or proteins.

Preferably, the promoter sequence used in the context of the present invention is operably linked to a coding sequence or open reading frame (ORF) encoding a cytokinin

oxidase protein or a homologue, derivative or an immunologically active and/or functional fragment thereof as defined supra.

"Downregulation of expression" as used herein means lowering levels of gene expression and/or levels of active gene product and/or levels of gene product activity.

5 Decreases in expression may be accomplished by e.g. the addition of coding sequences or parts thereof in a sense orientation (if resulting in co-suppression) or in an antisense orientation relative to a promoter sequence and furthermore by e.g. insertion mutagenesis (e.g. T-DNA insertion or transposon insertion) or by gene silencing strategies as described by e.g. Angell and Baulcombe (1998 - WO9836083), Lowe et al.
10 (1989 - WO9853083), Lederer et al. (1999 - WO9915682) or Wang et al. (1999 - WO9953050). Genetic constructs aimed at silencing gene expression may have the nucleotide sequence of said gene (or one or more parts thereof) contained therein in a sense and/or antisense orientation relative to the promoter sequence. Another method to downregulate gene expression comprises the use of ribozymes.

15 Modulating, including lowering, the level of active gene products or of gene product activity can be achieved by administering or exposing cells, tissues, organs or organisms to said gene product, a homologue, derivative and/or immunologically active fragment thereof. Immunomodulation is another example of a technique capable of downregulation levels of active gene product and/or of gene product activity and
20 comprises administration of or exposing to or expressing antibodies to said gene product to or in cells, tissues, organs or organisms wherein levels of said gene product and/or gene product activity are to be modulated. Such antibodies comprise "plantibodies", single chain antibodies, IgG antibodies and heavy chain camel antibodies as well as fragments thereof.

25 Modulating, including lowering, the level of active gene products or of gene product activity can furthermore be achieved by administering or exposing cells, tissues, organs or organisms to an agonist of said gene product or the activity thereof. Such agonists include proteins (comprising e.g. kinases and proteinases) and chemical compounds identified according to the current invention as described supra.

30 In the context of the current invention is envisaged the downregulation of the expression of a cytokinin oxidase gene as defined higher. Preferably said cytokinin oxidase gene is a plant cytokinin oxidase gene, more specifically an *AtCKX*. The invention further comprises downregulation of levels of a cytokinin oxidase protein or of a cytokinin oxidase activity whereby said cytokinin oxidase protein has been defined supra.

Preferably said cytokinin oxidase protein is a plant cytokinin oxidase, more specifically an AtCKX.

By "modifying cell fate and/or plant development and/or plant morphology and/or biochemistry and/or physiology" is meant that one or more developmental and/or morphological and/or biochemical and/or physiological characteristics of a plant is altered by the performance of one or more steps pertaining to the invention described herein.

"Cell fate" refers to the cell-type or cellular characteristics of a particular cell that are produced during plant development or a cellular process therefor, in particular during the cell cycle or as a consequence of a cell cycle process.

"Plant development" or the term "plant developmental characteristic" or similar term shall, when used herein, be taken to mean any cellular process of a plant that is involved in determining the developmental fate of a plant cell, in particular the specific tissue or organ type into which a progenitor cell will develop. Cellular processes relevant to plant development will be known to those skilled in the art. Such processes include, for example, morphogenesis, photomorphogenesis, shoot development, root development, vegetative development, reproductive development, stem elongation, flowering, and regulatory mechanisms involved in determining cell fate, in particular a process or regulatory process involving the cell cycle.

"Plant morphology" or the term "plant morphological characteristic" or similar term will, when used herein, be understood by those skilled in the art to refer to the external appearance of a plant, including any one or more structural features or combination of structural features thereof. Such structural features include the shape, size, number, position, colour, texture, arrangement, and patternation of any cell, tissue or organ or groups of cells, tissues or organs of a plant, including the root, stem, leaf, shoot, petiole, trichome, flower, petal, stigma, style, stamen, pollen, ovule, seed, embryo, endosperm, seed coat, aleurone, fibre, fruit, cambium, wood, heartwood, parenchyma, aerenchyma, sieve element, phloem or vascular tissue, amongst others.

"Plant biochemistry" or the term "plant biochemical characteristic" or similar term will, when used herein, be understood by those skilled in the art to refer to the metabolic and catalytic processes of a plant, including primary and secondary metabolism and the products thereof, including any small molecules, macromolecules or chemical compounds, such as but not limited to starches, sugars, proteins, peptides, enzymes, hormones, growth factors, nucleic acid molecules, celluloses, hemicelluloses, calloses,

lectins, fibres, pigments such as anthocyanins, vitamins, minerals, micronutrients, or macronutrients, that are produced by plants.

"Plant physiology" or the term "plant physiological characteristic" or similar term will, when used herein, be understood to refer to the functional processes of a plant, including developmental processes such as growth, expansion and differentiation, sexual development, sexual reproduction, seed set, seed development, grain filling, asexual reproduction, cell division, dormancy, germination, light adaptation, photosynthesis, leaf expansion, fibre production, secondary growth or wood production, amongst others; responses of a plant to externally-applied factors such as metals, chemicals, hormones, growth factors, environment and environmental stress factors (eg. anoxia, hypoxia, high temperature, low temperature, dehydration, light, daylength, flooding, salt, heavy metals, amongst others), including adaptive responses of plants to said externally-applied factors.

Means for introducing recombinant DNA into plant tissue or cells include, but are not limited to, transformation using CaCl_2 and variations thereof, in particular the method described by Hanahan (1983), direct DNA uptake into protoplasts (Krens *et al.*, 1982; Paszkowski *et al.*, 1984), PEG-mediated uptake to protoplasts (Armstrong *et al.*, 1990) microparticle bombardment, electroporation (Fromm *et al.*, 1985), microinjection of DNA (Crossway *et al.*, 1986), microparticle bombardment of tissue explants or cells (Christou *et al.*, 1988; Sanford, 1988), vacuum-infiltration of tissue with nucleic acid, or in the case of plants, T-DNA-mediated transfer from *Agrobacterium* to the plant tissue as described essentially by An *et al.* (1985), Dodds *et al.*, (1985), Herrera-Estrella *et al.* (1983a, 1983b, 1985). Methods for transformation of monocotyledonous plants are well known in the art and include *Agrobacterium*-mediated transformation (Cheng *et al.*, 1997 - WO9748814; Hansen 1998 - WO9854961; Hiei *et al.*, 1994 - WO9400977; Hiei *et al.*, 1998 - WO9817813; Rikiishi *et al.*, 1999 - WO9904618; Saito *et al.*, 1995 - WO9506722), microprojectile bombardment (Adams *et al.*, 1999 - US5969213; Bowen *et al.*, 1998 - US5736369; Chang *et al.*, 1994 - WO9413822; Lundquist *et al.*, 1999 - US5874265/US5990390; Vasil and Vasil, 1995 - US5405765. Walker *et al.*, 1999 - US5955362), DNA uptake (Eyal *et al.*, 1993 - WO9318168), microinjection of *Agrobacterium* cells (von Holt, 1994 - DE4309203) and sonication (Finer *et al.*, 1997 - US5693512).

For microparticle bombardment of cells, a microparticle is propelled into a cell to produce a transformed cell. Any suitable ballistic cell transformation methodology and apparatus

can be used in performing the present invention. Exemplary apparatus and procedures are disclosed by Stomp *et al.* (U.S. Patent No. 5,122,466) and Sanford and Wolf (U.S. Patent No. 4,945,050). When using ballistic transformation procedures, the gene construct may incorporate a plasmid capable of replicating in the cell to be transformed.

5 Examples of microparticles suitable for use in such systems include 1 to 5 μ m gold spheres. The DNA construct may be deposited on the microparticle by any suitable technique, such as by precipitation.

A whole plant may be regenerated from the transformed or transfected cell, in accordance with procedures well known in the art. Plant tissue capable of subsequent
10 clonal propagation, whether by organogenesis or embryogenesis, may be transformed with a gene construct of the present invention and a whole plant regenerated therefrom. The particular tissue chosen will vary depending on the clonal propagation systems available for, and best suited to, the particular species being transformed. Exemplary tissue targets include leaf disks, pollen, embryos, cotyledons, hypocotyls,
15 megagametophytes, callus tissue, existing meristematic tissue (e.g., apical meristem, axillary buds, and root meristems), and induced meristem tissue (e.g., cotyledon meristem and hypocotyl meristem).

The term "organogenesis", as used herein, means a process by which shoots and roots are developed sequentially from meristematic centres.

20 The term "embryogenesis", as used herein, means a process by which shoots and roots develop together in a concerted fashion (not sequentially), whether from somatic cells or gametes.

Preferably, the plant is produced according to the inventive method is transfected or transformed with a genetic sequence, or amenable to the introduction of a protein, by
25 any art-recognized means, such as microprojectile bombardment, microinjection, *Agrobacterium*-mediated transformation (including *in planta* transformation), protoplast fusion, or electroporation, amongst others. Most preferably said plant is produced by *Agrobacterium*-mediated transformation.

Agrobacterium-mediated transformation or agrolistic transformation of plants, yeast,
30 moulds or filamentous fungi is based on the transfer of part of the transformation vector sequences, called the T-DNA, to the nucleus and on integration of said T-DNA in the genome of said eukaryote.

With "*Agrobacterium*" is meant a member of the *Agrobacteriaceae*, more preferably *Agrobacterium* or *Rhizobacterium* and most preferably *Agrobacterium tumefaciens*.

With "T-DNA", or transferred DNA, is meant that part of the transformation vector flanked by T-DNA borders which is, after activation of the *Agrobacterium vir* genes, nicked at the T-DNA borders and is transferred as a single stranded DNA to the nucleus of an eukaryotic cell.

5 When used herein, with "T-DNA borders", "T-DNA border region", or "border region" are meant either right T-DNA border (RB) or left T-DNA border (LB). Such a border comprises a core sequence flanked by a border inner region as part of the T-DNA flanking the border and/or a border outer region as part of the vector backbone flanking the border. The core sequences comprise 22 bp in case of octopine-type vectors and 25
10 bp in case of nopaline-type vectors. The core sequences in the right border region and left border region form imperfect repeats. Border core sequences are indispensable for recognition and processing by the *Agrobacterium* nicking complex consisting of at least VirD1 and VirD2. Core sequences flanking a T-DNA are sufficient to promote transfer of said T-DNA. However, efficiency of transformation using transformation vectors carrying
15 said T-DNA solely flanked by said core sequences is low. Border inner and outer regions are known to modulate efficiency of T-DNA transfer (Wang et al. 1987). One element enhancing T-DNA transfer has been characterized and resides in the right border outer region and is called *overdrive* (Peralta et al. 1986, van Haaren et al. 1987).

With "T-DNA transformation vector" or "T-DNA vector" is meant any vector
20 encompassing a T-DNA sequence flanked by a right and left T-DNA border consisting of at least the right and left border core sequences, respectively, and used for transformation of any eukaryotic cell.

With "T-DNA vector backbone sequence" or "T-DNA vector backbone sequences" is meant all DNA of a T-DNA containing vector that lies outside of the T-DNA borders and,
25 more specifically, outside the nicking sites of the border core imperfect repeats.

The current invention includes optimized T-DNA vectors such that vector backbone integration in the genome of a eukaryotic cell is minimized or absent. With "optimized T-DNA vector" is meant a T-DNA vector designed either to decrease or abolish transfer of vector backbone sequences to the genome of a eukaryotic cell. Such T-DNA vectors are
30 known to the one familiar with the art and include those described by Hanson et al. (1999) and by Stuiver et al. (1999 - WO9901563).

The current invention clearly considers the inclusion of a DNA sequence encoding a cytokinin oxidase, homologue, derivative or immunologically active and/or functional fragment thereof as defined supra, in any T-DNA vector comprising binary

transformation vectors, super-binary transformation vectors, co-integrate transformation vectors, Ri-derived transformation vectors as well as in T-DNA carrying vectors used in agrolistic transformation. Preferably, said cytokinin oxidase is a plant cytokinin oxidase, more specifically an *Arabidopsis thaliana* (At)CKX.

- 5 With "binary transformation vector" is meant a T-DNA transformation vector comprising:
- (a) a T-DNA region comprising at least one gene of interest and/or at least one selectable marker active in the eukaryotic cell to be transformed; and
 - (b) a vector backbone region comprising at least origins of replication active in *E. coli* and *Agrobacterium* and markers for selection in *E. coli* and *Agrobacterium*.

- 10 The T-DNA borders of a binary transformation vector can be derived from octopine-type or nopaline-type Ti plasmids or from both. The T-DNA of a binary vector is only transferred to a eukaryotic cell in conjunction with a helper plasmid.

With "helper plasmid" is meant a plasmid that is stably maintained in *Agrobacterium* and is at least carrying the set of *vir* genes necessary for enabling transfer of the T-DNA.

- 15 Said set of *vir* genes can be derived from either octopine-type or nopaline-type Ti plasmids or from both.

With "super-binary transformation vector" is meant a binary transformation vector additionally carrying in the vector backbone region a *vir* region of the Ti plasmid pTiBo542 of the super-virulent *A. tumefaciens* strain A281 (EP0604662, EP0687730).

- 20 Super-binary transformation vectors are used in conjunction with a helper plasmid.

With "co-integrate transformation vector" is meant a T-DNA vector at least comprising:

- (a) a T-DNA region comprising at least one gene of interest and/or at least one selectable marker active in plants; and
 - (b) a vector backbone region comprising at least origins of replication active in *Escherichia coli* and *Agrobacterium*, and markers for selection in *E. coli* and *Agrobacterium*, and a set of *vir* genes necessary for enabling transfer of the T-DNA.
- 25

The T-DNA borders and said set of *vir* genes of a said T-DNA vector can be derived from either octopine-type or nopaline-type Ti plasmids or from both.

- 30 With "Ri-derived plant transformation vector" is meant a binary transformation vector in which the T-DNA borders are derived from a Ti plasmid and said binary transformation vector being used in conjunction with a 'helper' Ri-plasmid carrying the necessary set of *vir* genes.

As used herein, the term "selectable marker gene" or "selectable marker" or "marker for selection" includes any gene which confers a phenotype on a cell in which it is expressed to facilitate the identification and/or selection of cells which are transfected or transformed with a gene construct of the invention or a derivative thereof. Suitable
5 selectable marker genes contemplated herein include the ampicillin resistance (Amp^r), tetracycline resistance gene (Tc^r), bacterial kanamycin resistance gene (Kan^r), phosphinothricin resistance gene, neomycin phosphotransferase gene (*nptII*), hygromycin resistance gene, β -glucuronidase (GUS) gene, chloramphenicol acetyltransferase (CAT) gene, green fluorescent protein (*gfp*) gene (Haseloff *et al*,
10 1997), and luciferase gene, amongst others.

With "agrolistics", "agrolistic transformation" or "agrolistic transfer" is meant here a transformation method combining features of *Agrobacterium*-mediated transformation and of biolistic DNA delivery. As such, a T-DNA containing target plasmid is co-delivered with DNA/RNA enabling in planta production of VirD1 and VirD2 with or without VirE2
15 (Hansen and Chilton 1996; Hansen et al. 1997; Hansen and Chilton 1997 - WO9712046).

With "foreign DNA" is meant any DNA sequence that is introduced in the host's genome by recombinant techniques. Said foreign DNA includes e.g. a T-DNA sequence or a part thereof such as the T-DNA sequence comprising the selectable marker in an expressible
20 format. Foreign DNA furthermore include intervening DNA sequences as defined supra.

With "recombination event" is meant either a site-specific recombination event or a recombination event effected by transposon 'jumping'.

With "recombinase" is meant either a site-specific recombinase or a transposase.

With "recombination site" is meant either site-specific recombination sites or transposon
25 border sequences.

With "site specific recombination event" is meant an event catalyzed by a system generally consisting of three elements: a pair of DNA sequences (the site-specific recombination sequences or sites) and a specific enzyme (the site-specific recombinase). The site-specific recombinase catalyzes a recombination reaction only
30 between two site-specific recombination sequences depending on the orientation of the site-specific recombination sequences. Sequences intervening between two site-specific recombination sites will be inverted in the presence of the site-specific recombinase when the site-specific recombination sequences are oriented in opposite directions relative to one another (i.e. inverted repeats). If the site-specific recombination

sequences are oriented in the same direction relative to one another (i.e. direct repeats), then any intervening sequences will be deleted upon interaction with the site-specific recombinase. Thus, if the site-specific recombination sequences are present as direct repeats at both ends of a foreign DNA sequence integrated into a eukaryotic genome, such integration of said sequences can subsequently be reversed by interaction of the site-specific recombination sequences with the corresponding site specific recombinase.

A number of different site specific recombinase systems can be used including but not limited to the Cre/lox system of bacteriophage P1, the FLP/FRT system of yeast, the Gin recombinase of phage Mu, the Pin recombinase of *E. coli*, the PinB, PinD and PinF from *Shigella*, and the R/RS system of the pSR1 plasmid. Recombinases generally are integrases, resolvases or flippases. Also dual-specific recombinases can be used in conjunction with direct or indirect repeats of two different site-specific recombination sites corresponding to the dual-specific recombinase (WO99/25840). The two preferred site-specific recombinase systems are the bacteriophage P1 Cre/lox and the yeast FLP/FRT systems. In these systems a recombinase (Cre or FLP) interact specifically with its respective site-specific recombination sequence (lox or FRT respectively) to invert or excise the intervening sequences. The site-specific recombination sequences for each of these two systems are relatively short (34 bp for lox and 47 bp for FRT). Some of these systems have already been used with high efficiency in plants such as tobacco (Dale et al. 1990) and *Arabidopsis* (Osborne et al. 1995). Site-specific recombination systems have many applications in plant molecular biology including methods for control of homologous recombination (e.g. US5527695), for targeted insertion, gene stacking, etc. (WO99/25821) and for resolution of complex T-DNA integration patterns or for excision of a selectable marker (WO99/23202).

Although the site-specific recombination sequences must be linked to the ends of the DNA to be excised or to be inverted, the gene encoding the site specific recombinase may be located elsewhere. For example, the recombinase gene could already be present in the eukaryote's DNA or could be supplied by a later introduced DNA fragment either introduced directly into cells, through crossing or through cross-pollination. Alternatively, a substantially purified recombinase protein could be introduced directly into the eukaryotic cell, e.g. by micro-injection or particle bombardment. Typically, the site-specific recombinase coding region will be operably linked to regulatory sequences enabling expression of the site-specific recombinase in the eukaryotic cell.

With "recombination event effected by transposon jumping" or "transposase-mediated recombination" is meant a recombination event catalyzed by a system consisting of three elements: a pair of DNA sequences (the transposon border sequences) and a specific enzyme (the transposase). The transposase catalyzes a recombination reaction only between two transposon border sequences which are arranged as inverted repeats. A number of different transposon/transposase systems can be used including but not limited to the Ds/Ac system, the Spm system and the Mu system. These systems originate from corn but it has been shown that at least the Ds/Ac and the Spm system also function in other plants (Fedoroff et al. 1993, Schlappi et al. 1993, Van Sluys et al. 1987). Preferred are the Ds- and the Spm-type transposons which are delineated by 11 bp- and 13 bp- border sequences, respectively.

Although the transposon border sequences must be linked to the ends of the DNA to be excised, the gene encoding the transposase may be located elsewhere. For example, the recombinase gene could already be present in the eukaryote's DNA or could be supplied by a later introduced DNA fragment either introduced directly into cells, through crossing or through cross-pollination. Alternatively, a substantially purified transposase protein could be introduced directly into cells, e.g. by microinjection or by particle bombardment.

As part of the current invention, transposon border sequences are included in a foreign DNA sequence such that they lie outside said DNA sequence and transform said DNA into a transposon-like entity that can move by the action of a transposase.

As transposons often reintegrate at another locus of the host's genome, segregation of the progeny of the hosts in which the transposase was allowed to act might be necessary to separate transformed hosts containing e.g. only the transposon footprint and transformed hosts still containing the foreign DNA.

In performing the present invention, the genetic element is preferably induced to mobilize, such as, for example, by the expression of a recombinase protein in the cell which contacts the integration site of the genetic element and facilitates a recombination event therein, excising the genetic element completely, or alternatively, leaving a "footprint", generally of about 20 nucleotides in length or greater, at the original integration site. Those hosts and host parts that have been produced according to the inventive method can be identified by standard nucleic acid hybridization and/or amplification techniques to detect the presence of the mobilizable genetic element or a gene construct comprising the same. Alternatively, in the case of transformed host cells,

tissues, and hosts wherein the mobilizable genetic element has been excised, it is possible to detect a footprint in the genome of the host which has been left following the excision event, using such techniques. As used herein, the term "footprint" shall be taken to refer to any derivative of a mobilizable genetic element or gene construct comprising the same as described herein which is produced by excision, deletion or other removal of the mobilizable genetic element from the genome of a cell transformed previously with said gene construct. A footprint generally comprises at least a single copy of the recombination loci or transposon used to promote excision. However, a footprint may comprise additional sequences derived from the gene construct, for example nucleotide sequences derived from the left border sequence, right border sequence, origin of replication, recombinase-encoding or transposase-encoding sequence if used, or other vector-derived nucleotide sequences. Accordingly, a footprint is identifiable according to the nucleotide sequence of the recombination locus or transposon of the gene construct used, such as, for example, a sequence of nucleotides corresponding or complementary to a *lox* site or *frt* site.

The term "cell cycle" means the cyclic biochemical and structural events associated with growth and with division of cells, and in particular with the regulation of the replication of DNA and mitosis. Cell cycle includes phases called: G0, Gap1 (G1), DNA synthesis (S), Gap2 (G2), and mitosis (M). Normally these four phases occur sequentially, however, the cell cycle also includes modified cycles wherein one or more phases are absent resulting in modified cell cycle such as endomitosis, acytokinesis, polyploidy, polyteny, and endoreduplication.

The term "cell cycle progression" refers to the process of passing through the different cell cycle phases. The term "cell cycle progression rate" accordingly refers to the speed at which said cell cycle phases are run through or the time spans required to complete said cell cycle phases.

With "two-hybrid assay" is meant an assay that is based on the observation that many eukaryotic transcription factors comprise two domains, a DNA-binding domain (DB) and an activation domain (AD) which, when physically separated (i.e. disruption of the covalent linkage) do not effectuate target gene expression. Two proteins able to interact physically with one of said proteins fused to DB and the other of said proteins fused to AD will re-unite the DB and AD domains of the transcription factor resulting in target gene expression. The target gene in the yeast two-hybrid assay is usually a reporter gene such as the β -galactosidase gene. Interaction between protein partners in the

yeast two-hybrid assay can thus be quantified by measuring the activity of the reporter gene product (Bartel and Fields 1997). Alternatively, a mammalian two-hybrid system can be used which includes e.g. a chimeric green fluorescent protein encoding reporter gene (Shioda *et al.*, 2000).

5 Furthermore, folding simulations and computer redesign of structural motifs of the protein of the invention can be performed using appropriate computer programs (Olszewski, *Proteins* 25 (1996), 286-299; Hoffman, *Comput. Appl. Biosci.* 1 (1995), 675-679). Computer modeling of protein folding can be used for the conformational and energetic analysis of detailed peptide and protein models (Monge, *J. Mol. Biol.* 247
10 (1995), 995-1012; Renouf, *Adv. Exp. Med. Biol.* 376 (1995), 37-45). In particular, the appropriate programs can be used for the identification of interactive sites of the cytokinin oxidases, its ligands or other interacting proteins by computer assisted searches for complementary peptide sequences (Fassina, *Immunomethods* 5 (1994), 114-120). Further appropriate computer systems for the design of protein and peptides
15 are described in the prior art, for example in Berry, *Biochem. Soc. Trans.* 22 (1994), 1033-1036; Wodak, *Ann. N. Y. Acad. Sci.* 501 (1987), 1-13; Pabo, *Biochemistry* 25 (1986), 5987-5991. The results obtained from the above-described computer analysis can be used for, e.g. the preparation of peptidomimetics of the protein of the invention or fragments thereof. Such pseudopeptide analogues of the natural amino acid sequence
20 of the protein may very efficiently mimic the parent protein (Benkirane, *J. Biol. Chem.* 271 (1996), 33218-33224). For example, incorporation of easily available achiral Ω -amino acid residues into a protein of the invention or a fragment thereof results in the substitution of amino bonds by polymethylene units of an aliphatic chain, thereby providing a convenient strategy for constructing a peptidomimetic (Banerjee,
25 *Biopolymers* 39 (1996), 769-777). Superactive peptidomimetic analogues of small peptide hormones in other systems are described in the prior art (Zhang, *Biochem. Biophys. Res. Commun.* 224 (1996), 327-331). Appropriate peptidomimetics of the protein of the present invention can also be identified by the synthesis of peptidomimetic combinatorial libraries through successive amine alkylation and testing the resulting
30 compounds, e.g., for their binding, kinase inhibitory and/or immunological properties. Methods for the generation and use of peptidomimetic combinatorial libraries are described in the prior art, for example in Ostresh, *Methods in Enzymology* 267 (1996), 220-234 and Dorner, *Bioorg. Med. Chem.* 4 (1996), 709-715.

Furthermore, a three-dimensional and/or crystallographic structure of the protein of the invention can be used for the design of peptidomimetic inhibitors of the biological activity of the protein of the invention (Rose, *Biochemistry* 35 (1996), 12933-12944; Ruterber, *Bioorg. Med. Chem.* 4 (1996), 1545-1558).

5 The compounds to be obtained or identified in the methods of the invention can be compounds that are able to bind to any of the nucleic acids, peptides or proteins of the invention. Other interesting compounds to be identified are compounds that modulate the expression of the genes or the proteins of the invention in such a way that either the expression of said gene or protein is enhanced or decreased by the action of said
10 compound. Alternatively the compound can exert his action by enhancing or decreasing the activity of any of the proteins of the invention. Herein, preferred proteins are novel cytokinin oxidases.

Said compound or plurality of compounds may be comprised in, for example, samples, e.g., cell extracts from, e.g., plants, animals or microorganisms. Furthermore, said
15 compound(s) may be known in the art but hitherto not known to be capable of suppressing or activating cell cycle interacting proteins. The reaction mixture may be a cell free extract of may comprise a cell or tissue culture. Suitable set ups for the method of the invention are known to the person skilled in the art and are, for example, generally described in Alberts et al., *Molecular Biology of the Cell*, third edition (1994), in particular
20 Chapter 17. The plurality of compounds may be, e.g., added to the reaction mixture, culture medium or injected into the cell.

If a sample containing a compound or a plurality of compounds is identified in the method of the invention, then it is either possible to isolate the compound form the original sample identified as containing the compound capable of acting as an agonist,
25 or one can further subdivide the original sample, for example, if it consists of a plurality of different compounds, so as to reduce the number of different substances per sample and repeat the method with the subdivisions of the original sample. Depending on the complexity of the samples, the steps described above can be performed several times, preferably until the sample identified according to the method of the invention only
30 comprises a limited number of or only one substance(s). Preferably said sample comprises substances or similar chemical and/or physical properties, and most preferably said substances are identical. Preferably, the compound identified according to the above-described method or its derivative is further formulated in a form suitable for the application in plant breeding or plant cell and tissue culture.

The term “early vigor” refers to the ability of a plant to grow rapidly during early development, and relates to the successful establishment, after germination, of a well-developed root system and a well-developed photosynthetic apparatus.

5 The term “resistance to lodging” or “standability” refers to the ability of a plant to fix itself to the soil. For plants with an erect or semi-erect growth habit this term also refers to the ability to maintain an upright position under adverse (environmental) conditions. This trait relates to the size, depth and morphology of the root system.

As used herein, tblastn refers to an alignment tool that is part of the BLAST (Basic Local Alignment Search Tool) family of programs (<http://www.ncbi.nlm.nih.gov/BLAST/>).
10 BLAST aims to identify regions of optimal local alignment, i.e. the alignment of some portion of two nucleic acid or protein sequences, to detect relationships among sequences which share only isolated regions of similarity (Altschul et al., 1990). In the present invention, tblastn of the BLAST 2.0 suite of programs was used to compare the maize cytokinin oxidase protein sequence against a nucleotide sequence database
15 dynamically translated in all reading frames (Altschul et al., Nucleic Acids Res. 25: 3389-3402 (1997)).

The following examples and figures are given by means of illustration of the present invention and are in no way limiting. The contents of all references included in this application are incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Schematic representation of plant cytokinin oxidase genes.

Shown are the structures of different cytokinin oxidase genes isolated from maize (ZmCKX1, accession number AF044603, Biochem. Biophys. Res. Com. 255:328-333, 1999) and Arabidopsis (AtCKX1 to AtCKX4). Exons are denominated with 'E' and represented by shaded boxes. Introns are represented by white boxes. Further indicated are the gene sizes (in kb, on top of each structure), the gene accession numbers (under the names) and a size bar representing 0.5 kb.

Figure 2. Alignment of plant cytokinin oxidase amino acid sequences.

The amino acid sequences from cytokinin oxidases from maize (ZmCKX1) and Arabidopsis (AtCKX1 to AtCKX4) are aligned. Identical amino acid residues are marked by a black box, similar amino acid residues are in a grey box. Amino acid similarity groups: (M,I,L,V), (F,W,Y), (G,A), (S,T), (R,K,H), (E,D), (N,Q),

Figure 3. Northern blot analysis of *AtCKX1*-expressing tobacco and *Arabidopsis* plants.

(A) Northern blot analysis of constitutively expressing tobacco plants (lanes 1-8) compared to wild type SNN tobacco (lane 9)

(B) Comparison of tetracycline-induced gene expression in leaves after 12h of induction with a constitutively expressing clone. Lanes 2-9, leaves of four different *CKX1*-W38TetR clones (+,-, with or without tetracycline treatment), lane 1, constitutively expressing *35S::CKX1* clone.

(C) Northern blot analysis of *Arabidopsis* plants constitutively expressing *CKX1* gene. Lanes 2-4, three different constitutively expressing *35S::CKX1* clones compared to wild type *Arabidopsis* plant (lane 1).

Figure 4: Growth characteristics of *35S::CKX1* transgenic *Arabidopsis* plants.

(A) Two wild type seedlings (left) compared to two *35S::CKX1* expressing seedlings (right). Note the increased formation of adventitious roots and increased root branching in the transgenic seedlings. Pictures were taken 14 days after germination. Plants were grown *in vitro* on MS medium in petri dishes in a vertical position.

(B) Like A, but roots stained with toluidine blue.

(C) Top view of a petri dish with *35S::CKX1* transgenic seedlings three weeks after germination.

(D) A *35S::CKX1* transgenic plants grown in liquid culture. Roots of wild type seedlings grow poorly under these conditions (not shown).

5 (E) Transformants (T0) that express the *35S::CKX1* gene (three plants on the right), a wild type plant is shown on the left.

(F) Phenotype of T1 plants grown in soil. Wild type plant (left) compared to two *35S::CKX1* transgenic plants.

10 **Figure 5: Phenotype of *CKX2* overexpressing Arabidopsis plants.**

T1 generation of *35S::CKX2* expressing Arabidopsis plants (two plants on the right) compared to wild type (plant on the left).

15 **Figure 6. Northern blot analysis of *AtCKX2*-expressing tobacco and Arabidopsis plants.**

(A) Northern blot analysis of constitutively expressing tobacco plants (lanes 1-7) compared to wild type SNN tobacco (lane 8)

(B) Northern blot analysis of Arabidopsis plants constitutively expressing *CKX2* gene. Lanes 2-8, seven different constitutively expressing *35S::CKX2* clones compared to wild
20 type Arabidopsis plant (lane 1).

Figure 7. Shoot phenotype of *AtCKX1* and *AtCKX2* expressing tobacco plants.

(A) Top view of six week old plants.

(B) Tobacco plants at the flowering stage.

25 (C) Kinetics of stem elongation. Arrows mark the onset of flowering. Age of plants (days after germination) and leaf number at that stage are indicated above the arrows. Bars indicate SD; $n = 12$.

(D) Number of leaves ($n = 12$) formed between day 68 and day 100 after germination and final surface area of these leaves (100% of wild type is $3646 \pm 144 \text{ cm}^2$; $n = 3$).

30 (E) Comparison of leaf size and senescence. Leaves were from nodes number 4, 9, 12, 16 and 20 from the top (from left to right).

Figure 8. Root phenotype of *AtCKX* expressing transgenic tobacco plants.

(A) Seedlings 17 days after germination.

- (B) Root system of soil grown plants at the flowering stage.
- (C) Root length, number of lateral roots (LR) and adventitious roots (AR) on day 10 after germination.
- (D) Dose-response curve of root growth inhibition by exogenous cytokinin. Bars indicate \pm SD; $n = 30$.

Figure 9: Growth of axillary shoot meristems in 35S::CKX1 expressing tobacco plants.

- Figure 10: Histology of shoot meristems, leaves and root meristems of *AtCKX1* overexpressing tobacco plants versus wild type (WT) tobacco.**
- (A) Longitudinal median section through the vegetative shoot apical meristem. P, leaf primordia.
- (B) Vascular tissue in second order veins of leaves. X, xylem, PH, a phloem bundle.
- (C) Cross sections of fully developed leaves.
- (D) Scanning electron microscopy of the upper leaf epidermis.
- (E) Root apices stained with DAPI. RM, root meristem.
- (F) Longitudinal median sections of root meristems ten days after germination. RC, root cap; PM, promeristem.
- (G) Transverse root sections 10 mm from the apex. E, epidermis, C1-C4, cortical cell layer, X, xylem, PH, phloem. Bars are 100 μ m.

EXAMPLES

Example 1. Identification of candidate cytokinin oxidase encoding genes from *Arabidopsis thaliana*

5 Six different genes are identified from *Arabidopsis thaliana* that bear sequence similarity to a cytokinin oxidase gene from maize (Morris *et al.*, Biochem Biophys Res Comm 255:328-333, 1999; Houda-Herin *et al.* Plant J 17:615-626; WO 99/06571). These genes are found by screening 6-frame translations of nucleotide sequences from public genomic databases with the maize protein sequence, employing tblastn program. These
10 sequences are designated as *Arabidopsis thaliana* cytokinin oxidase-like genes or *AtCKX*. They are arbitrarily numbered as *AtCKX1* to *AtCKX6*. The below list summarizes the information on these genes. The predicted ORF borders and protein sequences are indicative, in order to illustrate by approximation the protein sequence divergence between the *Arabidopsis* and maize cytokinin oxidases, as well as amongst the different
15 *Arabidopsis* cytokinin oxidases. The ORF borders and protein sequences shown should not be taken as conclusive evidence for the mode of action of these *AtCKX* genes. The % identity/similarity values that are indicated amongst the *Arabidopsis* genes represent the lowest and highest values found with all combinations.

20 **A. Gene name: *AtCKX1*** (*Arabidopsis thaliana* cytokinin oxidase-like protein 1, SEQ ID NO1)

Location in database (accession number, location on bac): AC002510, *Arabidopsis thaliana* chromosome II section 225 of 255 of the complete sequence. Sequence from
25 clones T32G6.

ORF predicted in the database:

15517..16183, 16415..16542, 16631..16891, 16995..17257, 17344..17752

30 **Predicted protein sequence:** SEQ ID NO 2

Homologies

% identity with *Z. mays* gene:

31,5% (Dnastar/MegAlign - Clustal method)

35 % similarity with *Z. mays* protein:

32,2% (Dnastar/MegAlign - Clustal method)

% identity with other *Arabidopsis* genes (range):

38,2% (*AtCKX2*) - 54,1% (*AtCKX6*) (Dnastar/MegAlign - Clustal method)

5

% similarity with other *Arabidopsis* proteins (range):

37,1% (*AtCKX2*) - 58,1% (*AtCKX6*) (Dnastar/MegAlign - Clustal method)

B. Gene name: *AtCKX2* (*Arabidopsis thaliana* cytokinin oxidase-like protein 2, SEQ ID NO3)

10

Location in database (accession number, location on bac): AC005917, *Arabidopsis thaliana* chromosome II section 113 of 255 of the complete sequence. Sequence from clones F27F23, F3P11.

15

ORF predicted in the database:

complement, 40721..41012, 41054..41364, 41513..41770, 42535..42662, 43153..43711

Please note: The cDNA sequence is different than annotated in the database. Based on the cDNA sequence and using the gene prediction program NetPlantGene (<http://www.cbs.dtu.dk/services/NetGene2/>) the ORF predicted in the database is revised:

20

complement, 40721..41012, 41095..41364, 41513..41770, 42535..42662, 43153..43711

Predicted protein sequence, based on corrected ORF: SEQ ID NO 4

25

Homologies

% identity with *Z. mays* gene:

38,4% (Dnastar/MegAlign - Clustal method)

30

% similarity with *Z. mays* protein:

37,5% (Dnastar/MegAlign - Clustal method)

% identity with other *Arabidopsis* genes (range):

35

34,9% (*AtCKX6*) – 64,5% (*AtCKX4*) (Dnastar/MegAlign - Clustal method)

% similarity with other *Arabidopsis* proteins (range):

36,5% (*AtCKX6*) – 66,1% (*AtCKX4*) (Dnastar/MegAlign - Clustal method)

C. Gene name: *AtCKX3* (*Arabidopsis thaliana* cytokinin oxidase-like protein 3, SEQ ID NO 5)

5

Location in database (accession number, location on bac): AB024035, *Arabidopsis thaliana* genomic DNA, chromosome 5, P1 clone: MHM17, complete sequence.

No prediction of the ORF in the database.

10 The gene is identified by several gene prediction programs including GRAIL (<ftp://arthur.epm.ornl.gov/pub/xgrail>), Genscan (<http://CCR-081.mit.edu/GENSCAN.html>) and NetPlantGene (<http://www.cbs.dtu.dk/services/NetGene2/>):

complement, 29415..29718, 29813..30081, 30183..30443, 30529..30656, 32107..32716

15

Predicted protein sequence, based on own ORF prediction: SEQ ID NO 6

Homologies

% identity with *Z. mays* gene:

20 38,7% (Dnastar/MegAlign - Clustal method)

% similarity with *Z. mays* protein:

39,2% (Dnastar/MegAlign - Clustal method)

25 % identity with other *Arabidopsis* genes (range):

38,8% (*AtCKX6*) – 51,0% (*AtCKX2*) (Dnastar/MegAlign - Clustal method)

% similarity with other *Arabidopsis* proteins (range):

39,9% (*AtCKX6*) – 46,7% (*AtCKX2*) (Dnastar/MegAlign - Clustal method)

30

D. Gene name: *AtCKX4* (*Arabidopsis thaliana* cytokinin oxidase-like protein 4, SEQ ID NO 7)

Location in database (accession number, location on bac):

35 1) AL079344, *Arabidopsis thaliana* DNA chromosome 4, BAC clone T16L4 (ESSA project)

2) AL161575, *Arabidopsis thaliana* DNA chromosome 4, contig fragment No. 71.

ORF predicted in the database:

1) 76187..76814, 77189..77316, 77823..78080, 78318..78586, 78677..78968

2) 101002..101629, 102004..102131, 102638..102895, 103133..103401,

5 103492..103783

Predicted protein sequence: SEQ ID NO 8

Homologies

10 % identity with *Z. mays* gene:

41,0% (Dnastar/MegAlign - Clustal method)

% similarity with *Z. mays* protein:

41,0% (Dnastar/MegAlign - Clustal method)

15

% identity with other *Arabidopsis* genes (range):

35,2% (*AtCKX6*) – 64,5% (*AtCKX2*) (Dnastar/MegAlign - Clustal method)

% similarity with other *Arabidopsis* proteins (range):

20 35,1% (*AtCKX6*) – 66,1% (*AtCKX2*) (Dnastar/MegAlign - Clustal method)

E. Gene name: *AtCKX5* (*Arabidopsis thaliana* cytokinin oxidase-like protein 5, SEQ ID NO 9)

25 **Location in database** (accession number, location on bac): AC023754, F1B16, complete sequence, chromosome 1

No prediction of the ORF in the database.

The gene can be identified by several gene prediction programs including GRAIL
30 (<ftp://arthur.epm.ornl.gov/pub/xgrail>), Genscan (<http://CCR-081.mit.edu/GENSCAN.html>) and NetPlantGene (<http://www.cbs.dtu.dk/services/NetGene2/>)

43756..44347, 44435..44562, 44700..44966, 45493..45755, 46200..46560

35 **Predicted protein sequence: SEQ ID NO 10**

Homologies

% identity with *Z. mays* gene:

39,1% (Dnastar/MegAlign - Clustal method)

% similarity with *Z. mays* protein:

36,6% (Dnastar/MegAlign - Clustal method)

5

% identity with other *Arabidopsis* genes (range):

40,1% (*AtCKX2*) – 44,0% (*AtCKX3*) (Dnastar/MegAlign - Clustal method)

% similarity with other *Arabidopsis* proteins (range):

10

41,6% (*AtCKX4*) – 46,4% (*AtCKX6*) (Dnastar/MegAlign - Clustal method)

F. Gene name: *AtCKX6* (*Arabidopsis thaliana* cytokinin oxidase-like protein 6, SEQ ID NO 11)

15

Location in database (accession number, location on bac): AL163818, *Arabidopsis thaliana* DNA chromosome 3, P1 clone MAA21 (ESSA project).

ORF predicted in the database:

20

46630..47215, 47343..47470, 47591..47806, 47899..48161, 48244..48565

Predicted protein sequence: SEQ ID NO 12

Homologies

25

% identity with *Z. mays* gene:

37,3% (Dnastar/MegAlign - Clustal method)

% similarity with *Z. mays* protein:

36,1% (Dnastar/MegAlign - Clustal method)

30

% identity with other *Arabidopsis* genes (range):

34,9% (*AtCKX2*) – 54,1% (*AtCKX1*) (Dnastar/MegAlign - Clustal method)

% similarity with other *Arabidopsis* proteins (range):

35

35,1% (*AtCKX4*) – 58,1% (*AtCKX1*) (Dnastar/MegAlign - Clustal method)

Genes *AtCKX3* and *AtCKX5* are not annotated as putative cytokinin oxidases in the database and ORFs for these genes are not given. Furthermore, the ORF (and

consequently the protein structures) predicted for *AtCKX2* is different from our own prediction.

A comparison of the gene structure of the *Arabidopsis AtCKX* genes 1 to 4 and the maize *CKX* gene is shown in Fig 1.

5 The predicted proteins encoded by the *Arabidopsis AtCKX* genes show between 32% and 41% sequence similarity with the maize protein, while they show between 35% and 66% sequence similarity to each other. Because of this reduced sequence conservation, it is not clear *a priori* whether the *Arabidopsis AtCKX* genes encode proteins with cytokinin oxidase activity. An alignment of the *Arabidopsis AtCKX* predicted proteins 1 to
10 4 and the maize *CKX* gene is shown in Fig 2.

Example 2. Transgenic plants overexpressing *AtCKX1* show increased cytokinin oxidase activity and altered plant morphology

15 1. Description of the cloning process

The following primers are used to PCR amplify the *AtCKX1* gene from *Arabidopsis thaliana*, accession Columbia:

Sequence of 5' primer: cggtcgacATGGGATTGACCTCATCCTTACG (SEQ ID NO:13)

Sequence of 3' primer: gcgtcgacTTATACAGTTCTAGGTTTCGGCAGTAT (SEQ ID NO:
20 14)

A 2235-bp PCR fragment, amplified by these primers, is inserted in the *Sal* I site of pUC19. The insert is sequenced to confirm that the PCR amplification has not introduced mutations. The *Sall*/*Sall* fragment of this vector is subcloned in the *Sall* site
25 downstream of a modified CaMV 35S promoter (carrying three tetracycline operator sequences) in the binary vector pBinHyg-Tx (Gatz *et al.*, 1992). The resulting construct is introduced into tobacco and *Arabidopsis thaliana* through *Agrobacterium*-mediated transformation, using standard transformation protocols.

30 2. Molecular analysis of the transgenic lines

Several transgenic lines are identified that synthesize the *AtCKX1* transcript at high levels (Fig 3). Transgenic lines expressing *AtCKX1* transcript also show increased cytokinin oxidase activity. This is exemplified for 2 tobacco and 2 *Arabidopsis* lines in

Table 6. This result proves that the *AtCKX1* gene encodes a protein with cytokinin oxidase activity.

Table 6. Cytokinin oxidase activity in *AtCKX1* transgenic plant tissues

Leaf sample		
Plant species	Plant line	Cytokinin oxidase activity (nmol Ade/mg protein.h)
<i>Arabidopsis</i>	Col-0 wild-type	0.009
	CKX1-11	0.024
	CKX1-22	0.026
	CKX1-22	0.027
Tobacco	SNN wild-type	0.004
	CKX1-SNN-8	0.016
	CKX1-SNN-28	0.021

3. Phenotypic description of the transgenic lines

In *Arabidopsis* (see also Fig 4):

- onset of germination same as for wt
- the number of adventitious roots early after germination is enhanced; the growth of aerial organs (hypocotyl, cotyledons and leaves) is delayed and reduced resulting in a dwarfed phenotype
- the number of leaves in rosette is increased
- the life cycle is longer compared to wt

In tobacco (see also Fig 7 to 10):

The plants have a dwarfed phenotype, with reduced apical dominance and increased root production.

Five categories of phenotype:

- 1) strong - 2 clones
- 2) intermediate - 3 clones
- 3) weak - 4 clones

4) tall plants (as WT) with large inflorescence - 5 clones

5) similar to wt, 9 clones

Height (see Fig. 7)

- 5
- wt: between 100-150 cm
 - weak: approximately 75 cm
 - intermediate: appr. 40-45 cm (main stem app. 25 cm but overgrown by side branches.
 - strong: appr. 10 cm

10

Roots (see Fig. 8)

In vitro grown plants highly expressing the gene are easily distinguishable from the WT by their ability to form more roots which are thicker (stronger) as well as by forming aerial roots along the stem.

15

Roots in soil (4-4,5 month after transfer to the green house):

- strong: good root system (as WT) despite the strong reduction of aerial parts
- intermediate: large increase in root system (biomass)
- weak: also increase in root biomass compared to WT

20

Internodes distance

- wt: 5th internode below inflorescence app. 5 cm, 9th internode about 2 cm long
- intermediate class: 5th internode below inflorescence about 2.5 cm, 9th internode app. 0,5 cm long

25

Seed capsules

Expressing plants have in general less capsules, which are of similar size as wt (even in strong expressors)

30

- strong: 2-4 capsules
- intermediate: about 25
- wt: more than 60

Flower

35

Size is not reduced. The first flowers are aborted in the transgenic expressors.

Leaves (see Figure 7)

The shape of leaves of *AtCKX1* transgenic expressors is lanceolate (longer and narrow). The width-to-length ratio of mature leaves was reduced from 1:2 in wild type plants to 1:3 in *AtCKX1* transgenics. A prominent difference was also noted for progression of leaf senescence. In wt tobacco, leaf senescence starts in the most basal leaves and leads to a uniform reduction of leaf pigment. By contrast, ageing leaves of strongly expressing *AtCKX1* plants stay green along the leaf veins and turn yellow in the intercostal regions, indicating altered leaf senescence. The texture of older leaves is more rigid.

Stem

More side branches are formed indicating reduced apical dominance compared to WT plants (see Figure 9). The side branches overgrow the main stem, reaching a height of 40-45 cm for intermediate *AtCKX1* expressors. Even secondary branches appear.

Example 3. Transgenic plants overexpressing *AtCKX2* show increased cytokinin oxidase activity and altered plant morphology

1. Description of the cloning process

The following primers are used to PCR amplify the *AtCKX2* gene from *Arabidopsis thaliana*, accession Columbia:

Sequence of 5' primer: gcggtaccAGAGAGAGAAACATAAACAATGGC (SEQ ID NO:15)

Sequence of 3' primer: gcggtaccCAATTTTACTTCCACCAAATGC (SEQ ID NO:16)

A 3104-bp PCR fragment, amplified by these primers, is inserted in the KpnI site of pUC19. The insert is sequenced to check that no differences to the published sequence are introduced by the PCR procedure. The KpnI/KpnI fragment of this vector is subcloned in the KpnI site downstream of a modified CaMV 35S promoter (carrying three tetracycline operator sequences) in the binary vector pBinHyg-Tx (Gatz *et al.*, 1992). The resulting construct is introduced into tobacco and *Arabidopsis thaliana* through *Agrobacterium*-mediated transformation, using standard transformation protocols.

2. Molecular analysis of the transgenic lines

Several transgenic lines are identified that synthesize the *AtCKX2* transcript at high levels (Fig 6). Transgenic lines expressing *AtCKX2* transcript also show increased cytokinin oxidase activity. This is exemplified for 2 tobacco and 3 Arabidopsis lines in Table 7. This result proves that the *AtCKX2* gene encodes a protein with cytokinin oxidase activity.

Table 7. Cytokinin oxidase activity in *AtCKX2* transgenic plant tissues

Sample		
Plant species and tissue	Plant line	Cytokinin oxidase activity (nmol Ade/mg protein.h)
<i>Arabidopsis</i> callus	Col-0 wild-type	0.037
	CKX2-15	0.351
	CKX2-17	0.380
	CKX2-55	0.265
Tobacco leaves	SNN wild-type	0.009
	CKX2-SNN-18	0.091
	CKX2-SNN-19	0.091

3. Phenotypic description of the transgenic lines

In Arabidopsis (see Fig 5):

Basically similar to *CKX1* (no quantitative comparisons with *AtCKX1* available)

In tobacco (see Fig 7 to 10):

Three categories of phenotype:

- 1) strong - 15 clones (similar to intermediate phenotype of *AtCKX1*)
- 2) weak - 6 clones
- 3) others - similar to wt plants, 7 clones

Roots

In vitro grown plants highly expressing the gene are easily distinguishable from wt plants by their ability to form more roots which are thicker (stronger) as well as by forming aerial roots along the stem.

- 5 Roots in soil (4-4,5 month after transfer to the green house):
- strong: very significant increase in root biomass for strongest expressing clones
 - weak: also increase in root biomass compared to wt
- 10 The observations concerning plant height, internode distance, branching, seed set, leaf form and yellowing are similar as for *AtCKX1* transgenics with some generally minor quantitative differences.
- 15 Interestingly, the increase in cytokinin oxidase activity and in root production is more pronounced in *AtCKX2* than in *AtCKX1* expressing tobacco lines. This is also illustrated by the lower cytokinin content of *AtCKX2* plants versus *AtCKX1* plants (see Table 9 below). These results indicate that *AtCKX2* may be a preferential tool for the embodiments of this patent application as compared to *AtCKX1*.

Example 4. Transgenic plants overexpressing *AtCKX3* show altered plant morphology

1. Description of the cloning process

The following primers are used to PCR amplify the *AtCKX3* gene from *Arabidopsis thaliana*, accession Columbia:

- 25 Sequence of 5' primer: gcggtaccTTCATTGATAAGAATCAAGCTATTCA (SEQ ID NO:17)

Sequence of 3' primer: gcggtaccCAAAGTGGTGAGAACGACTAACA (SEQ ID NO:18)

- 30 A 3397-bp PCR fragment, produced by this PCR amplification, is inserted in the KpnI site of pBluescript. The insert is sequenced to confirm that the PCR product has no sequence changes as compared to the gene. The KpnI/KpnI fragment of this vector is subcloned in the KpnI site downstream of a modified CaMV 35S promoter (carrying three tetracycline operator sequences) in the binary vector pBinHyg-Tx (Gatz *et al.*, 1992).

2. Plant phenotypic analysis

The phenotypes generated by overexpression of the *AtCKX3* gene in tobacco and *Arabidopsis* are basically similar as those of *AtCKX1* and *AtCKX2* expressing plants, i.e. enhanced rooting and dwarfing.

Example 5. Transgenic plants overexpressing *AtCKX4* show altered plant morphology

1. Description of the cloning process

The following primers are used to PCR amplify the *AtCKX4* gene from *Arabidopsis thaliana*, accession Columbia:

Sequence of 5' primer: gcggtaccCCCATTAACCTACCCGTTTG (SEQ ID NO:19)

Sequence of 3' primer: gcggtaccAGACGATGAACGTACTTGTCTGTA (SEQ ID NO:20)

A 2890-bp PCR fragment, produced by this PCR amplification, is inserted in the KpnI site of pBluescript. The insert is sequenced to confirm that the PCR product has no sequence changes as compared to the gene. The KpnI/KpnI fragment of this vector is subcloned in the KpnI site downstream of a modified CaMV 35S promoter (carrying three tetracycline operator sequences) in the binary vector pBinHyg-Tx (Gatz *et al.*, 1992).

2. Molecular analysis of the transgenic lines

Several transgenic lines are identified that show increased cytokinin oxidase activity. This is exemplified for 3 *Arabidopsis* lines in Table 8. This result proves that the *AtCKX4* gene encodes a protein with cytokinin oxidase activity.

Table 8. Cytokinin oxidase activity in *AtCKX4* transgenic plant tissues

Sample		
Plant species and tissue	Plant line	Cytokinin oxidase activity (nmol Ade/mg protein.h)
<i>Arabidopsis</i> callus	Col-0 wild-type	0.037
	CKX4-37	0.244
	CKX4-40	0.258
	CKX4-41	0.320

3. Plant phenotypic analysis

The phenotypes generated by overexpression of the *AtCKX4* gene in tobacco and *Arabidopsis* are basically similar as those of *AtCKX1* and *AtCKX2* expressing plants, i.e. enhanced rooting, reduced apical dominance, dwarfing and yellowing of intercostal regions in older leaves of tobacco. An additional phenotype in tobacco are lanceolate leaves (altered length-to-wide ratio).

Example 6. Cloning of the *AtCKX5* gene

The following primers are used to PCR amplify the *AtCKX5* gene from *Arabidopsis thaliana*, accession Columbia:

Sequence of 5' primer: ggggtaccGTGAAATGACGTCAAGCTTTCTT (SEQ ID NO:21)

Sequence of 3' primer: ggggtaccCTTTCCTCTTGGTTTTGTCCTGT (SEQ ID NO:22)

A 2833-bp PCR fragment, produced by this PCR amplification, is inserted as a blunt-end product in pCR-Blunt II-TOPO cloning vector (Invitrogen).

Example 7. Cloning of the *AtCKX6* gene

The following primers are used to PCR amplify the *AtCKX6* gene from *Arabidopsis thaliana*, accession Columbia:

Sequence of 5' primer: gctctagaTCAGGAAAAGAACCATGCTTATAG (SEQ ID NO:23)

Sequence of 3' primer: gctctagaTCATGAGTATGAGACTGCCTTTTG (SEQ ID NO:24)

A 1949-bp PCR fragment, produced by this PCR amplification, is inserted as a blunt-end product in pCR-Blunt II-TOPO cloning vector (Invitrogen).

Example 8. Expression of the *AtCKX2* gene under a root-specific promoter in transgenic tobacco leads to increased root production

The *AtCKX2* gene (see example 3) is cloned under control of the WRKY6 promoter of *Arabidopsis*, which is a promoter that drives root-specific expression.

Transgenic plants expressing the *AtCKX2* gene specifically in the roots show increased root production without negatively affecting growth and development of the aerial parts of the plant.

Example 9. Tobacco seedling growth test demonstrate early vigor of *AtCKX* transgenics

Seeds of *AtCKX1*-, *AtCKX2*-overexpressing and wt tobacco were sown in vitro, brought
5 to culture room after 4 days (after cold treatment), and germinated after 6 days.
Observation on seedling growth were made 13 days after sowing:

Wild type:

just two cotyledons, tiny leaves visible;

10 root length 9-11 mm, no side root, no adventitious root

***AtCKX1*:**

clone 50 (strongest phenotype in green house): root length 18-21 mm, 1-2 side branches
(sb), 1-2 adventitious roots (ar)

15 clone 8: root length 13-16 mm, 1 ar, 1 sb

clone 2: root length 17-20 mm, 1-2 ar, 1-2 sb

***AtCKX2*:**

clone 2: root length 14-18 mm

20 clone 38: root length 16-19 mm

clone 40: root length 15-20 mm

clone 2 (very low expresser): root length 10 mm

formation of more adventitious roots also evident for *AtCKX2* transgenics

25 ***AtCKX1* and *AtCKX2* plants, general observations:**

Longer primary root (up to 100%!) which has already branched (1-2 side branches),
more adventitious roots (1-2). Primary true leaves are advanced, cotyledons are
somewhat more expanded. These results show that overexpression of cytokinin oxidase
enhances the growth and development of both the main root and the adventitious roots,
30 resulting in early vigor.

Example 10. Histological analysis of altered plant morphology in *AtCKX1* overexpressing tobacco plants

Microscopic analysis of different tissues revealed that the morphological changes in *AtCKX* transgenics are reflected by distinct changes in cell number and rate of cell formation (see Figure 10). The shoot apical meristem (SAM) of *AtCKX1* transgenics is smaller than in wild type and fewer cells occupy the space between the central zone and the peripheral zone of lateral organ formation, but the cells are of the same size (Figure 10 A). The reduced cell number and size of the SAM as a consequence of a reduced cytokinin content indicates that cytokinins have a role in the control of SAM proliferation. No obvious changes in the differentiation pattern occurred, suggesting that the spatial organization of the differentiation zones in the SAM is largely independent from cell number and from the local cytokinin concentration. The overall tissue pattern of leaves in cytokinin oxidase overexpressers is unchanged. However, the size of the phloem and xylem is significantly reduced (Figure 10 B). By contrast, the average cell size of leaf parenchyma and epidermal cells is increased four- to fivefold (Figure 10 C, D). New cells of *AtCKX1* transgenics are formed at 3-4% of the rate of wild type leaves and final leaf cell number is estimated to be in the range of 5-6% of wild type. This indicates an absolute requirement for cytokinins in leaves to maintain the cell division cycle. Neither cell size nor cell form of floral organs was altered and seed yield per capsule was similar in wild type and *AtCKX* transgenic plants. The cell population of root meristems of *AtCKX1* transgenic plants was enlarged approximately 4-fold and the cell numbers in both the central and lateral columnella were enhanced (Figure 10 E, F). The final root diameter was increased by 60% due to an increased diameter of all types of root cells. The radial root patterns was identical in wild type and transgenics, with the exception that frequently a fourth layer of cortex cells was noted in transgenic roots (Figure 10 G). The increased cell number and the slightly reduced cell length indicates that the enhanced root growth is due to an increased number of cycling cells rather than increased cell growth. In the presence of lowered cytokinin content, root meristem cells must undergo additional rounds of mitosis before they leave the meristem and start to elongate. We conclude that the exit from the meristem is regulated by a mechanism that is sensitive to cytokinins. Apparently, cytokinins have a negative regulatory role in the root meristem and wild type cytokinin concentrations are inhibitory to the development of a maximal root system. Therefore, reducing the level of active cytokinins by overexpressing cytokinin oxidases stimulates root development which results in an increase in the size of the root with more lateral and adventitious roots as compared to wt plants.

Example 11. The endogenous concentration of different cytokinin metabolites is significantly reduced in *AtCKX* expressing transgenic tobacco seedlings.

Among the 16 different cytokinin metabolites that were measured, the greatest change occurred in the iP-type cytokinins in *AtCKX2* overexpressers (Table 9). Smaller alterations were noted for Z-type cytokinins, which could be due to a different accessibility of the substrate or a lower substrate specificity of the protein. The total content of iP and Z metabolites in individual transgenic clones was between 31% and 63% of wild type. The cytokinin reserve pool of O-glucosides was also lowered in the transgenics (Table 9). The concentration of N-glucosides and DHZ-type cytokinins was very low and was not or only marginally, altered in transgenic seedlings (data not shown).

Table 9. Cytokinin content of *AtCKX* transgenic plants. Cytokinin extraction, immunopurification, HPLC separation and quantification by ELISA methods was carried out as described by Faiss et al., 1997. Three independently pooled samples of approximately 100 two week old seedlings (2.5 g per sample) were analyzed for each clone. Concentrations are in pmol x g fresh weight⁻¹. Abbreviations: iP, N⁶-(Δ^2 isopentenyl)adenine; iPR, N⁶-(Δ^2 isopentenyl)adenine riboside; iPRP, N⁶-(Δ^2 isopentenyl)adenine riboside 5'-monophosphate; Z, *trans*-zeatin; ZR, zeatin riboside; ZRP, zeatin riboside 5'-monophosphate; ZOG, zeatin O-glucoside; ZROG, zeatin riboside O-glucoside.

Line	Wild-type	AtCKX1-2		AtCKX1-28		AtCKX2-38		AtCKX2-40	
Cytokinin metabolite	Concentration	Concentration	% of WT	Concentration	% of WT	Concentration	% of WT	Concentration	% of WT
iP	5,90 ± 1,80	4,76 ± 0,82	81	4,94 ± 2,62	84	1,82 ± 0,44	31	2,85 ± 0,62	48
iPR	2,36 ± 0,74	1,53 ± 0,14	65	0,75 ± 0,27	32	0,55 ± 0,39	23	0,89 ± 0,07	38
iPRP	3,32 ± 0,73	0,87 ± 0,26	26	1,12 ± 0,13	34	0,80 ± 0,48	24	1,68 ± 0,45	51
Z	0,24 ± 0,06	0,17 ± 0,02	71	0,22 ± 0,03	92	0,21 ± 0,06	88	0,22 ± 0,02	92
ZR	0,60 ± 0,13	0,32 ± 0,12	53	0,34 ± 0,03	57	0,34 ± 0,15	57	0,32 ± 0,05	53
ZRP	0,39 ± 0,17	0,42 ± 0,11	107	0,28 ± 0,15	72	0,06 ± 0,01	15	0,17 ± 0,06	44
ZOG	0,46 ± 0,20	0,32 ± 0,09	70	0,26 ± 0,13	57	0,20 ± 0,07	43	0,12 ± 0,02	26
ZROG	0,48 ± 0,17	0,30 ± 0,06	63	0,47 ± 0,02	98	0,23 ± 0,05	48	0,30 ± 0,13	63
Total	13,75	8,69	63	8,38	61	4,21	31	6,55	48

Example 12. Suppression of a *AtCKX* gene under a senescence-induced promoter in transgenic plants leads to delayed leaf senescence and enhanced seed yield.

5 A chimeric gene construct derived from a *AtCKX* gene (see example 3) and designed to suppress expression of endogenous cytokinin oxidase gene(s) is cloned under control of a senescence-induced promoter. For example, promoters derived from senescence-associated genes (SAG) such as the SAG12 promoter can be used (Quirino et al., 2000). Transgenic plants suppressing endogenous cytokinin oxidase gene(s) specifically in senescing leaves show delayed leaf senescence and higher seed yield
10 without negatively affecting the morphology and growth and development of the plant.

Example 13. Overexpression of a *AtCKX* gene in the female reproductive organs leads to parthenocaropic fruit development

15 The open reading frame of an *AtCKX* gene is cloned under control of a promoter that confers overexpression in the female reproductive organs such as for example the DefH9 promoter from *Antirrhinum majus* or one of its homologues which has a high expression specificity in the placenta and ovules. Transgenic plants with enhanced cytokinin oxidase activity in these tissues show parthenocarpic fruit development.

REFERENCES

WO0105985. Method to modulate the expression of genes inducing the parthenocarpic trait in plants.

- 5 Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J. D. (1994). "Molecular Biology of the Cell." Garland Publishing Inc.
- Altschul, S.F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W. & Lipman, D.J. (1997) "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs." *Nucl. Acids Res.* **25**, 3389-3402.
- 10 An, G., Watson, B. D., Stachel, S., Gordon, M. P., and Nester, E. W. (1985). New cloning vehicles for transformation of higher plants. *EMBO J.* **4**, 277-284.
- Armstrong, C. L., Petersen, W. P., Buchholz, W. G., Bowen, B. A., and Sulc, S. L. (1990). Factors affecting PEG-mediated stable transformation of maize protoplasts. *Plant Cell Reports* **9**, 335-339.
- 15 Banerjee, A., Pramanik, A., Bhattacharjya, S., and Balaram, P. (1996). Omega amino acids in peptide design: incorporation into helices. *Biopolymers* **39**, 769-777.
- Baron, M. H. and Baltimore, D. (1982). Antibodies against the chemically synthesized genome-linked protein of poliovirus react with native virus-specific proteins. *Cell* **28**, 395-404.
- 20 Bartel, P. L. and Fields, S. (1997). "The Yeast Two-Hybrid System." Oxford University Press.
- Benkirane, N., Guichard, G., Briand, J. P., and Muller, S. (1996). Exploration of requirements for peptidomimetic immune recognition. Antigenic and immunogenic properties of reduced peptide bond pseudopeptide analogues of a histone hexapeptide.
- 25 *J.Biol Chem.* **271**, 33218-33224.
- Berry, A. and Brenner, S. E. (1994). A prototype computer system for de novo protein design. *Biochem.Soc.Trans.* **22**, 1033-1036.
- Christou, P., McCabe, D. E., and Swain, W. F. (1988). Stable transformation of soybean callus by DNA-coated gold particles. *Plant Physiol.* **87**, 671-674.

- Crossway, A., Oakes, J. V., Irvine, J. M., Ward, B., Knauf, V. C., and Shewmaker, C. K. (1986). Integration of foreign DNA following microinjection of tobacco mesophyll protoplasts. *Mol.Gen.Genet.* **202**, 179-185.
- 5 Dale, E. C. and Ow, D. W. (1990). Intra- and intermolecular site-specific recombination in plant cells mediated by bacteriophage P1 recombinase. *Gene* **91**, 79-85.
- Dodds, J. H. (1985). "Plant genetic engineering." Cambridge University Press.
- Doerner, P., Jorgensen, J. E., You, R., Steppuhn, J., and Lamb, C. (1996). Control of root growth and development by cyclin expression. *Nature* **380**, 520-523.
- 10 Dorner, B., Husar, G. M., Ostresh, J. M., and Houghten, R. A. (1996). The synthesis of peptidomimetic combinatorial libraries through successive amide alkylations. *Bioorg.Med.Chem.* **4**, 709-715.
- Ellis, J. G., Llewellyn, D. J., Dennis, E. S., and Peacock, W. J. (1987). Maize Adh-1 promoter sequences control anaerobic regulation: addition of upstream promoter elements from constitutive genes is necessary for expression in tobacco. *EMBO J.* **6**, 11-16.
- 15 Faiss, M., Zalubilová, J., Strnad, M., Schmülling, T. (1997). Conditional transgenic expression of the ipt gene indicates a function for cytokinins in paracrine signaling in whole tobacco plants. *Plant J.* **12**, 401-415.
- Fassina, G. and Melli, M. (1994). Identification of interactive sites of proteins and protein receptors by computer-assisted searches for complementary peptide sequences. *Immunomethods.* **5**, 114-120.
- 20 Fedoroff, N. V. and Smith, D. L. (1993). A versatile system for detecting transposition in Arabidopsis. *Plant J.* **3**, 273-289.
- Hanahan, D. (1983). Studies on transformation of Escherichia coli with plasmids. *J.Mol.Biol* **166**, 557-580.
- 25 Hansen, G. and Chilton, M. D. (1996). "Agrolistic" transformation of plant cells: integration of T-strands generated in planta. *Proc.Natl.Acad.Sci.U.S.A* **93**, 14978-14983.
- Hansen, G., Shillito, R. D., and Chilton, M. D. (1997). T-strand integration in maize protoplasts after codelivery of a T-DNA substrate and virulence genes. *Proc.Natl.Acad.Sci.U.S.A* **94**, 11726-11730.
- 30

Hanson, B., Engler, D., Moy, Y., Newman, B., Ralston, E., and Gutterson, N. (1999). A simple method to enrich an *Agrobacterium*-transformed population for plants containing only T-DNA sequences. *Plant J.* **19**, 727-734.

Harlow, E. and Lane, D. (1988). "Antibodies: A Laboratory Manual." Cold Spring Harbor Laboratory Press.

Herrera-Estrella, L., De Block, M., Messens, E. H. J. P., Van Montagu, M., and Schell, J. (1983). Chimeric genes as dominant selectable markers in plant cells. *EMBO J.* **2**, 987-995.

Hoffman, D. L., Laiter, S., Singh, R. K., Vaisman, I. I., and Tropsha, A. (1995). Rapid protein structure classification using one-dimensional structure profiles on the bioSCAN parallel computer. *Comput.Appl.Biosci.* **11**, 675-679.

Krens, F. A., Molendijk, L., Wullems, G. J., and Schilperoort, R. A. (1982). *In vitro* transformation of plant protoplasts with Ti-plasmid DNA. *Nature* **296**, 72-74.

Lerner, R. A. (1982). Tapping the immunological repertoire to produce antibodies of predetermined specificity. *Nature* **299**, 593-596.

Lerner, R. A., Green, N., Alexander, H., Liu, F. T., Sutcliffe, J. G., and Shinnick, T. M. (1981). Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles. *Proc.Natl.Acad.Sci.U.S.A* **78**, 3403-3407.

Liddle, J. E. and Cryer, A. (1991). "A Practical Guide to Monoclonal Antibodies." Wiley New York.

Loffler, J., Langui, D., Probst, A., and Huber, G. (1994). Accumulation of a 50 kDa N-terminal fragment of beta-APP695 in Alzheimer's disease hippocampus and neocortex. *Neurochem.Int.* **24**, 281-288.

Monge, A., Lathrop, E. J., Gunn, J. R., Shenkin, P. S., and Friesner, R. A. (1995). Computer modeling of protein folding: conformational and energetic analysis of reduced and detailed protein models. *J.Mol.Biol* **247**, 995-1012.

Murakami, T., Simonds, W. F., and Spiegel, A. M. (1992). Site-specific antibodies directed against G protein beta and gamma subunits: effects on alpha and beta gamma subunit interaction. *Biochemistry* **31**, 2905-2911.

- Olszewski, K. A., Kolinski, A., and Skolnick, J. (1996). Folding simulations and computer redesign of protein A three-helix bundle motifs. *Proteins* **25**, 286-299.
- Osborne, B. I., Wirtz, U., and Baker, B. (1995). A system for insertional mutagenesis and chromosomal rearrangement using the Ds transposon and Cre-lox. *Plant J.* **7**, 687-701.
- 5 Ostresh, J. M., Blondelle, S. E., Dorner, B., and Houghten, R. A. (1996). Generation and use of nonsupport-bound peptide and peptidomimetic combinatorial libraries. *Methods Enzymol.* **267**, 220-234.
- Pabo, C. O. and Suchanek, E. G. (1986). Computer-aided model-building strategies for protein design. *Biochemistry* **25**, 5987-5991.
- 10 Paszkowski, J., Shillito, R. D., Saul, M., Mandak, V., and Hohn, T. H. B. P. I. (1984). Direct gene transfer to plants. *EMBO J.* **3**, 2717-2722.
- Peralta, E. G., Hellmiss, R., and Ream, W. (1986). Overdrive, a T-DNA transmission enhancer on the A. tumefaciens tumour-inducing plasmid. *EMBO J.* **5**, 1137-1142.
- Quirino, B.F., Noh, Y.-S., Himmelbau, E., and Amasino, R.M. (2000). Molecular aspects of
15 leaf senescence. *Trends in Plant Science* **5**, 278-282.
- Renouf, D. V. and Hounsell, E. F. (1995). Molecular modelling of glycoproteins by homology with non-glycosylated protein domains, computer simulated glycosylation and molecular dynamics. *Adv.Exp.Med.Biol* **376**, 37-45.
- Rose, R. B., Craik, C. S., Douglas, N. L., and Stroud, R. M. (1996). Three-dimensional
20 structures of HIV-1 and SIV protease product complexes. *Biochemistry* **35**, 12933-12944.
- Rutenber, E. E., McPhee, F., Kaplan, A. P., Gallion, S. L., Hogan, J. C., Jr., Craik, C. S., and Stroud, R. M. (1996). A new class of HIV-1 protease inhibitor: the crystallographic structure, inhibition and chemical synthesis of an aminimide peptide isostere.
25 *Bioorg.Med.Chem.* **4**, 1545-1558.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). "Molecular Cloning: A Laboratory Manual." Cold Spring Harbor Laboratory Press.
- Schlappi, M., Smith, D., and Fedoroff, N. (1993). TnpA trans-activates methylated maize Suppressor-mutator transposable elements in transgenic tobacco. *Genetics* **133**, 1009-
30 1021.

Shioda, T., Andriole, S., Yahata, T., and Isselbacher, K. J. (2000). A green fluorescent protein-reporter mammalian two-hybrid system with extrachromosomal maintenance of a prey expression plasmid: Application to interaction screening. *Proc.Natl.Acad.Sci.U.S.A* **97** , 5220-5224.

- 5 Tamura, R. N., Cooper, H. M., Collo, G., and Quaranta, V. (1991). Cell type-specific integrin variants with alternative alpha chain cytoplasmic domains. *Proc.Natl.Acad.Sci.U.S.A* **88**, 10183-10187.

Van Haaren, M. J., Sedee, N. J., Schilperoort, R. A., and Hooykaas, P. J. (1987). Overdrive is a T-region transfer enhancer which stimulates T-strand production in
10 *Agrobacterium tumefaciens*. *Nucleic Acids Res.* **15**, 8983-8997.

Van Sluys, M. A., Tempe, J., and Fedoroff, N. (1987). Studies on the introduction and mobility of the maize Activator element in *Arabidopsis thaliana* and *Daucus carota*. *EMBO J.* **6**, 3881-3889.

- 15 Wang, K., Genetello, C., Van Montagu, M., and Zambryski, P. C. (1987). Sequence context of the T-DNA border repeat element determines its relative activity during T-DNA transfer to plant cells. *Mol.Gen.Genet.* **210**, 338-346.

Woulfe, J., Lafortune, L., de Nadai, F., Kitabgi, P., and Beaudet, A. (1994). Post-translational processing of the neurotensin/neuromedin N precursor in the central nervous system of the rat—II. Immunohistochemical localization of maturation products.
20 *Neuroscience* **60**, 167-181.

Zhang, Y. L., Dawe, A. L., Jiang, Y., Becker, J. M., and Naider, F. (1996). A superactive peptidomimetic analog of a farnesylated dodecapeptide yeast pheromone. *Biochem.Biophys.Res.Comm.* **224**, 327-331.

THIS PAGE BLANK (USPTO)

~~BEST AVAILABLE COPY~~

CLAIMS

1. A method for stimulating root growth and/or enhancing the formation of lateral and adventitious roots and/or altering root geotropism comprising expression of a plant cytokinin oxidase or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts.
2. An isolated nucleic acid encoding a novel plant protein having cytokinin oxidase activity or encoding an immunologically active and/or functional fragment of such a protein selected from the group consisting of:
 - (a) nucleic acid sequences comprising a DNA sequence as given in any of SEQ ID NOs 1, 3, 5, 7, 9 or 11, or the complement thereof,
 - (b) nucleic acid sequences comprising the RNA sequences corresponding to any of SEQ ID NOs 1, 3, 5, 7, 9 or 11, or the complement thereof,
 - (c) nucleic acid sequences hybridizing to the nucleotide sequence as defined in (a) or (b),
 - (d) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 35% similar to the amino acid sequence as given in SEQ ID NO 2,
 - (e) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 40% similar to the amino acid sequence as given in SEQ ID NO 4,
 - (f) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 42% similar to the amino acid sequence as given in SEQ ID NO 6,
 - (g) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 44% similar to the amino acid sequence as given in SEQ ID NO 8,
 - (h) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 40% similar to the amino acid sequence as given in SEQ ID NO 10,
 - (i) nucleic acid sequences encoding a protein with an amino acid sequence which is at least 40% similar to the amino acid sequence as given in SEQ ID NO 12,
 - (j) nucleic acid sequences encoding a protein comprising the amino acid sequence as given in any of SEQ ID NOs 2, 4, 6, 8, 10 or 12,
 - (k) nucleic acid sequences which are degenerated as a result of the genetic code to a nucleotide sequence of a nucleic acid as given in any of SEQ ID NOs 1, 3, 5, 7, 9 or 11, or as defined in (a) to (j),

- (l) nucleic acid sequences which are diverging due to the differences in codon usage between the organisms to a nucleotide sequence encoding a protein as given in any of SEQ ID NOs 2, 4, 6, 8, 10, 12 or as defined in (a) to (j),
- 5 (m) nucleic acid sequences which are diverging due to the differences between alleles encoding a protein as given in SEQ ID NOs 2, 4, 6, 8, 10 or 12, or as defined in (a) to (j),
- (n) nucleic acid sequences encoding an immunologically active and/or functional fragment of a protein encoded by a DNA sequence as given in any of SEQ ID NOs 1, 3, 5, 7, 9 or 11, or a functional fragment of a nucleic acid as defined in
- 10 any one of (a) to (m), and,
- (o) nucleic acid sequences encoding a protein as defined in SEQ ID NO 2, 4, 6, 8, 10 or 12 or a nucleic acid as defined in any one of (a) to (n) characterized in that said sequence is a cDNA sequence.
3. An isolated nucleic acid according to claim 2 which is DNA, cDNA, genomic DNA or
- 15 synthetic DNA, or RNA wherein T is replaced by U.
4. A nucleic acid molecule of at least 15 nucleotides in length hybridizing specifically with a nucleic acid of claim 2 or 3.
5. A nucleic acid molecule of at least 15 nucleotides in length specifically amplifying a nucleic acid of claim 2 or 3.
- 20 6. A vector comprising a nucleic acid sequence according to claim 2 or 3.
7. A vector according to claim 6 which is an expression vector wherein the nucleic acid sequence is operably linked to one or more control sequences allowing the expression of said sequence in prokaryotic and/or eukaryotic host cells.
8. A host cell containing a nucleic acid molecule according to claim 2 or 3 or a vector
- 25 according to claim 6 or 7.
9. The host cell of claim 8, wherein the host cell is a bacterial, insect, fungal, plant or animal cell.
10. An isolated polypeptide encodable by a nucleic acid of claim 2 or 3, or a homologue or a derivative thereof, or an immunologically active and/or functional fragment
- 30 thereof.

11. The polypeptide of claim 10 which has an amino acid sequence as given in SEQ ID NO 2, 4, 6, 8, 10 or 12, or a homologue or a derivative thereof, or an immunologically active and/or functional fragment thereof.
12. A method for producing a polypeptide according to claim 10 or 11 comprising
5 culturing a host cell of claim 8 or 9 under conditions allowing the expression of the polypeptide and recovering the produced polypeptide from the culture.
13. An antibody specifically recognizing a polypeptide of claim 10 or 11 or a specific epitope thereof.
14. A method for the production of transgenic plants, plant cells or plant tissues
10 comprising the introduction of a nucleic acid molecule according to any of claims 2 or 3 in an expressible format or a vector according to claim 6 or 7 in said plant, plant cell or plant tissue.
15. A method for the production of altered plants, plant cells or plant tissues comprising the introduction of a polypeptide of claim 10 or 11 directly into a cell, a tissue or an
15 organ of said plant.
16. A method for effecting the expression of a polypeptide of claim 10 or 11 comprising the introduction of a nucleic acid molecule of claim 2 or 3 operably linked to one or more control sequences or a vector according to claim 6 or 7 stably into the genome of a plant cell.
- 20 17. The method of claim 15 or 16 further comprising regenerating a plant from said plant cell.
18. A transgenic plant cell comprising a nucleic acid sequence of claim 2 or 3 which is operably linked to regulatory elements allowing transcription and/or expression of said nucleic acid in plant cells or obtainable by a method of claim 15 or 16.
- 25 19. The transgenic plant cell of claim 18 wherein said nucleic acid of claim 2 or 3 is stably integrated into the genome of said plant cell.
20. A transgenic plant or plant tissue comprising plant cells of claim 18 or 19.
21. A harvestable part of a plant of claim 20.
22. The harvestable part of claim 21 which is selected from the group consisting of
30 seeds, leaves, fruits, stem cultures, rhizomes, roots, tubers and bulbs.

23. The progeny derived from any of the plants or plant parts of any of claims 20 to 22.
24. A method for stimulating root growth comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts.
- 5 25. A method for enhancing the formation of lateral and adventitious roots comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts.
26. A method for altering root geotropism comprising altering the expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts.
- 10 27. A method of any of claims 24 to 26, said method leading to an increase in yield.
28. The method of any of claims 24 to 27 wherein said expression of said nucleic acid occurs under the control of a strong constitutive promoter.
29. The method of any of claims 24 to 27 wherein said expression of said nucleic acid occurs under the control of a promoter that is preferentially expressed in roots.
- 15 30. A method for identifying and obtaining proteins interacting with a polypeptide of claim 10 or 11 comprising a screening assay wherein a polypeptide of claim 10 or 11 is used.
31. The method of claim 30 comprising a two-hybrid screening assay wherein a polypeptide of claim 10 or 11 as a bait and a cDNA library as prey are used.
- 20 32. A method for modulating the interaction between a polypeptide of claim 10 or 11 and interacting protein partners obtainable by a method according to claim 30 or 31.
33. A method for identifying and obtaining compounds interacting with a polypeptide of claim 10 or 11 comprising the steps of:
- 25 (a) providing a two-hybrid system wherein a polypeptide of claim 10 or 11 and an interacting protein partner obtainable by a method according to claim 30 or 31 are expressed,
- (b) interacting said compound with the complex formed by the expressed polypeptides as defined in a), and,
- 30 (c) performing measurement of interaction of said compound with said polypeptide or the complex formed by the expressed polypeptides as defined in (a).

34. A method for identifying compounds or mixtures of compounds which specifically bind to a polypeptide of claim 10 or 11, comprising:

(a) combining a polypeptide of claim 10 or 11 with said compound or mixtures of compounds under conditions suitable to allow complex formation, and,

(b) detecting complex formation, wherein the presence of a complex identifies a compound or mixture which specifically binds said polypeptide.

35. A method of any of claims 30 to 34 wherein said compound or mixture inhibits the activity of said polypeptide of claim 10 or 11 and can be used for the rational design of chemicals.

36. Use of a compound or mixture identified by means of a method of any of claims 30 to 34 as a plant growth regulator or herbicide.

37. A method for production of a plant growth regulator or herbicide composition comprising the steps of the method of any of claims 30 to 34 and formulating the compounds obtained from said steps in a suitable form for the application in agriculture or plant cell or tissue culture.

38. A method for the design of or screening for growth-promoting chemicals or herbicides comprising the use of a nucleic acid of claim 2 or 3 or a vector of claim 6 or 7.

39. Use of a nucleic acid molecule of claim 2 or 3, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 for increasing yield.

40. Use of a nucleic acid molecule of claim 2 or 3, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 for stimulating root growth.

41. Use of a nucleic acid molecule of claim 2 or 3, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 for enhancing the formation of lateral and adventitious roots.

42. Use of a nucleic acid molecule of claim 2 or 3, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 for altering root geotropism.

43. Diagnostic composition comprising at least a nucleic acid molecule of any of claims 2 to 5, the vector of claim 6 or 7, a polypeptide of claim 10 or 11 or an antibody of claim 13.

44. A method for increasing the size of the root meristem comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another nucleic acid encoding a protein that reduces the level of active cytokinins in plants or plant parts, preferably in roots.
- 5 45. A method for increasing the root size comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another nucleic acid encoding a protein that reduces the level of active cytokinins in plants or plant parts, preferably in roots.
46. A method for increasing the size of the shoot meristem comprising downregulation of expression of a nucleic acid of claim 2 or 3, preferably in shoots.
- 10 47. A method for delaying leaf senescence comprising downregulation of expression of a nucleic acid of claim 2 or 3 in leaves, preferably in senescing leaves.
48. A method for altering leaf senescence comprising expression of a nucleic acid of claim 2 or 3 in senescing leaves.
- 15 49. A method for increasing leaf thickness comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another nucleic acid encoding a protein that reduces the level of active cytokinins in plants or plant parts, preferably in leaves.
50. A method for reducing the vessel size comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another nucleic acid encoding a protein that reduces the level of active cytokinins in vessels.
- 20 51. A method for increasing the vessel size comprising downregulation of expression of a nucleic acid of claim 2 or 3 in vessels.
52. A method for inducing parthenocarpy comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another nucleic acid encoding a protein that reduces the level of active cytokinins in plants or plant parts, preferably in the placenta, ovules and tissues derived therefrom.
- 25 53. A method for improving standability of seedlings comprising expression of a nucleic acid of claim 2 or 3 or comprising expression of another protein that reduces the level of active cytokinins in seedlings, preferably in roots.

54. A method for increasing branching comprising expression of a nucleic acid of claim 2 or 3 in plants or plant parts, preferably in stems or axillary buds
55. A method for improving lodging resistance comprising expression of a nucleic acid of claim 2 or 3 in plants or plant parts, preferably in stems or axillary buds

THIS PAGE BLANK (USPTO)

ABSTRACT

The present invention relates to methods for stimulating root growth and/or enhancing the formation of lateral and adventitious roots and/or altering root geotropism comprising
5 expression of a plant cytokinin oxidase or comprising expression of another protein that reduces the level of active cytokinins in plants or plant parts.

The invention also relates to novel plant cytokinin oxidase proteins, nucleic acid sequences encoding cytokinin oxidase proteins as well as to vectors, host cells, transgenic cells and plants comprising said sequences. The invention also relates to the
10 use of said sequences for increasing yield and/or enhancing early vigor and/or modifying root/shoot ratio and/or improving resistance to lodging and/or increasing drought tolerance and/or promoting in vitro propagation of explants and/or modifying cell fate and/or plant development and/or plant morphology and/or plant biochemistry and/or plant physiology. The invention also relates to the use of said sequences in the above
15 mentioned methods.

The invention also relates to methods for identifying and obtaining proteins and compounds interacting with cytokinin oxidase proteins. The invention also relates to the use of said compounds as a plant growth regulator or herbicide.

THIS PAGE BLANK (USPTO)




FIGURE 1

ZmCKX1	1	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85	90	95	100
AtCKX1	1	MGLTSSLRPHRQNNKTFGLGIFMILVLSICIPGRNLCNHS	TPKELPSSNPSPDIRSSVSLDLEGISFDD	HNVAKDFGNRYQLPPLA	LHPRSVFD																
AtCKX2	1																				
AtCKX3	1																				
AtCKX4	1																				
ZmCKX1	82	VAL	SAANSTPG																		
AtCKX1	101	SS	KHIVHLGTSN																		
AtCKX2	70	SRE	OYAANGK																		
AtCKX3	83	TDL	KLSDSOLS																		
AtCKX4	77	ARL	RFANGGFSYNGKSTSPAST	K	AARGQHSIRGQASAPGGVVMNMT	C	AMAAPAA	V	SADGTVADVA	T	W	VL	AA	DRG	EV	WTDVLY					
ZmCKX1	173	LTVGGTLSN	GISGQAFRHPGPOI	NVLE	DVITGKE	TCSEKQ	NA	LFD	VLGGLGQFG	ITRARI	A	PAPASA	WVR	F	Y	DFAAF	ADQER	T	P		
AtCKX1	190	LTVGGTLSN	GISGQAFRHPGPOI	NVLE	DVITGKE	TCSEKQ	NA	LFD	VLGGLGQFG	ITRARI	A	PAPASA	WVR	F	Y	DFAAF	ADQER	T	P		
AtCKX2	154	LTVGGTLSN	GISGQAFRHPGPOI	NVLE	DVITGKE	TCSEKQ	NA	LFD	VLGGLGQFG	ITRARI	A	PAPASA	WVR	F	Y	DFAAF	ADQER	T	P		
AtCKX3	171	LTVGGTLSN	GISGQAFRHPGPOI	NVLE	DVITGKE	TCSEKQ	NA	LFD	VLGGLGQFG	ITRARI	A	PAPASA	WVR	F	Y	DFAAF	ADQER	T	P		
AtCKX4	177	LTVGGTLSN	GISGQAFRHPGPOI	NVLE	DVITGKE	TCSEKQ	NA	LFD	VLGGLGQFG	ITRARI	A	PAPASA	WVR	F	Y	DFAAF	ADQER	T	P		
ZmCKX1	273	RPGGGGASFGP	S	EGS	F	NOSLATDLAN	GF	TDADVA	VA	AGE	NATTVS	EATLVNDATAAAA	DQE	AS	LG	LS	EGEA	QRDVA	VA		
AtCKX1	290	EK																			
AtCKX2	254	ANDIG																			
AtCKX3	271	T	DG																		
AtCKX4	277	TNDLG																			
ZmCKX1	373	AFDRV	GEVALNKLGLWRVPHPLN	VP	SR	IADEDRGVPFGILQ	Q	TDIVG	PL	YPLN	SMDDCGSAATP	SEDV	FVA	SLLFS	VAP	---	N				
AtCKX1	377	FLDRV	IAERKL	AKGLW	VPHPLN	L	P	SSIVQATEVFNILTS	NNNG	PL	YPLN	OSKWK	TSLITP	NED	FYL	FLPSAVPNSSGXN					
AtCKX2	340	FLNRV	VEENKL	SLGLW	PHPLN	VP	SR	ILDFHNGVVKD	ILLKOKSASGLAL	YPTN	NKWDN	MSAMIPEDDV	LYL	LLQSATP	---	K					
AtCKX3	358	FLNRV	ATGELN	SKGOM	VPHPLN	VP	Q	ISFDDGVPFGI	LRNNTSGPVL	YPMN	NKWD	MSAIP	EEDV	FVA	FLRSAG	F	---	D			
AtCKX4	363	FLNRV	NEEDKL	SLGLW	VPHPLN	VP	Q	ISFDDGVPFGI	LRNNTSGPVL	YPTN	NKWDN	MSAIP	EEDV	FVA	FLRSAG	F	---	D			
ZmCKX1	466	DLAR	QEQNR	RFCDLAG	QYKVTJA	H	DRS	WRHFGAA	WNRFEVENK	DKR	LSPGQDIF										
AtCKX1	473	DLEV	JKQO	NFCAAN	N	KQVLP	YETQK	MSHFG	K	METFAQ	KQA	DPLA	L	PGORIF	KTTGKLSPIQLAKS	KATGSPQRYHVYASILPKPRTV					
AtCKX2	435	DLPEK	ESVNE	RFCKDSG	K	KQVLM	Y	SKEW	EHFG	S	WDDFSK	KDL	DKR	LSPGQDIF							
AtCKX3	451	NWEAPQENME	KFCEDAN	G	IQVLPYH	SOEGM	RHFG	P	WNIIVE	KYK	DKM	LSPGQDIF	KINSS								
AtCKX4	457	NWQE	ENLND	QFCENSG	K	REYLM	Y	RKE	W	KHFG	P	WDDFLR	KIM	DKR	LSPGQDIF						

FIGURE 2




Figure 3

4/10




Figure 4

BEST AVAILABLE COPY

5/10



Figure 5




Figure 6




Figure 7




Figure 8



Figure 9

BEST AVAILABLE COPY




Figure 10

SEQUENCE LISTING

<110> CropDesign N.V.

<120> Method for modifying plant morphology, biochemistry and physiology

<130> CROP-005-EP

<140>

<141>

<160> 24

<170> PatentIn Ver. 2.1

<210> 1

<211> 2236

<212> DNA

<213> Arabidopsis thaliana

<400> 1

```

atgggattga cctcaccctt acggttccat agacaaaaca acaagacttt cctcggaatc 60
ttcatgatct tagttctaag ctgtatacca ggtagaacca atctttgttc caatcattct 120
gttagtacc caaaagaatt accttcttca aatccttcag atattcgttc ctcattagtt 180
tcactagatt tggagggtta tataagcttc gacgatgtcc acaatgtggc caaggacttt 240
ggcaacagat accagttacc acctttggca attctacatc caaggtcagt ttttgatatt 300
tcacgatga tgaagcatat agtacatctg ggctccacct caaatcttac agtagcagct 360
agaggccatg gtcactcgct tcaaggacaa gctctagctc atcaagggtg tgtcatcaaa 420
atggagtcac ttcgaagtc tgaatcagg atttataagg ggaagcaacc atatgttgat 480
gtctcaggtg gtgaaatatg gataaacatt ctacgcgaga ctctaaaata cggctcttca 540
ccaaagtcct ggacagacta ccttcatttg accgttggag gtacactatc taatgctgga 600
atcagcggtc aagcattcaa gcatggacc caaatcaaca acgtctacca gctagagatt 660
gttacaggta tttcattcat gctttatctc tgcggtagtc tcaaaaaaat atgcacctgt 720
aaagaatatc catctcttca tgagcaaaaa cactgacgac tttaaataat ttttgactat 780
aaaacaagag tgcataggca caaatgtgaa atatgcaaca cacaattgta acttgcacca 840
agaaaaaagt tataaaaaa aacaactgat aagcaatata tttccaatat ttaatcaggg 900
aaaggagaag tcgtaacctg ttctgagaag cgggaattctg aacttttctt cagtgttctt 960
ggcgggcttg gacagtttgg cataatcacc cgggcacgga tctctcttga accagcaccg 1020
catatggtaa agttctatct tgaacaaagt tcaacaata tacgctatga ttctaagaac 1080
cactttcctg acacagtcaa ataactttta ataggttaaa tggatcaggg tactctactc 1140
tgacttttct gcattttcaa gggaccaaga atatctgatt tcgaaggaga aaacttttga 1200
ttacgttgaa ggatttgtga taatcaatag aacagacctt ctcaataatt ggcatcgctc 1260
attcagtcac aacgattcca cacaggcaag cagattcaag tcagatggga aaactcttta 1320
ttgcctagaa gtgggtcaaat atttcaaccc agaagaagct agctctatgg atcaggttaag 1380
atgtgaaagc aatatataac tagacttagt ttccacagag agctccaaat caaccgttgg 1440
ctactagcct actaacataa tgaatggttg ccgtgcagga aactggcaag ttactttcag 1500
agttaaatta tattccatcc actttgtttt catctgaagt gccatatatc gaggtttctg 1560

```

atcgcgtgca tatcgcagag agaaaactaa gagcaaaggg tttatgggag gttccacatc 1620
 cctggctgaa tctcctgatt cctaagagca gcatatacca atttgctaca gaagttttca 1680
 acaacattct cacaagcaac aacaacggtc ctatccttat ttatccagtc aatcaatcca 1740
 agtaagttag caaaatgcca aaagcaaatg cgtccagtga ttctgaaaca taaattacta 1800
 accatatcca acattttgtg gtttcagggtg gaagaaacat acatctttga taactccaaa 1860
 tgaagatata ttctatctcg tagcctttct cccctctgca gtgccaaatt cctcagggaa 1920
 aaacgatcta gagtaccttt tgaaacaaaa ccaaagagtt atgaacttct gcgcagcagc 1980
 aaacctcaac gtgaagcagt atttgcccc aatatgaaact caaaaagagt ggaaatcaca 2040
 ctttggcaaa agatgggaaa catttgcaca gaggaacaa gcctacgacc ctctagcgat 2100
 tctagcacct ggccaaagaa tattccaaaa gacaacagga aaattatctc ccattccaaact 2160
 cgcaaagtca aaggcaacag gaagtcctca aaggtaccat tacgcatcaa tactgccgaa 2220
 acctagaact gtataa 2236

<210> 2

<211> 575

<212> PRT

<213> Arabidopsis thaliana

<400> 2

Met	Gly	Leu	Thr	Ser	Ser	Leu	Arg	Phe	His	Arg	Gln	Asn	Asn	Lys	Thr
1				5					10					15	
Phe	Leu	Gly	Ile	Phe	Met	Ile	Leu	Val	Leu	Ser	Cys	Ile	Pro	Gly	Arg
			20					25					30		
Thr	Asn	Leu	Cys	Ser	Asn	His	Ser	Val	Ser	Thr	Pro	Lys	Glu	Leu	Pro
	35						40					45			
Ser	Ser	Asn	Pro	Ser	Asp	Ile	Arg	Ser	Ser	Leu	Val	Ser	Leu	Asp	Leu
	50					55					60				
Glu	Gly	Tyr	Ile	Ser	Phe	Asp	Asp	Val	His	Asn	Val	Ala	Lys	Asp	Phe
65					70					75					80
Gly	Asn	Arg	Tyr	Gln	Leu	Pro	Pro	Leu	Ala	Ile	Leu	His	Pro	Arg	Ser
				85					90					95	
Val	Phe	Asp	Ile	Ser	Ser	Met	Met	Lys	His	Ile	Val	His	Leu	Gly	Ser
		100						105					110		
Thr	Ser	Asn	Leu	Thr	Val	Ala	Ala	Arg	Gly	His	Gly	His	Ser	Leu	Gln
	115							120				125			
Gly	Gln	Ala	Leu	Ala	His	Gln	Gly	Val	Val	Ile	Lys	Met	Glu	Ser	Leu
	130					135					140				
Arg	Ser	Pro	Asp	Ile	Arg	Ile	Tyr	Lys	Gly	Lys	Gln	Pro	Tyr	Val	Asp

145		150		155		160
Val Ser Gly Gly Glu Ile Trp Ile Asn Ile Leu Arg Glu Thr Leu Lys						
	165		170		175	
Tyr Gly Leu Ser Pro Lys Ser Trp Thr Asp Tyr Leu His Leu Thr Val						
	180		185		190	
Gly Gly Thr Leu Ser Asn Ala Gly Ile Ser Gly Gln Ala Phe Lys His						
	195		200		205	
Gly Pro Gln Ile Asn Asn Val Tyr Gln Leu Glu Ile Val Thr Gly Lys						
	210		215		220	
Gly Glu Val Val Thr Cys Ser Glu Lys Arg Asn Ser Glu Leu Phe Phe						
225		230		235		240
Ser Val Leu Gly Gly Leu Gly Gln Phe Gly Ile Ile Thr Arg Ala Arg						
	245		250		255	
Ile Ser Leu Glu Pro Ala Pro His Met Val Lys Trp Ile Arg Val Leu						
	260		265		270	
Tyr Ser Asp Phe Ser Ala Phe Ser Arg Asp Gln Glu Tyr Leu Ile Ser						
	275		280		285	
Lys Glu Lys Thr Phe Asp Tyr Val Glu Gly Phe Val Ile Ile Asn Arg						
	290		295		300	
Thr Asp Leu Leu Asn Asn Trp Arg Ser Ser Phe Ser Pro Asn Asp Ser						
305		310		315		320
Thr Gln Ala Ser Arg Phe Lys Ser Asp Gly Lys Thr Leu Tyr Cys Leu						
	325		330		335	
Glu Val Val Lys Tyr Phe Asn Pro Glu Glu Ala Ser Ser Met Asp Gln						
	340		345		350	
Glu Thr Gly Lys Leu Leu Ser Glu Leu Asn Tyr Ile Pro Ser Thr Leu						
	355		360		365	
Phe Ser Ser Glu Val Pro Tyr Ile Glu Phe Leu Asp Arg Val His Ile						
	370		375		380	
Ala Glu Arg Lys Leu Arg Ala Lys Gly Leu Trp Glu Val Pro His Pro						
385		390		395		400
Trp Leu Asn Leu Leu Ile Pro Lys Ser Ser Ile Tyr Gln Phe Ala Thr						

405	410	415
Glu Val Phe Asn Asn Ile Leu Thr Ser Asn Asn Asn Gly Pro Ile Leu		
420	425	430
Ile Tyr Pro Val Asn Gln Ser Lys Trp Lys Lys His Thr Ser Leu Ile		
435	440	445
Thr Pro Asn Glu Asp Ile Phe Tyr Leu Val Ala Phe Leu Pro Ser Ala		
450	455	460
Val Pro Asn Ser Ser Gly Lys Asn Asp Leu Glu Tyr Leu Leu Lys Gln		
465	470	475
Asn Gln Arg Val Met Asn Phe Cys Ala Ala Ala Asn Leu Asn Val Lys		
485	490	495
Gln Tyr Leu Pro His Tyr Glu Thr Gln Lys Glu Trp Lys Ser His Phe		
500	505	510
Gly Lys Arg Trp Glu Thr Phe Ala Gln Arg Lys Gln Ala Tyr Asp Pro		
515	520	525
Leu Ala Ile Leu Ala Pro Gly Gln Arg Ile Phe Gln Lys Thr Thr Gly		
530	535	540
Lys Leu Ser Pro Ile Gln Leu Ala Lys Ser Lys Ala Thr Gly Ser Pro		
545	550	555
Gln Arg Tyr His Tyr Ala Ser Ile Leu Pro Lys Pro Arg Thr Val		
565	570	575

<210> 3

<211> 2991

<212> DNA

<213> Arabidopsis thaliana

<400> 3

```

atggctaatac ttcgtttaat gatcacttta atcacgggttt taatgatcac caaatcatca 60
aacggtatta aaattgattt acctaaatcc cttaacctca ccctctctac cgatccttcc 120
atcatctccg cagcctctca tgacttcgga aacataacca ccgtgacccc cggcggcgta 180
atctgccct cctccaccgc tgatatctct cgtctcctcc aatacgccgc aaacggaaaa 240
agtacattcc aagtagcggc tcgtggccaa ggccactcct taaacggcca agcctcggtc 300
tccggcggag taatcgtcaa catgacgtgt atcactgacg tgggtggtttc aaaagacaag 360
aagtagcgtg acgtggcggc cgggacgtta tgggtggatg tgcttaagaa gacggcggag 420
aaaggggtgt cgccgggttc ttggacggat tatttgcata taaccgtcgg aggaacgttg 480

```

tcgaatgggtg	gaattgggtgg	tcaagtgttt	cgaaacggtc	ctcttggttag	taacgtcctt	540
gaattgggacg	ttattactgg	tacgcattctt	ctaaactttg	atgtacatac	aacaacaaaa	600
actgtttttg	ttttatagta	tttttcattt	tttgtaccat	aggttttatg	ttttatagtt	660
gtgctaaact	tcttgcacca	cacgtaagtc	ttcgaaacac	aaaatgcgta	acgcattctat	720
atgttttttg	tacatatattga	atgtttgttca	tgagaaataa	agtaattaca	tatacacaca	780
tttattgtcg	tacatatata	aataattaaa	gacaaatttt	cacaattggt	agcgtgttaa	840
tttgggattt	ttgtaatgta	catgcatgac	gcatgcatat	ggagcttttc	ggttttctta	900
gatttgtgta	gtatttcaaa	tatatcattt	attttctttc	gaataaagag	gtggtatatt	960
tttaaaatag	caacatttca	gaatttttct	ttgaatttac	actttttaaa	ttgttattgt	1020
taatattgat	tttgaataaa	taatttcagg	gaaagggtgaa	atgttgacat	gctcgcgaca	1080
gctaaaccca	gaattgttct	atggagtgtt	aggagggtttg	ggtcaatttg	gaattataac	1140
gagagccaga	attgttttgg	accatgcacc	taaacgggta	cgtatcatca	tattttacca	1200
tttgttttag	tcagcattca	tttttcatta	gtaattccgt	ttcaatttct	aaattttttt	1260
agtcaataga	aaatgattct	tatgtcagag	cttgattatt	tagtgatttt	tattgagata	1320
aaataaaata	taacctaacg	gaaataatta	ttttactaat	cggataatgt	ctgattaaaa	1380
cattttatga	tattacacta	agagagttag	agacgtatgg	atcacaaaac	atgaagcttt	1440
cttagatggg	atcctaaaaac	taaagttagg	tacaagtttg	gaatttaggt	caaagcttta	1500
agttgcatta	atgtgaacaa	aatctatgca	ttgaataaaa	aaaagatatg	gattatttta	1560
taaagtatag	tccttgtaat	cctaggactt	gttgtcta	cttgtcttat	gcgtgcaaat	1620
ctttttgatg	tcaatatata	atccttgttt	attagagtca	agctctttca	ttagtcaact	1680
actcaaata	actccaaagt	ttagaatata	gtcttctgac	taattagaat	cttacaaccg	1740
ataaacgtta	caatttggtt	atcattttta	aaaacagatt	tggtcataat	atacgatgac	1800
gttctgtttt	agtttcatct	atcacaaaat	tttatataat	tattttcaag	aaaatattga	1860
aatactatac	tgtaatatgg	tttctttata	tatgtgtgta	taaattaaat	gggattgttt	1920
tctctaaatg	aaattgtgta	ggccaaatgg	tttcggatgc	tctacagtga	tttcacaaact	1980
tttacaagg	accaagaacg	tttgatatca	atggcacaacg	atattggagt	cgactattta	2040
gaaggcaca	tatttctatc	aaacgggtgc	gttgacacct	cttttttccc	accttcagat	2100
caatctaaag	tcgctgatct	agtcaagcaa	cacgggtatca	tctatgttct	tgaagtagcc	2160
aagtattatg	atgatcccaa	tctcccatc	atcagcaagg	tactacacat	ttacattttc	2220
atcatcgttt	ttatcatacc	ataagatatt	taaatgattc	atcattgcac	cacattaaga	2280
tattcatcat	catcatcggt	acattttttt	ttgcatctta	tgcttctcat	aatctactat	2340
tgtgtagggt	attgacacat	taacgaaaac	attaagttac	ttgcccgggt	tcatatcaat	2400
gcacgacgtg	gcctacttcg	atctcttgaa	ccgtgtacat	gtcgaagaaa	ataaactcag	2460
atctttggga	ttatgggaac	ttcctcatcc	ttggcttaac	ctctacgttc	ctaaatctcg	2520
gattctcgat	tttcataacg	gtgttgtaaa	agacattctt	cttaagcaaa	aatcagcttc	2580
gggactcgct	cttctctatc	caacaaaccg	gaataagtac	atacttctct	tcattcatat	2640
ttatcttcaa	gaaccaaagt	aaataaattt	ctatgaactg	attatgctgt	tattgttaga	2700
tgggacaatc	gtatgtcggc	gatgatacca	gagatcgatg	aagatgttat	atatattatc	2760
ggactactac	aatccgctac	cccaaaggat	cttcagaag	tggagagcgt	taacgagaag	2820
ataattagggt	tttgcaagga	ttcaggtatt	aagattaagc	aatatcta	gcattatact	2880
agtaaagaag	attggattga	gcatttttga	tcaaaatggg	atgatttttc	gaagaggaaa	2940
gatctatttg	atcccaagaa	actgttatct	ccagggcaag	acatcttttg	a	2991

<210> 4

<211> 501

<212> PRT

<213> Arabidopsis thaliana

<400> 4

Met Ala Asn Leu Arg Leu Met Ile Thr Leu Ile Thr Val Leu Met Ile
1 5 10 15

Thr Lys Ser Ser Asn Gly Ile Lys Ile Asp Leu Pro Lys Ser Leu Asn
20 25 30

Leu Thr Leu Ser Thr Asp Pro Ser Ile Ile Ser Ala Ala Ser His Asp
35 40 45

Phe Gly Asn Ile Thr Thr Val Thr Pro Gly Gly Val Ile Cys Pro Ser
50 55 60

Ser Thr Ala Asp Ile Ser Arg Leu Leu Gln Tyr Ala Ala Asn Gly Lys
65 70 75 80

Ser Thr Phe Gln Val Ala Ala Arg Gly Gln Gly His Ser Leu Asn Gly
85 90 95

Gln Ala Ser Val Ser Gly Gly Val Ile Val Asn Met Thr Cys Ile Thr
100 105 110

Asp Val Val Val Ser Lys Asp Lys Lys Tyr Ala Asp Val Ala Ala Gly
115 120 125

Thr Leu Trp Val Asp Val Leu Lys Lys Thr Ala Glu Lys Gly Val Ser
130 135 140

Pro Val Ser Trp Thr Asp Tyr Leu His Ile Thr Val Gly Gly Thr Leu
145 150 155 160

Ser Asn Gly Gly Ile Gly Gly Gln Val Phe Arg Asn Gly Pro Leu Val
165 170 175

Ser Asn Val Leu Glu Leu Asp Val Ile Thr Gly Lys Gly Glu Met Leu
180 185 190

Thr Cys Ser Arg Gln Leu Asn Pro Glu Leu Phe Tyr Gly Val Leu Gly
195 200 205

Gly Leu Gly Gln Phe Gly Ile Ile Thr Arg Ala Arg Ile Val Leu Asp
210 215 220

His Ala Pro Lys Arg Ala Lys Trp Phe Arg Met Leu Tyr Ser Asp Phe
225 230 235 240

Thr Thr Phe Thr Lys Asp Gln Glu Arg Leu Ile Ser Met Ala Asn Asp

<210> 5
 <211> 3302
 <212> DNA
 <213> *Arabidopsis thaliana*

<400> 5
 atggcgagtt ataatcttcg ttcacaagtt cgtcttatag caataacaat agtaatcatc 60
 attactctct caactccgat cacaaccaac acatcaccac aaccatggaa tatectttca 120
 cacaacgaat tcgcgggaaa actcacctcc tctcctcct ccgtcgaatc agccgccaca 180
 gatttcggcc acgtcaccaa aatcttccct tccgccgtct taatcccttc ctccgttgaa 240
 gacatcacag atctcataaa actctctttt gactctcaac tgtcttttcc tttagccget 300
 cgtgggtcacg gacacagcca ccgtggccaa gcctcggcta aagacggagt tgtgggtcaac 360
 atgcggtcca tggtaaaccg ggatcgaggt atcaagggtgt ctaggacctg tttatatgtt 420
 gacgtggacg ctgcgtgggt atggattgag gtgttgaata aaacttttga gttaggggtta 480
 acgccggttt cttggacgga ttatttgtat ttaacagtcg gtgggacgtt atcaaacggc 540
 ggaattagtg gacaaacgtt tcggtacggt ccacagatca ctaatgttct agagatggat 600
 gttattactg gtacgtacca cgatcttttt cacacagaga ttaaaaaaaaa cagtaatagt 660
 gattttaact tcgtacgttt ctgatagaca acaaagaact tcgtacgttt ttcgaagttt 720
 tttcgtcttt ttcatttttag atctgcgcgg ccattttttg ttatgctatt gtttgtttgt 780
 attgtttgtc tctgtttatt tatttctcga acttgttgat agcttttctt cttttcacac 840
 atcaatctaa tcaccttttt tggctttaag attagaaaga agatacggac taggtaaaaa 900
 taggtggttg taaacgtaga cgcattaaaa aaatattggt ttttttattt tttgataagc 960
 aaaattggtg gttggtctaa gattataaac ttgatattaa tgcaaagggt gatctagcaa 1020
 tagaagatta atcaatattc ttggtgtttt aacaacagat tatttcatca ttaaaatcgt 1080
 gaaacaaaga aatttttggt gtatacatca cgtgtagttt tgttagttta ttaaaaaaaaa 1140
 tagtatatag ttttgttaaa acgcgattta tttagtaaca cattagtata ttacacgttt 1200
 aaccaactaa actttttttt ttgaataatt atgttctata tttcttactc aaattatgca 1260
 aatttcgtgg attcgaagtc aaattttctgc gaaatttaca tgggtcatata ttataaaact 1320
 gttcatataa cccggtgaac aaacagacaa ttaagggttt gaatgggttac ggcggttggg 1380
 gcggacacaa ccgtcaatag atcagaccgt tttttattta ccattcatca attatatcc 1440
 gcagtgggtt ggggtaaaaa aaatagaaga aaaccgcagc ggaccaattc cataccgttt 1500
 ttacatacaa ataaacatgg tgcgcaacgg tttattgtcc gcctcaaaaa tgaaatggac 1560
 taaaccgcag ataaattaga ccgctttgtc cgctgcctcc attcatagac taaaaaaaaa 1620
 caacaaaaaa aaaaatggtc ccacgcccat gattttacac gaggtttctt gtggcgtaag 1680
 gacaaaactc aaaagttcat aacgtttggt cctaaccagg tgtaatggat taagtaacag 1740
 tcaattttct tattatagct gtatccatta tgtccacata tgcattcata tacattacac 1800
 tgttgggtct aagtgtagtt agattacgaa gactttcaag ttccattttt tgggttaggag 1860
 ataaacataa tttaatgata ccgacttttag cactctagge tcaaaacaag tacagaagag 1920
 aatagtttta tttcaaactc gttgcattgt tgtatcaatt aattgtgtta gtctttgtat 1980
 attcttacat aacggtccaa gtttggtgaa atagtttact tactaaaact ttcctaatgg 2040
 ggtcaaattt tatttttatag gaaaaggaga gattgcaact tgttccaagg acatgaactc 2100
 ggatcttttc ttcgcggtgt taggagggtt ggggtcaattc ggcattataa caagagccag 2160
 aattaaactt gaagtagctc cgaaaagggt atgttaaatt tgtaaattat gcaactacag 2220
 aaaattctat gaaatttatg aatgaacata tatgcatttt tggatttttg taggccaaagt 2280

```

ggttaagggtt tctatacata gatttctccg aattcacaag agatcaagaa cgagtgatat 2340
cgaaaacgga cgggtgtagat ttcttagaag gttccattat ggtggaccat ggcccaccgg 2400
ataactggag atccacgtat tatccaccgt cggatcactt gaggatcgcc tcaatgggtca 2460
aacgacatcg tgatcatctac tgccttgaag tcgtcaagta ttacgacgaa acttctcaat 2520
acacagtcaa cgaggtcctg acatacatat aatcataaat catacatgta taattggggag 2580
atctttatgc attattcaat tatattaatt tacttttagtt atttaactta tgcaggaaat 2640
ggaggagtta agcgatagtt taaaccatgt aagaggggtt atgtacgaga aagatgtgac 2700
gtatatggat ttcctaaacc gagttcgaac cggagagcta aacctgaaat ccaaaggcca 2760
atgggatggt ccacatccat ggcttaatct cttcgtacca aaaactcaaa tctccaaatt 2820
tgatgatggt gtttttaagg gtattatcct aagaaataac atcactagcg gtctgtttct 2880
tgtttatcct atgaatcgca acaagtaagt ttaactcgat attgcaaaat ttactatcta 2940
cattttcgtt ttggaatccg aaatattctt acaagctaatt tttatgcggc gtttttaggt 3000
ggaatgatcg gatgtctgcc gctatacccg aggaagatgt attttatgcy gtaggggttt 3060
taagatccgc gggttttgac aattgggagg cttttgatca agaaaacatg gaaatactga 3120
agttttgtga ggatgctaatt atgggggtta tacaatatct tccttatcat tcatcacaag 3180
aaggatgggt tagacatttt ggtccgaggt ggaatatatt cgtagagaga aaatataaat 3240
atgatcccaa aatgatatta tcaccgggac aaaatatatt tcaaaaaata aactcgagtt 3300
ag                                                                 3302

```

<210> 6
 <211> 523
 <212> PRT
 <213> Arabidopsis thaliana

```

<400> 6
Met Ala Ser Tyr Asn Leu Arg Ser Gln Val Arg Leu Ile Ala Ile Thr
  1             5             10             15

Ile Val Ile Ile Ile Thr Leu Ser Thr Pro Ile Thr Thr Asn Thr Ser
      20             25             30

Pro Gln Pro Trp Asn Ile Leu Ser His Asn Glu Phe Ala Gly Lys Leu
      35             40             45

Thr Ser Ser Ser Ser Ser Val Glu Ser Ala Ala Thr Asp Phe Gly His
      50             55             60

Val Thr Lys Ile Phe Pro Ser Ala Val Leu Ile Pro Ser Ser Val Glu
      65             70             75             80

Asp Ile Thr Asp Leu Ile Lys Leu Ser Phe Asp Ser Gln Leu Ser Phe
      85             90             95

Pro Leu Ala Ala Arg Gly His Gly His Ser His Arg Gly Gln Ala Ser
      100            105            110

Ala Lys Asp Gly Val Val Val Asn Met Arg Ser Met Val Asn Arg Asp

```

115							120						125			
Arg	Gly	Ile	Lys	Val	Ser	Arg	Thr	Cys	Leu	Tyr	Val	Asp	Val	Asp	Ala	
130						135					140					
Ala	Trp	Leu	Trp	Ile	Glu	Val	Leu	Asn	Lys	Thr	Leu	Glu	Leu	Gly	Leu	
145					150					155					160	
Thr	Pro	Val	Ser	Trp	Thr	Asp	Tyr	Leu	Tyr	Leu	Thr	Val	Gly	Gly	Thr	
				165					170					175		
Leu	Ser	Asn	Gly	Gly	Ile	Ser	Gly	Gln	Thr	Phe	Arg	Tyr	Gly	Pro	Gln	
			180					185					190			
Ile	Thr	Asn	Val	Leu	Glu	Met	Asp	Val	Ile	Thr	Gly	Lys	Gly	Glu	Ile	
		195					200					205				
Ala	Thr	Cys	Ser	Lys	Asp	Met	Asn	Ser	Asp	Leu	Phe	Phe	Ala	Val	Leu	
	210					215					220					
Gly	Gly	Leu	Gly	Gln	Phe	Gly	Ile	Ile	Thr	Arg	Ala	Arg	Ile	Lys	Leu	
225					230					235					240	
Glu	Val	Ala	Pro	Lys	Arg	Ala	Lys	Trp	Leu	Arg	Phe	Leu	Tyr	Ile	Asp	
				245					250					255		
Phe	Ser	Glu	Phe	Thr	Arg	Asp	Gln	Glu	Arg	Val	Ile	Ser	Lys	Thr	Asp	
			260					265					270			
Gly	Val	Asp	Phe	Leu	Glu	Gly	Ser	Ile	Met	Val	Asp	His	Gly	Pro	Pro	
		275					280					285				
Asp	Asn	Trp	Arg	Ser	Thr	Tyr	Tyr	Pro	Pro	Ser	Asp	His	Leu	Arg	Ile	
	290					295					300					
Ala	Ser	Met	Val	Lys	Arg	His	Arg	Val	Ile	Tyr	Cys	Leu	Glu	Val	Val	
305					310					315					320	
Lys	Tyr	Tyr	Asp	Glu	Thr	Ser	Gln	Tyr	Thr	Val	Asn	Glu	Glu	Met	Glu	
			325						330					335		
Glu	Leu	Ser	Asp	Ser	Leu	Asn	His	Val	Arg	Gly	Phe	Met	Tyr	Glu	Lys	
			340					345					350			
Asp	Val	Thr	Tyr	Met	Asp	Phe	Leu	Asn	Arg	Val	Arg	Thr	Gly	Glu	Leu	
	355						360					365				
Asn	Leu	Lys	Ser	Lys	Gly	Gln	Trp	Asp	Val	Pro	His	Pro	Trp	Leu	Asn	

370		375		380
Leu Phe Val Pro Lys Thr Gln Ile Ser Lys Phe Asp Asp Gly Val Phe				
385		390		395
				400
Lys Gly Ile Ile Leu Arg Asn Asn Ile Thr Ser Gly Pro Val Leu Val				
	405		410	415
Tyr Pro Met Asn Arg Asn Lys Trp Asn Asp Arg Met Ser Ala Ala Ile				
	420		425	430
Pro Glu Glu Asp Val Phe Tyr Ala Val Gly Phe Leu Arg Ser Ala Gly				
	435		440	445
Phe Asp Asn Trp Glu Ala Phe Asp Gln Glu Asn Met Glu Ile Leu Lys				
	450		455	460
Phe Cys Glu Asp Ala Asn Met Gly Val Ile Gln Tyr Leu Pro Tyr His				
465		470		475
				480
Ser Ser Gln Glu Gly Trp Val Arg His Phe Gly Pro Arg Trp Asn Ile				
	485		490	495
Phe Val Glu Arg Lys Tyr Lys Tyr Asp Pro Lys Met Ile Leu Ser Pro				
	500		505	510
Gly Gln Asn Ile Phe Gln Lys Ile Asn Ser Ser				
	515		520	

<210> 7
 <211> 2782
 <212> DNA
 <213> Arabidopsis thaliana

<400> 7
 atgactaata ctctctgttt aagcctcatc accctaataa cgctttttat aagttttaacc 60
 ccaaccttaa tcaaatacaga tgagggcatt gatgttttct taccatatac actcaacctt 120
 acggtcctaa ccgatccctt ctccatctct gccgcttctc acgacttcgg taacataacc 180
 gacgaaaatc ccggcgccgt cctctgccct tcctccacca cggaggtggc tcgtctcctc 240
 cgtttcgcta acggaggatt ctcttacaat aaaggctcaa ccagccccgc gtctactttc 300
 aaagtggctg ctcgaggcca aggccactcc ctccgtggcc aagcctctgc acccggagggt 360
 gtcgtcgtga acatgacgtg tctcgccatg gcggctaaac cagcggcggt tgttatctcg 420
 gcagacggga cttacgctga cgtggctgcc gggacgatgt ggggtggatgt tctgaaggcg 480
 gcggtggata gaggcgtctc gccggttaca tggacggatt atttgtatct cagcgtcggc 540
 gggacgttgt cgaacgctgg aatcggtggg cagacgttta gacacggccc tcagattagt 600
 aacgttcatt agcttgacgt tattaccggg acgtaaatac caaaacttca ctaatctcgt 660

```

tacaatTTTT taatTTTTtg gtaatataaa ttttgtacgg ctcaactctt aattaagaat 720
gaaacagtat ctatgatctt ctagatgctc tttttttgtc tgcaagcttt aattgtagta 780
acatcagcga tatatatatc acatgcatgt gtattattga tgataatata taatgtttta 840
gttacaaaatt tgattctcaa ggtaaaaactc acacgccata accagtataa aactccaaaa 900
atcacgtttt ggtcagaaat acatatcctt cattaacagt agttatgcta taatttgtga 960
ttataaataa ctccggagtt tgttcacaat actaaatttc aggaaaaggt gaaatgatga 1020
cttgctctcc aaagttaaac cctgaattgt tctatggagt tttaggaggt ttgggtcaat 1080
tcggtattat aacgagggcc aggattgctg tggatcatgc accacaagg gtatgtatca 1140
tgcactctata gtgtaatcaa tttataaatt taatgtagtg gtcctaaatc caaaatttga 1200
tttgatttgg ttggaacgta cgtatatata ataagtcaaa aggctgattt tgaagacgaa 1260
tttatatact tttgttgaat taaatctgat tttgcttacg ttttattaga ttctgcgtaa 1320
taaatacctag gacttgctcg agtgtaatct tgtcttatgc ttgcaaactc tgttgatgct 1380
aatatctaat cttttttatt atatttccct acgtaagttt tagatatagt tatttttaaac 1440
tgctataaat tgtgtacgta tagactttag ataaaaagtt gtggtcgctt gcacctattt 1500
gtttatcgct atagtgatc aaaggtctat atatgattct tggtttttct ttttgaaaaa 1560
aatagaccat acaatccaag gaagatgatc ttaaattggac taatttatgg atataaattg 1620
atatacaaat ctgcaggtga aatgggtctg catactctac agtgacttct cggcttttaa 1680
aagagaccaa gagcgtttta tatcaatgac caatgatctc ggagttgact ttttggaagg 1740
tcaacttatg atgtcaaatg gcttcgtaga cacctcttct tccactctc ccgatcaaac 1800
aagagtcgca tctcttgtga atgaccaccg gatcatctat gttctcgaag tagccaagta 1860
ttatgacaga accacccttc ccattattga ccaggtaact aaatccatta ttcgatgta 1920
ttatcttcac acaatcagta tcatcaccaa ttaccatcat cacttgatcat atatgatcca 1980
aagtaaatat atcacatgat ataaataaat cgttcaaact ttttttttta aagaataaaa 2040
gaatcatttt caagcattac tcatcacat ctacgaatca ccgtgaccat atataaccat 2100
acgcttatta aataatcatt tttgtttgta ggtgattgac acgttaagta gaactctagg 2160
tttcgctcca gggtttatgt tcgtacaaga tgttcgctat ttcgatttct tgaaccgtgt 2220
ccgaaacgaa gaagataaac tcagatcttt aggactatgg gaagttctc atccatggct 2280
taacatcttt gtcccggggc ctggaatcca agattttcat gatgggtgta ttaatggcct 2340
tcttctaaac caaacctcaa cttctggtgt tactctcttc tatcccacaa accgaaacaa 2400
gtaaatattt actttttgat tttgttttat ttgaaagtat atcccaataa tgtatgttaa 2460
attgttaaca agaatttatt ttattaatag atggaacaac cgcagtgtcaa cgatgacacc 2520
ggacgaagat gttttttatg tgatcggatt actgcaatca gctgggtggat ctcaaaattg 2580
gcaagaactt gaaaatctca acgacaagggt tattcagttt tgtgaaaact cgggaattaa 2640
gattaaggaa tatttgatgc actatacaag aaaagaagat tgggttaaac attttgacc 2700
aaaatgggat gattttttaa gaaagaaaat tatgtttgat cccaaaagac tattgtctcc 2760
aggacaagac atatttaatt aa 2782

```

<210> 8

<211> 524

<212> PRT

<213> *Arabidopsis thaliana*

<400> 8

Met Thr Asn Thr Leu Cys Leu Ser Leu Ile Thr Leu Ile Thr Leu Phe

1

5

10

15

Ile Ser Leu Thr Pro Thr Leu Ile Lys Ser Asp Glu Gly Ile Asp Val

275	280	285
Leu Met Met Ser Asn Gly Phe Val Asp Thr Ser Phe Phe Pro Leu Ser		
290	295	300
Asp Gln Thr Arg Val Ala Ser Leu Val Asn Asp His Arg Ile Ile Tyr		
305	310	315
Val Leu Glu Val Ala Lys Tyr Tyr Asp Arg Thr Thr Leu Pro Ile Ile		
	325	330
Asp Gln Val Ile Asp Thr Leu Ser Arg Thr Leu Gly Phe Ala Pro Gly		
	340	345
Phe Met Phe Val Gln Asp Val Pro Tyr Phe Asp Phe Leu Asn Arg Val		
	355	360
Arg Asn Glu Glu Asp Lys Leu Arg Ser Leu Gly Leu Trp Glu Val Pro		
	370	375
His Pro Trp Leu Asn Ile Phe Val Pro Gly Ser Arg Ile Gln Asp Phe		
	385	390
His Asp Gly Val Ile Asn Gly Leu Leu Leu Asn Gln Thr Ser Thr Ser		
	405	410
Gly Val Thr Leu Phe Tyr Pro Thr Asn Arg Asn Lys Trp Asn Asn Arg		
	420	425
Met Ser Thr Met Thr Pro Asp Glu Asp Val Phe Tyr Val Ile Gly Leu		
	435	440
Leu Gln Ser Ala Gly Gly Ser Gln Asn Trp Gln Glu Leu Glu Asn Leu		
	450	455
Asn Asp Lys Val Ile Gln Phe Cys Glu Asn Ser Gly Ile Lys Ile Lys		
	465	470
Glu Tyr Leu Met His Tyr Thr Arg Lys Glu Asp Trp Val Lys His Phe		
	485	490
Gly Pro Lys Trp Asp Asp Phe Leu Arg Lys Lys Ile Met Phe Asp Pro		
	500	505
Lys Arg Leu Leu Ser Pro Gly Gln Asp Ile Phe Asn		
	515	520

<210> 9
 <211> 2805
 <212> DNA
 <213> Arabidopsis thaliana

<400> 9
 atgacgtcaa gcttttcttct cctgacgttc gccatatgta aactgatcat agccgtgggt 60
 ctaaacgtgg gccccagtga gctcctccgc atcggagcca tagatgtcga cggccacttc 120
 accgtccacc cttccgactt agcctccgtc tcctcagact tcggtatgct gaagtcacct 180
 gaagagccat tggccgtgct tcatccatca tcggccgaag acgtggcacg actcgtcaga 240
 acagcttacg gttcagccac ggcgtttccg gtctcagccc gagggcacgg ccattccata 300
 aacggacaag ccgcggcggg gaggaacggg gtggtggttg aaatgaacca cggcgtaacc 360
 gggacgcca agccactcgt ccgaccggat gaaatgtatg tggatgtatg ggggtggagag 420
 ttatgggtcg atgtgttgaa gaaaacgttg gagcatggct tagcaccaaa atcatggacg 480
 gattacttgt atctaaccgt tggaggtaca ctctccaatg caggaatcag tggatcaagct 540
 tttcaccatg gtcctcaa at tagtaacgtc cttgagctcg acgttgtaac tggtagtat 600
 taaaacattc aagttcatat attttaaatg cttttgtctg aagttttact aataacaaga 660
 aattgatacc aaaaagtagg gaaaggagag gtgatgagat gctcagaaga agagaacaca 720
 aggctattcc atggagttct tgggtggatta ggtcaatttg ggatcatcac tcgagcacga 780
 atctctctcg aaccagctcc ccaaagggtg atattttttt aatgactagc tatcaaaaat 840
 ccctggcggg tccatacgtt gtaatctttt tagtttttac tgttgatggg attttttata 900
 tattttggat aataaaacc taaaatggta tattgtgatg acaggtgaga tggatacggg 960
 tattgtattc gagcttcaaa gtgtttacgg aggaccaaga gtacttaatc tcaatgcatg 1020
 gtcaattaaa gtttgattac gtggaagggt ttgtgattgt ggacgaagga ctctgtcaaca 1080
 attggagatc ttctttcttc tctccacgta acccctgtaa gatctctctt gttagttcca 1140
 acggctctgt tttgtattgc cttgagatca ccaagaacta ccacgactcc gactccgaaa 1200
 tcgttgatca ggtcactttc attattcact tagaaaaaag cgatattttt attttttata 1260
 ttgatgaata tctggaagga tttaacgcta tgcgactatt gggaaatcat tatgaaaaaa 1320
 tatttagttt atatgattga aagtgggtct catagtattt ttgttgtgtc gactttatta 1380
 taacttaaat ttggaagagg acatgaagaa gaagccagag aggatctaca gagatctagc 1440
 ttttccacct gaacttaata atgcacattt atataattat ttttcttctt cttaaagttta 1500
 gtttatcact agcgaattaa tcatggttac taattaagta gtggacaggg tcatggacca 1560
 ctactcacc aaataatgat tcctctttac tcttaagttt aatttttaata aaaccaactc 1620
 tactggaatc ttaacttata cttgggtttt gtaggctttt atagcaacac ggttttttta 1680
 attttcttat tccagatttt gtatatataa tgtcgatttt ttttcttttt gtttcaggaa 1740
 gttgagattc tgatgaagaa attgaatttc ataccgacat cggctctttac aacggattta 1800
 caatatgtgg actttctcga ccgggtacac aaggccgaat tgaagctcgg gtccaagaat 1860
 ttatgggagg ttccacaccc atggctcaac ctcttcgtgc caaaatcaag aatctctgac 1920
 ttcgataaag gcgtttttcaa gggcattttt ggaaataaaa caagtggccc tattcttata 1980
 taccatga acaaagacaa gtaagtcttg acattaccat tgattactac ttctaaattt 2040
 cttctctaga aaaaagaata aaacgagttt tgcattgcat gcatgcaaag ttacacttgt 2100
 ggggattaat tagtgggtcca agaaaaaag tttgtcaaaa ttgaaaaaaa ctagacacgt 2160
 ggtacatggg attgtccgaa aaacgttggt cacatgtgca tcgaaccage taagattgac 2220
 aacaacactt cgtcgggtcg tatttctctt tttgttttgt gaccaaattc gatggtccag 2280
 attgggttta tttgttttta agttcctaga actcatgggt ggtgggtccc aatcagattc 2340
 tcctagacca aaccgatctc aacgaacct ccgcacatca ttgattatta cattaatata 2400
 gatattgtcg ttgctgacgt gtcgtaattt gatgttattg tcagatggga cgagaggagc 2460

tcagccgtga cgccggatga ggaagttttc tatctggtgg ctctattgag atcagcttta 2520
acggacggtg aagagacaca gaagctagag tatctgaaag atcagaaccg tcggatcttg 2580
gagttctgtg aacaagccaa gatcaatgtg aagcagtatc ttcttcacca cgcaacacag 2640
gaagagtggg tggctcattt tggggacaag tgggatcggc tcagaagctt aaaggctgag 2700
tttgatccgc gacacatact cgctactggt cagagaatct ttcaaaaccc atctttgtct 2760
ttgtttcctc cgtcgtcgtc ttcttcgtca gcggttcac ggtga 2805

<210> 10

<211> 536

<212> PRT

<213> Arabidopsis thaliana

<400> 10

Met Thr Ser Ser Phe Leu Leu Leu Thr Phe Ala Ile Cys Lys Leu Ile
1 5 10 15

Ile Ala Val Gly Leu Asn Val Gly Pro Ser Glu Leu Leu Arg Ile Gly
20 25 30

Ala Ile Asp Val Asp Gly His Phe Thr Val His Pro Ser Asp Leu Ala
35 40 45

Ser Val Ser Ser Asp Phe Gly Met Leu Lys Ser Pro Glu Glu Pro Leu
50 55 60

Ala Val Leu His Pro Ser Ser Ala Glu Asp Val Ala Arg Leu Val Arg
65 70 75 80

Thr Ala Tyr Gly Ser Ala Thr Ala Phe Pro Val Ser Ala Arg Gly His
85 90 95

Gly His Ser Ile Asn Gly Gln Ala Ala Ala Gly Arg Asn Gly Val Val
100 105 110

Val Glu Met Asn His Gly Val Thr Gly Thr Pro Lys Pro Leu Val Arg
115 120 125

Pro Asp Glu Met Tyr Val Asp Val Trp Gly Gly Glu Leu Trp Val Asp
130 135 140

Val Leu Lys Lys Thr Leu Glu His Gly Leu Ala Pro Lys Ser Trp Thr
145 150 155 160

Asp Tyr Leu Tyr Leu Thr Val Gly Gly Thr Leu Ser Asn Ala Gly Ile
165 170 175

Ser Gly Gln Ala Phe His His Gly Pro Gln Ile Ser Asn Val Leu Glu

180	185	190
Leu Asp Val Val Thr Gly Lys	Gly Glu Val Met Arg Cys Ser Glu Glu	
195	200	205
Glu Asn Thr Arg Leu Phe His	Gly Val Leu Gly Gly Leu Gly Gln Phe	
210	215	220
Gly Ile Ile Thr Arg Ala Arg Ile Ser Leu Glu Pro Ala Pro Gln Arg		
225	230	235
Val Arg Trp Ile Arg Val Leu Tyr Ser Ser Phe Lys Val Phe Thr Glu		
245	250	255
Asp Gln Glu Tyr Leu Ile Ser Met His Gly Gln Leu Lys Phe Asp Tyr		
260	265	270
Val Glu Gly Phe Val Ile Val Asp Glu Gly Leu Val Asn Asn Trp Arg		
275	280	285
Ser Ser Phe Phe Ser Pro Arg Asn Pro Val Lys Ile Ser Ser Val Ser		
290	295	300
Ser Asn Gly Ser Val Leu Tyr Cys Leu Glu Ile Thr Lys Asn Tyr His		
305	310	315
Asp Ser Asp Ser Glu Ile Val Asp Gln Glu Val Glu Ile Leu Met Lys		
325	330	335
Lys Leu Asn Phe Ile Pro Thr Ser Val Phe Thr Thr Asp Leu Gln Tyr		
340	345	350
Val Asp Phe Leu Asp Arg Val His Lys Ala Glu Leu Lys Leu Arg Ser		
355	360	365
Lys Asn Leu Trp Glu Val Pro His Pro Trp Leu Asn Leu Phe Val Pro		
370	375	380
Lys Ser Arg Ile Ser Asp Phe Asp Lys Gly Val Phe Lys Gly Ile Leu		
385	390	395
Gly Asn Lys Thr Ser Gly Pro Ile Leu Ile Tyr Pro Met Asn Lys Asp		
405	410	415
Lys Trp Asp Glu Arg Ser Ser Ala Val Thr Pro Asp Glu Glu Val Phe		
420	425	430
Tyr Leu Val Ala Leu Leu Arg Ser Ala Leu Thr Asp Gly Glu Glu Thr		

435		440		445
Gln Lys Leu Glu Tyr Leu Lys Asp Gln Asn Arg Arg Ile Leu Glu Phe				
450		455		460
Cys Glu Gln Ala Lys Ile Asn Val Lys Gln Tyr Leu Pro His His Ala				
465		470		475
				480
Thr Gln Glu Glu Trp Val Ala His Phe Gly Asp Lys Trp Asp Arg Phe				
	485		490	495
Arg Ser Leu Lys Ala Glu Phe Asp Pro Arg His Ile Leu Ala Thr Gly				
	500		505	510
Gln Arg Ile Phe Gln Asn Pro Ser Leu Ser Leu Phe Pro Pro Ser Ser				
515		520		525
Ser Ser Ser Ser Ala Ala Ser Trp				
530		535		

<210> 11
 <211> 1936
 <212> DNA
 <213> Arabidopsis thaliana

<400> 11

atgcttatag	taagaagttt	caccatcttg	cttctcagct	gcatagcctt	taagttggct	60
tgctgcttct	ctagcagcat	ttcttctttg	aaggcgcttc	ccctagtagg	ccatttggag	120
tttgaacatg	tccatcacgc	ctccaaagat	tttggaatc	gataccagtt	gatccctttg	180
gcggtcttac	atcccaaatc	ggtaagcgac	atcgctcaa	cgatacgaca	catctggatg	240
atgggcactc	attcacagct	tacagtggca	gcgagaggtc	gtggacattc	actccaaggc	300
caagctcaaa	caagacatgg	aattgttata	cacatggaat	cactccatcc	ccagaagctg	360
caggtctaca	gtgtggattc	ccctgctcca	tatgttgatg	tgtctgggtg	tgagctgtgg	420
ataaacattt	tgcattgagc	cctcaagtac	gggcttgcac	caaatcatg	gacggattac	480
ctgcatttaa	ctgtaggtgg	tactctgtcc	aatgctggaa	taagcggcca	ggcattccga	540
catggaccac	agatcagcaa	tgttcatcaa	ctggagattg	tcacagggtta	gttcagagtt	600
gcagtattcg	tgttttgaaa	gcatagactc	tatatggttg	gtgactatta	acaacatgaa	660
gagattcccg	agaatagcta	cccactaatg	tcatgcctat	ttattgactg	caggaaaagg	720
cgagatccta	aactgtacaa	agaggcgaaa	cagcgactta	tttaatggtg	ttcttgggtg	780
tttaggtcag	tttggcatca	taacgcgggc	aagaatagca	ttggaaccag	caccaaccat	840
ggtaaacaa	aaataaataa	aaaacttaaa	aactgaacac	gcgtgtgtcc	tcctaactct	900
gtataatgga	caggtaaaat	ggataagagt	gttataacctg	gattttgcag	cttttgccaa	960
ggaccaagag	caactaatat	ctgcccaggg	ccacaaattc	gattacatag	aagggtttgt	1020
gataataaac	aggacaggcc	tcctgaacag	ctggagggtg	tctttcaccg	cagaagagcc	1080
tttagaagca	agccaattca	agttttgatg	aaggactctg	tattgtctgg	agctagccaa	1140
gtatttgaag	caagataaca	aagacgtaat	caaccagggtg	agaaaacaga	gtagaagcaa	1200

```

tcggtagaat cttcttttggg agatgacatt cattggaact gaaaatatat atatatttgt 1260
ccaatccagg aagtgaaga aacattatca gagctaagct acgtgacgtc gacactgttt 1320
acaacggagg tagcatatga agcattcttg gacagggtac atgtgtctga ggtaaaactc 1380
cgatcgaaag ggcagtggga ggtgccacat ccattggtga acctcctggt accaagaagc 1440
aaaatcaatg aatttgcaag aggtgtattt ggaaacatac taacggatac aagcaacggc 1500
ccagtcacgc tctaccagc gaacaaatca aagtaagaaa gaaagaaaga aagagctagt 1560
catgattttg tttcttttca cttgttgaca aaacaaaagc atgttggtga gcagggtggga 1620
caatcaaaca tcagcagtaa caccggagga agaggatttc tacctggtgg cgatcctaac 1680
atcggcacat ccagggtcgg caggaaagga tggagtagaa gagatcttga ggcggaacag 1740
aagaatactg gaattcagtg aagaagcagg gatagggttg aagcagtatc tgccacatta 1800
cacgacaaga gaagagtggg gatcccat tggggacaag tgggggagaat ttgtgaggag 1860
gaaatccaga tatgatccat tggcaattct tgcgcctggc caccgaattt ttcaaaaggc 1920
agtctcatat tcatga 1936

```

<210> 12

<211> 504

<212> PRT

<213> Arabidopsis thaliana

<400> 12

```

Met Leu Ile Val Arg Ser Phe Thr Ile Leu Leu Leu Ser Cys Ile Ala
  1             5             10             15

```

```

Phe Lys Leu Ala Cys Cys Phe Ser Ser Ser Ile Ser Ser Leu Lys Ala
      20             25             30

```

```

Leu Pro Leu Val Gly His Leu Glu Phe Glu His Val His His Ala Ser
    35             40             45

```

```

Lys Asp Phe Gly Asn Arg Tyr Gln Leu Ile Pro Leu Ala Val Leu His
    50             55             60

```

```

Pro Lys Ser Val Ser Asp Ile Ala Ser Thr Ile Arg His Ile Trp Met
    65             70             75             80

```

```

Met Gly Thr His Ser Gln Leu Thr Val Ala Ala Arg Gly Arg Gly His
      85             90             95

```

```

Ser Leu Gln Gly Gln Ala Gln Thr Arg His Gly Ile Val Ile His Met
    100            105            110

```

```

Glu Ser Leu His Pro Gln Lys Leu Gln Val Tyr Ser Val Asp Ser Pro
    115            120            125

```

```

Ala Pro Tyr Val Asp Val Ser Gly Gly Glu Leu Trp Ile Asn Ile Leu
    130            135            140

```

His	Glu	Thr	Leu	Lys	Tyr	Gly	Leu	Ala	Pro	Lys	Ser	Trp	Thr	Asp	Tyr		
145						150				155					160		
Leu	His	Leu	Thr	Val	Gly	Gly	Thr	Leu	Ser	Asn	Ala	Gly	Ile	Ser	Gly		
				165					170					175			
Gln	Ala	Phe	Arg	His	Gly	Pro	Gln	Ile	Ser	Asn	Val	His	Gln	Leu	Glu		
			180					185					190				
Ile	Val	Thr	Gly	Lys	Gly	Glu	Ile	Leu	Asn	Cys	Thr	Lys	Arg	Gln	Asn		
		195					200					205					
Ser	Asp	Leu	Phe	Asn	Gly	Val	Leu	Gly	Gly	Leu	Gly	Gln	Phe	Gly	Ile		
	210					215					220						
Ile	Thr	Arg	Ala	Arg	Ile	Ala	Leu	Glu	Pro	Ala	Pro	Thr	Met	Asp	Gln		
225					230					235					240		
Glu	Gln	Leu	Ile	Ser	Ala	Gln	Gly	His	Lys	Phe	Asp	Tyr	Ile	Glu	Gly		
				245					250					255			
Phe	Val	Ile	Ile	Asn	Arg	Thr	Gly	Leu	Leu	Asn	Ser	Trp	Arg	Leu	Ser		
			260					265					270				
Phe	Thr	Ala	Glu	Glu	Pro	Leu	Glu	Ala	Ser	Gln	Phe	Lys	Phe	Asp	Gly		
	275						280					285					
Arg	Thr	Leu	Tyr	Cys	Leu	Glu	Leu	Ala	Lys	Tyr	Leu	Lys	Gln	Asp	Asn		
	290					295					300						
Lys	Asp	Val	Ile	Asn	Gln	Glu	Val	Lys	Glu	Thr	Leu	Ser	Glu	Leu	Ser		
305				310					315					320			
Tyr	Val	Thr	Ser	Thr	Leu	Phe	Thr	Thr	Glu	Val	Ala	Tyr	Glu	Ala	Phe		
				325					330				335				
Leu	Asp	Arg	Val	His	Val	Ser	Glu	Val	Lys	Leu	Arg	Ser	Lys	Gly	Gln		
		340						345					350				
Trp	Glu	Val	Pro	His	Pro	Trp	Leu	Asn	Leu	Leu	Val	Pro	Arg	Ser	Lys		
	355						360					365					
Ile	Asn	Glu	Phe	Ala	Arg	Gly	Val	Phe	Gly	Asn	Ile	Leu	Thr	Asp	Thr		
	370					375				380							
Ser	Asn	Gly	Pro	Val	Ile	Val	Tyr	Pro	Val	Asn	Lys	Ser	Lys	Trp	Asp		
385					390					395					400		

Asn Gln Thr Ser Ala Val Thr Pro Glu Glu Glu Val Phe Tyr Leu Val
 405 410 415
 Ala Ile Leu Thr Ser Ala Ser Pro Gly Ser Ala Gly Lys Asp Gly Val
 420 425 430
 Glu Glu Ile Leu Arg Arg Asn Arg Arg Ile Leu Glu Phe Ser Glu Glu
 435 440 445
 Ala Gly Ile Gly Leu Lys Gln Tyr Leu Pro His Tyr Thr Thr Arg Glu
 450 455 460
 Glu Trp Arg Ser His Phe Gly Asp Lys Trp Gly Glu Phe Val Arg Arg
 465 470 475 480
 Lys Ser Arg Tyr Asp Pro Leu Ala Ile Leu Ala Pro Gly His Arg Ile
 485 490 495
 Phe Gln Lys Ala Val Ser Tyr Ser
 500

<210> 13
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:oligonucleotide

<400> 13
 cggtcgacat gggattgacc tcatccttac g

31

<210> 14
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:oligonucleotide

<400> 14
 gcgtcgactt atacagttct aggttttcggc agtat

35

<210> 15

<211> 33
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 15
gcggtaccag agagagaaac ataaacaaat ggc

33

<210> 16
<211> 31
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 16
gcggtaccga attttacttc caccaaaatg c

31

<210> 17
<211> 34
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 17
gcggtacctt cattgataag aatcaagcta ttca

34

<210> 18
<211> 31
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 18
gcggtaccga aagtgggtgag aacgactaac a

31

<210> 19

<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide

<400> 19
gcggtacccc cattaaccta cccgtttg 28

<210> 20
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide

<400> 20
gcggtaccag acgatgaacg tacttgtctg ta 32

<210> 21
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide

<400> 21
ggggtaccgt gaaatgacgt caagctttct t 31

<210> 22
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide

<400> 22
ggggtaccct ttctctttgg ttttgtctg t 31

<210> 23

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 23

gctctagatc aggaaaagaa ccatgcttat ag

32

<210> 24

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 24

gctctagatc atgagtatga gactgccttt tg

32

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)